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ENGINEERING ENZYMES THROUGH 
GENETIC SELECTION 
CROSS-REFERENCED TO RELATED 
APPLICATIONS 
This application is a continuation-in-part of and claims 
benefit of and priority to pending U.S. patent application Ser. 
No. 10/579,683 filed on May 17, 2006. This application also 
claims benefit of and priority to U.S. Provisional Patent 
Application No. 60/520,754 filed on Nov. 17, 2003, U.S. 
Provisional Patent Application No. 60/520,813, also filed on 
Nov. 17, 2003, and U.S. Provisional Patent Application No. 
60/619,671 filed on Oct. 18, 2004, and where permissible, 
each of which is incorporated by reference in their entirety. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
This invention was made in part with government support 
under grant nos. NIH AI064817 and NIH GM075832 award 
by the National Institutes of Health. The government has 
certain rights in this invention. 
SEQUENCE LISTING 
The present disclosure includes a sequence listing incor-
porated herein by reference in its entirety. 
FIELD OF THE DISCLOSURE 
Aspects of the present disclosure are generally directed to 
systems and methods for generating ligand-receptor pairs for 
transcriptional control by small molecules. 
BACKGROUND 
Directed molecular evolution of enzymes is a developing 
field in the biotechnology industry and occurs through the 
single or repeated application of two steps: diversity/library 
generation followed by screening or selecting for function. 
The last several years have produced much progress in each of 
these areas. Techniques of diversity generation in the creation 
of libraries range from methods with no structure/function 
prejudice (error-prone PCR; mutator strains) to highly 
focused randomization based on structural information (site-
directed mutagenesis; cassette mutagenesis ). DNA recombi-
nation (DNA-shuffling, StEP, SCRATCHY, RACHITT, 
RDA-PCR) requires no structural information but works on 
the premise that Nature has already solved the problem of 
creating functional proteins from amino acids. By randomly 
recombining the genes for related proteins, new combinations 
of the different solutions are created which may be better than 
any of the original individual proteins. Structure-based 
approaches can be combined with other methods to generate 
greater diversity. 
Advances have also been made in screening the generated 
libraries for proteins with desired properties. In a screen each 
protein in the library is analyzed for function, which limits 
library size. In contrast, genetic selection evaluates entire 
libraries at once, in a highly parallel fashion, because only 
functional members of the library survive the selective pres-
sure. In selection, nonfunctional members of the library are 
not individually evaluated. For screens, each variant must be 
individually assayed and the data evaluated, requiring more 
time and materials. In vivo genetic selection strategies enable 
the exhaustive analysis of protein libraries with up to about 
2 
1010 different members. The quoted throughputs are maximal 
values for industrial, robot driven laboratories. Realistically, 
experience indicates that an academic, individual investigator 
laboratory can achieve up to 104 samples/day for screening in 
yeast and 107 samples/day for genetic selection in yeast. In 
summary, genetic selection is generally preferable to screen-
ing not only because it is higher throughput, but also because 
it requires less time and materials. 
With regard to selection, there are several common con-
lO ventional selection strategies, such as (i) antibiotic resistance, 
(ii) substrate selected growth, where degradation of sub-
strates provides elements essential for growth (such as C, N, 
P, and S), iii) auxotrophic complementation to restore meta-
15 bolic function, and iv) phage display, which displays peptides 
or proteins on a virus surface and segregates them on the basis 
of binding affinity. Although powerful, these selection strat-
egies are not general enough to apply to engineering enzymes 
for many interesting reactions. Conventional systems rely on 
20 screening techniques rather than selection techniques 
because selections are more difficult. 
The generation of libraries has spawned many companies, 
in fact, spawned an industry. What has so far failed to be 
addressed is a general method of evaluating libraries (no 
25 matter how they are generated) through genetic selection. 
30 
Accordingly, there is a need for new compositions and meth-
ods for engineering polypeptides and rapidly identifying 
engineered polypeptides having desirable characteristics. 
SUMMARY 
The embodiments of the present disclosure provide aver-
satile system, and methods of using, that allow for the selec-
tion of variant nuclear receptor ligand binding domains, or for 
35 the selection of variant enzymes, or combinations thereof, 
that may have an enhanced ability to synthesize a nuclear 
receptor ligand or a precursor thereof. 
One aspect of the present disclosure, therefore, encom-
passes embodiments of a yeast cell comprising: (i) a yeast 
40 transcription modulating system comprising a first heterolo-
gous nucleic acid expression system encoding a recombinant 
nuclear receptor polypeptide comprising a ligand-binding 
domain operably linked to a DNA-binding domain and 
optionally to a flexible hinge domain, where the recombinant 
45 nuclear receptor polypeptide, when it is expressed in the yeast 
cell in the presence of a nuclear receptor ligand, specifically 
binds to the recombinant nuclear receptor polypeptide, 
thereby activating expression of a selective genetic locus; and 
a secondheterologous nucleic acid expression system encod-
50 ing an adapter polypeptide comprising a coactivator domain 
operably linked to a yeast transcriptional activator, and where 
the first heterologous nucleic acid expression system and the 
first heterologous nucleic acid expression system are each 
independently encoded by individual heterologous poly-
55 nucleotides or are encoded by the same heterologous poly-
nucleotide; (ii) a nuclear receptor ligand generating system 
comprising a third heterologous nucleic acid expression sys-
tem encoding a heterologous enzyme system for the genera-
tion of a nuclear receptor ligand from a substrate, where the 
60 nuclear receptor ligand is characterized as specifically bind-
ing to the recombinant nuclear receptor polypeptide; and (iii) 
a selective genetic locus expressed in the presence of the 
recombinant nuclear receptor polypeptide and a nuclear 
receptor ligand specifically bound to the recombinant nuclear 
65 receptor polypeptide. 
In embodiments of this aspect of the disclosure, the coregu-
lator domain can be SRC-1 or ACTR. 
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In embodiments of this aspect of the disclosure, the third 
heterologous nucleic acid expression system may comprise a 
heterologous polynucleotide encoding a heterologous 
polypeptide, said heterologous polypeptide having an enzy-
mic activity characterized as generating a candidate nuclear 
receptor ligand from a substrate. 
In other embodiments of this aspect of the disclosure, the 
third heterologous nucleic acid expression system may com-
prise a heterologous polynucleotide encoding a plurality of 
heterologous polypeptides, where said heterologous 
polypeptides cooperate to generate a candidate nuclear recep-
tor ligand from a substrate. 
In yet other embodiments of this aspect of the disclosure, 
the third heterologous nucleic acid expression system may 
comprise a plurality ofheterologous polynucleotides encod-
ing a plurality ofheterologous polypeptides, where said het-
erologous polypeptides cooperate to generate a candidate 
nuclear receptor ligand from a substrate. 
In embodiments of this aspect of the disclosure, the ligand-
binding domain of the recombinant nuclear receptor polypep-
tide can be derived from a ligand-binding domain of a human 
nuclear receptor polypeptide, or a variant thereof. 
In embodiments of this aspect of the disclosure, the coac-
tivator domain of the adapter polypeptide can be derived from 
a coactivator domain of a human coactivator, or a variant 
thereof, where the coactivator binds to the ligand-binding 
domain of the recombinant nuclear receptor polypeptide in 
the presence of a ligand to activate expression of a genetic 
locus. 
In embodiments of this aspect of the disclosure, expression 
of the genetic locus can allows proliferation of the yeast cell 
on a selective medium. 
In embodiments of this aspect of the disclosure, expression 
of the genetic locus can inhibit proliferation of the yeast cell 
on a selective medium. 
In embodiments of this aspect of the disclosure, the heter-
ologous enzyme system for the generation of a nuclear recep-
tor ligand from a substrate can comprise a modified enzyme, 
where the modified enzyme catalyzes the formation of a 
receptor ligand characterized as binding to the recombinant 
receptor polypeptide. 
In some embodiments of this aspect of the disclosure, the 
heterologous enzyme system for the generation of a nuclear 
receptor ligand from a substrate comprises vitamin D3 25-hy-
droxylase and 25-hydroxyvitamin D3 la-hydroxylase, 
wherein said heterologous enzyme system catalyzes the for-
mation of la,25-dihydroxyvitamin D3 , and wherein the 
1 a,25-dihydroxyvitamin D3 binds to the recombinant nuclear 
receptor polypeptide comprising the ligand-binding domain 
4 
coactivator domain operably linked to a yeast transcriptional 
activator, and wherein the first heterologous nucleic acid 
expression system and the second heterologous nucleic acid 
expression system are each independently encoded by indi-
vidual heterologous polynucleotides or are encoded by the 
same heterologous polynucleotide; (ii) a nuclear receptor 
ligand generating system comprising a third heterologous 
nucleic acid expression system encoding a heterologous 
enzyme system for the generation of a nuclear receptor ligand 
10 from a substrate, wherein the nuclear receptor ligand is char-
acterized as specifically binding to the recombinant nuclear 
receptor polypeptide; and (iii) a selective yeast genetic locus 
expressed in the presence of the recombinant nuclear receptor 
15 polypeptide and a nuclear receptor ligand specifically bound 
to the recombinant nuclear receptor polypeptide; and (2) cul-
turing the yeast cell under conditions allowing the yeast cell 
to synthesize a nuclear receptor ligand from a substrate, 
whereupon the nuclear receptor ligand specifically binds to 
20 the recombinant nuclear receptor polypeptide, thereby induc-
ing transcription of the selective yeast genetic locus. 
In some embodiments of this aspect of the disclosure, the 
step of providing a yeast cell or population of yeast cells may 
comprise delivering to a yeast cell or population of yeast cells 
25 a plurality of third heterologous nucleic acid expression sys-
tems encoding a plurality of enzyme systems suspected of 
generating from a substrate a nuclear receptor ligand specifi-
cally binding the recombinant nuclear receptor polypeptide, 
and where the step of culturing the yeast cell under conditions 
30 allowing the yeast cell to synthesize a nuclear receptor ligand 
from a substrate identifies a third heterologous nucleic acid 
expression system encoding an enzyme system generating 
the nuclear receptor ligand. 
In embodiments of this aspect of the disclosure, the sub-
35 strate can be endogenous to the yeast cell. 
In other embodiments of this aspect of the disclosure, the 
substrate can be exogenous to the yeast cell. 
In embodiments of this aspect of the disclosure, the method 
may further comprise the step of modifying the first heterolo-
40 gous nucleic acid expression system encoding the recombi-
nant nuclear receptor polypeptide, thereby providing a vari-
ant recombinant nuclear receptor polypeptide specifically 
binding to the nuclear receptor ligand. 
In embodiments of this aspect of the disclosure, the method 
45 may further comprise the step of modifying the third heter-
ologous nucleic acid expression system encoding the heter-
ologous enzyme system, thereby allowing the heterologous 
enzyme system to generate the nuclear receptor ligand from 
the substrate. 
of a vitamin D receptor, thereby inducing expression of a 50 
genetic locus allowing the yeast cell to proliferate on a culture 
medium not having histidine therein. 
In other embodiments of this aspect of the disclosure, the 
third heterologous nucleic acid expression system may com-
prise a heterologous polynucleotide encoding a heterologous 
polypeptide, the heterologous polypeptide having an enzy-
mic activity characterized as generating a candidate nuclear 
receptor ligand from a substrate. 
Another aspect of the present disclosure provides methods 
of modulating the transcription of a gene of a yeast cell, the 
methods comprising (1) providing a yeast cell or population 55 
of yeast cells, wherein said yeast cell or population of yeast 
cells comprises: (i) a yeast transcription modulating system 
comprising a first heterologous nucleic acid expression sys-
tem encoding a recombinant nuclear receptor polypeptide 
comprising a ligand-binding domain operably linked to a 60 
DNA-binding domain and optionally to a flexible hinge 
domain, where the recombinant nuclear receptor polypeptide, 
when expressed in the yeast cell in the presence of a nuclear 
receptor ligand specifically binding to the recombinant 
nuclear receptor polypeptide, activates expression of a 65 
genetic locus; and a second heterologous nucleic acid expres-
sion system encoding an adapter polypeptide, comprising a 
In embodiments of this aspect of the disclosure, the third 
heterologous nucleic acid expression system may comprise a 
heterologous polynucleotide encoding a plurality ofheterolo-
gous polypeptides, where said heterologous polypeptides 
cooperate to generate a candidate nuclear receptor ligand 
from a substrate. 
In embodiments of this aspect of the disclosure, the third 
heterologous nucleic acid expression system may comprise a 
plurality ofheterologous polynucleotides encoding a plural-
ity of heterologous polypeptides, where said heterologous 
polypeptides cooperate to generate a candidate nuclear recep-
tor ligand from a substrate. 
US 8,492,088 B2 
5 
In embodiments of this aspect of the disclosure, the ligand-
binding domain of the recombinant nuclear receptor polypep-
tide can be derived from a ligand-binding domain of a human 
nuclear receptor polypeptide, or a variant thereof. 
In embodiments of this aspect of the disclosure, the coac- 5 
tivator domain of the adapter polypeptide may be derived 
from a coactivator domain of a human coactivator, or a variant 
thereof, and the coactivator binds to the ligand-binding 
domain of the recombinant nuclear receptor polypeptide in 
the presence of a ligand to activate expression of a genetic 10 
locus. 
In embodiments of this aspect of the disclosure, transcrip-
tion of the yeast gene allows the yeast cell to proliferate on a 
selective culture medium. 
In other embodiments of this aspect of the disclosure, 
transcription of the yeast gene inhibits yeast cell proliferation 
on a selective culture medium. 
15 
In embodiments of this aspect of the disclosure, the method 
may further comprise contacting the yeast cell with at least 20 
one compound suspected of modulating the activity of at least 
one enzyme of the heterologous enzyme system, thereby 
allowing the identification of the at least one compound as an 
activator or inhibitor of the at least one enzyme. 
In some embodiments of this aspect of the disclosure, the at 25 
least one compound can be suspected of enhancing the activ-
ity of at least one enzyme of the heterologous enzyme system. 
In embodiments of this aspect of the disclosure, the at least 
one compound can be suspected of inhibiting the activity of at 
least one enzyme of the heterologous enzyme system. 30 
In other embodiments of this aspect of the disclosure, the 
method may further comprise contacting the yeast cell with at 
least one compound suspected of modulating the transcrip-
tional activity of the third heterologous nucleic acid expres- 35 
sion system encoding a heterologous enzyme system, thereby 
allowing the identification of the at least one compound as an 
activator or inhibitor of the transcriptional activity of the third 
heterologous nucleic acid expression system. 
40 
BRIEF DESCRIPTION OF THE FIGURES 
FIG.1 shows a schematic depicting an exemplary chemical 
complementation scheme. For selection, yeast strain PJ69-
4A has the ADE2 gene under the control of a Gal4 response 45 
element (Gal4RE). This strain is transformed with a plasmid 
expressing ACTR:GAD. Plasmids created through homolo-
gous recombination in PJ69-4A express a variant GBD:RXR. 
In media lacking adenine, yeast will grow only in the presence 
ofa ligand that causes the RXR-LBD to associate withACTR 50 
and activate transcription of ADE2. For clarity, only one 
ACTR:GAD is depicted. 
FIGS. 2a-o are line graphs showing selection assay (SC-
Ade-Trp-Leu+ ligand) data for yeast growth in the presence of 
9cRA (closed circles) and LG335 (open circles) for43 hours. 55 
FIGS. 3a-o are line graphs showing screen assay (SC-Trp-
Leu+ligand) data for ~-galactosidase activity with o-Nitro-
phenyl ~-D-galactopyranoside (ONPG) substrate in the pres-
ence of 9cRA (closed circles) and LG335 (open circles). 
Miller units normalize the change in absorbance at 405 nm for 60 
the change optical density at 630 nm, which reflects the 
number of cells per well. 
FIGS. 4a and bare line graphs showing data from mam-
malian cell culture using a luciferase reporter with wtRXR 
(solid circle), I268A;I310S;F313A;L436F (solid dot), I268V; 65 
A272V;I310M;F313S;L436M (inverted triangle), I268A; 
I310M;F313A;L436T (gray square), I268V;A272V;I310L; 
6 
F313M (upright triangle), or I268A;I310A;F313A;L436F 
(grey circle) in response to (a) 9cRA and (b) LG335. 
RLU=relative light units. 
FIGS. Sa-g are photographs of culture plates showing yeast 
transformed with bothACTR:GAD and GBD:RXR growing 
in the presence of various concentrations of 9cRA. 
FIGS. 6a-g are photographs of culture plates showing yeast 
transformed with both SRC-1 :GAD and GBD:RXR grow in 
the presence of various concentrations of 9cRA. 
FIGS. 7 a:f are photographs of culture plates showing nega-
tive selection of yeast transformed with bothACTR:GAD and 
GBD:RXR in the presence of various concentrations of 
9cRA. 
FIGS. Sa-t are photographs of culture plates showing 
growth due to the indicated transformants of variant GBD: 
RXRs due to various concentrations of 9cRA. 
FIGS. 9a-e are schematics of exemplary embodiments for 
the selection of desired transformants. 
FIG. 10 is a schematic ofan exemplary embodiment for the 
selection of selective receptor modulators in transformants 
incorporating a human nuclear receptor coactivator fused to a 
repression domain. 
FIG.11 is a schematic of an exemplary embodiment forthe 
selection of receptor antagonists. 
FIG. 12 is a schematic of an exemplary embodiment for 
chemical complementation selection of transformants to 
obtain isotype or isoform selective receptor agonists. 
FIG. 13 is a schematic of an exemplary embodiment for 
chemical complementation selection oftransformants incor-
porating a nuclear receptor coactivator fused to an activation 
domain for the selection of receptor agonists. 
FIG. 14 is a Ligplot depiction of hydrophobic interactions 
between the RXR LBD and 9cRA. 
FIGS. lSa-b show the structure of exemplary ligands used 
in chemical complementation of one embodiment. 
FIGS. l6a-b show schematics of exemplary methods for 
the construction of pGBDRXR:3stop (a) or an insert cassette 
library (b). 
FIGS. l 7a-b are diagrams of exemplary constructs accord-
ing to one embodiment of the present disclosure. 
FIG.18 shows schemes for creating a library ofreceptors to 
bind the desired small molecule. On the left is the scheme for 
creating the vector cassette and the variant receptors. Once 
these genes are made, they are introduced into yeast and put 
through chemical complementation shown to the right. If the 
variant receptor is able to bind and activate in response to the 
ligand, the yeast will be able to grow on media lacking 
adenine because the ADE2 will be turned on. Colonies that 
are able to grow on plates containing the small molecule and 
no adenine are "hits" and will then be sequenced and used for 
the next step. 
FIG. 19 schematically shows when cells grow on media 
lacking adenine with precursors A and B. 
FIG. 20 illustrates compounds targeted as ligands. 
FIG. 21 schematically shows nuclear receptors with 
genetic selection strategy for the directed evolution of amine 
dehydrogenases (AmDH). The nuclear receptor is a dimer 
bound to DNA at the Gal4 response element (GalRE) through 
the Gal4 DNA binding domain (DBD), regulating transcrip-
tion of an essential gene (either HIS3 or ADE2). First, a 
nuclear receptor ligand-binding domain (LBD) is engineered 
to activate transcription in response to the desired (R)-amine. 
Second, libraries of AmDH are transformed into the microbe 
and grown on media supplemented with the appropriate 
ketone. Only microbes with a functional AmDH that converts 
the ketone into the (R)-amine survive. 
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FIG. 22 schematically shows the pathway of the conver-
sion of an endogenous precursor molecule to an active vita-
min D that is able to interact with the human VDR. 
FIG. 23 is a series of digital images showing yeast growth 
on CM-His plates after 2 days at 30° C.All yeast on the plates 
were expressing the GBD:VDR andACTR:GAD fusion pro-
teins. Yeast in the four quadrants of the plates were also 
expressing: neither P450 enzyme, one of the P450 enzymes, 
8 
features of any of the other several embodiments without 
departing from the scope or spirit of the present disclosure. 
Any recited method can be carried out in the order of events 
recited or in any other order that is logically possible. 
Embodiments of the present disclosure will employ, unless 
otherwise indicated, techniques of medicine, organic chem-
istry, biochemistry, molecular biology, pharmacology, and 
the like, which are within the skill of the art. Such techniques 
or both P450 enzymes, according to the map shown on the 
left. The positive control plate in the center image contained 10 
1 nM calcitriol, a known VDR ligand, and did not require 
P450 enzyme activity for the yeast to express HIS3 and grow 
are explained fully in the literature. 
It must be noted that, as used in the specification and the 
appended claims, the singular forms "a," "an," and "the" 
include plural referents unless the context clearly dictates 
otherwise. Thus, for example, reference to "a support" 
includes a plurality of supports. In this specification and in the 
on the media lacking histidine. The plate on the right con-
tained no exogenous VDR ligand. In this case, only the quad-
rant with both P450 enzymes present in the yeast could syn-
thesize the ligand for VDR which then expressed HIS3 and 
grew on the media lacking histidine. 
15 claims that follow, reference will be made to a number of 
terms that shall be defined to have the following meanings 
unless a contrary intention is apparent. 
FIG. 24 schematically shows the relationships between the 
precursors of the ligand able to specifically bind to the VDR 
ligand binding domain, and the enzymes for the conversion of 20 
substrates to the final ligand molecules. 
As used herein, the following terms have the meanings 
ascribed to them unless specified otherwise. In this disclo-
sure, "comprises," "comprising," "containing" and "having" 
and the like can have the meaning ascribed to them in U.S. 
DETAILED DESCRIPTION 
Before the present disclosure is described in greater detail, 25 
it is to be understood that this disclosure is not limited to 
patent law and can mean "includes," "including," and the like; 
"consisting essentially of' or "consists essentially" or the 
like, when applied to methods and compositions encom-
passed by the present disclosure refers to compositions like 
those disclosed herein, but which may contain additional 
particular embodiments described, and as such may, of 
course, vary. It is also to be understood that the terminology 
used herein is for the purpose of describing particular 
embodiments only, and is not intended to be limiting, since 
the scope of the present disclosure will be limited only by the 
appended claims. 
Where a range of values is provided, it is understood that 
each intervening value, to the tenth of the unit of the lower 
limit unless the context clearly dictates otherwise, between 
the upper and lower limit of that range and any other stated or 
intervening value in that stated range, is encompassed within 
the disclosure. The upper and lower limits of these smaller 
ranges may independently be included in the smaller ranges 
and are also encompassed within the disclosure, subject to 
any specifically excluded limit in the stated range. Where the 
stated range includes one or both of the limits, ranges exclud-
ing either or both of those included limits are also included in 
the disclosure. 
Unless defined otherwise, all technical and scientific terms 
used herein have the same meaning as commonly understood 
structural groups, composition components or method steps 
(or analogs or derivatives thereof as discussed above). Such 
additional structural groups, composition components or 
30 method steps, etc., however, do not materially affect the basic 
and novel characteristic( s) of the compositions or methods, 
compared to those of the corresponding compositions or 
methods disclosed herein. "Consisting essentially of' or 
"consists essentially" or the like, when applied to methods 
35 and compositions encompassed by the present disclosure 
have the meaning ascribed in U.S. patent law and the term is 
open-ended, allowing for the presence of more than that 
which is recited so long as basic or novel characteristics of 
that which is recited is not changed by the presence of more 
40 than that which is recited, but excludes prior art embodi-
ments. 
Prior to describing the various embodiments, the following 
definitions are provided and should be used unless otherwise 
indicated. 
45 Definitions 
by one of ordinary skill in the art to which this disclosure 
belongs. Although any methods and materials similar or 
equivalent to those described herein can also be used in the 
practice or testing of the present disclosure, the preferred 50 
methods and materials are now described. 
The term "nucleic acid" as used herein refers to any natural 
and synthetic linear and sequential arrays of nucleotides and 
nucleosides, for example cDNA, genomic DNA, mRNA, 
tRNA, oligonucleotides, oligonucleosides and derivatives 
thereof. For ease of discussion, such nucleic acids may be 
collectively referred to herein as "constructs," "plasmids," or 
All publications and patents cited in this specification are 
herein incorporated by reference as if each individual publi-
cation or patent were specifically and individually indicated 
to be incorporated by reference and are incorporated herein 
by reference to disclose and describe the methods and/or 
materials in connection with which the publications are cited. 
The citation of any publication is for its disclosure prior to the 
filing date and should not be construed as an admission that 
the present disclosure is not entitled to antedate such publi-
cation by virtue of prior disclosure. Further, the dates of 
publication provided could be different from the actual pub-
lication dates that may need to be independently confirmed. 
"vectors." Representative examples of the nucleic acids of the 
present invention include bacterial plasmid vectors including 
expression, cloning, cosmid and transformation vectors such 
55 as, but not limited to, pBR322, animal viral vectors such as, 
but not limited to, modified adenovirus, influenza virus, polio 
virus, pox virus, retrovirus, and the like, vectors derived from 
bacteriophage nucleic acid, and synthetic oligonucleotides 
like chemically synthesized DNA or RNA. The term "nucleic 
60 acid" further includes modified or derivatizednucleotides and 
nucleosides such as, but not limited to, halogenated nucle-
otides such as, but not only, 5-bromouracil, and derivatized 
nucleotides such as biotin-labeled nucleotides. 
As will be apparent to those of skill in the art upon reading 
this disclosure, each of the individual embodiments described 65 
and illustrated herein has discrete components and features 
which may be readily separated from or combined with the 
The terms "polynucleotide," "oligonucleotide," and 
"nucleic acid sequence" are used interchangeably herein and 
include, but are not limited to, coding sequences (polynucle-
otide(s) or nucleic acid sequence( s) which are transcribed and 
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translated into polypeptide in vitro or in vivo when placed 
under the control of appropriate regulatory or control 
sequences); control sequences (e.g., translational start and 
stop codons, promoter sequences, ribosome binding sites, 
polyadenylation signals, transcription factor binding sites, 
transcription termination sequences, upstream and down-
stream regulatory domains, enhancers, silencers, and the 
like); and regulatory sequences (DNA sequences to which a 
transcription factor( s) binds and alters the activity of a gene's 
promoter either positively (induction) or negatively (repres-
sion)). No limitation as to length or to synthetic origin is 
suggested by the terms described herein. 
As used herein the terms "polypeptide" and "protein" refer 
to a polymer of amino acids of three or more amino acids in a 
serial array, linked through peptide bonds. The term 
"polypeptide" includes proteins, protein fragments, protein 
analogues, oligopeptides and the like. The term "polypep-
tides" contemplates polypeptides as defined above that are 
encoded by nucleic acids, produced through recombinant 
technology (isolated from an appropriate source such as a 
bird), or synthesized. The term "polypeptides" further con-
templates polypeptides as defined above that include chemi-
cally modified amino acids or amino acids covalently or non-
covalently linked to labeling ligands. 
The term "gene" or "genes" as used herein refers to nucleic 
acid sequences (including both RNA or DNA) that encode 
genetic information for the synthesis of a whole RNA, a 
whole protein, or any portion of such whole RNA or whole 
protein. Genes that are not naturally part of a particular organ-
ism's genome are referred to as "foreign genes," "heterolo-
gous genes" or "exogenous genes" and genes that are natu-
rally a part of a particular organism's genome are referred to 
as "endogenous genes". The term "gene product" refers to 
RN As or proteins that are encoded by the gene. "Foreign gene 
products" are RNA or proteins encoded by "foreign genes" 
and "endogenous gene products" are RNA or proteins 
encoded by endogenous genes. "Heterologous gene prod-
ucts" are RNAs or proteins encoded by "foreign, heterolo-
gous or exogenous genes" and are, therefore, not naturally 
expressed in the cell. 
The term "expressed" or "expression" as used herein refers 
to the transcription from a gene to give an RNA nucleic acid 
molecule at least complementary in part to a region of one of 
the two nucleic acid strands of the gene. The term "expressed" 
or "expression" as used herein also refers to the translation 
from said RNA nucleic acid molecule to give a protein, a 
polypeptide, or a portion or fragment thereof. 
10 
of the vector DNA. The "transcription modulating system" 
may precede, but is not limited to, the region of a nucleic acid 
sequence that is in the region 5' of the end of a protein coding 
sequence that may be transcribed into mRNA. Transcrip-
tional regulatory sequences may also be located within a 
protein coding region, in regions of a gene that are identified 
as "intron" regions, or may be in regions of nucleic acid 
sequence that are in the region of nucleic acid. 
The term "promoter" as used herein refers to the DNA 
10 sequence that determines the site of transcription initiation 
from an RNA polymerase. A "promoter-proximal element" 
may be a regulatory sequence within about 200 base pairs of 
the transcription start site. 
The term "coding region" as used herein refers to a con-
15 tinuous linear arrangement of nucleotides that may be trans-
lated into a protein. A full length coding region is translated 
into a full length protein; that is, a complete protein as would 
be translated in its natural state absent any post-translational 
modifications. A full length coding region may also include 
20 any leader protein sequence or any other region of the protein 
that may be excised naturally from the translated protein. 
The term "expression vector" as used herein refers to a 
nucleic acid vector that comprises a gene expression control 
region operably linked to a nucleotide sequence coding at 
25 least one polypeptide. As used herein, the term "regulatory 
sequences" includes promoters, enhancers, and other ele-
ments that may control gene expression. Standard molecular 
biology textbooks (for example, Sambrook et al., eds., 1989, 
"Molecular Cloning: A Laboratory Manual," 2nd ed., Cold 
30 Spring Harbor Press) may be consulted to design suitable 
expression vectors that may further include an origin of rep-
lication and selectable gene markers. It should be recognized, 
however, that the choice of a suitable expression vector and 
the combination of functional elements therein depends upon 
35 multiple factors including the choice of the host cell to be 
transformed and/or the type of protein to be expressed. 
The terms "transformation" and "transfection" as used 
herein refer to the process of inserting a nucleic acid into a 
host. Many techniques are well known to those skilled in the 
40 art to facilitate transformation ortransfection of a nucleic acid 
into a prokaryotic or eukaryotic organism. These methods 
involve a variety of techniques, such as treating the cells with 
high concentrations of salt such as, but not only, a calcium or 
magnesium salt, an electric field, detergent, or liposome 
45 mediated transfection, to render the host cell competent for 
the uptake of the nucleic acid molecules, and by such methods 
as sperm-mediated and restriction-mediated integration. 
The term "recombinant cell" refers to a cell that has a new 
combination of nucleic acid segments that are not covalently 
50 linked to each other in nature. A new combination of nucleic 
The term "operably linked" refers to an arrangement of 
elements wherein the components so described are config-
ured so as to perform their usual function. Control sequences 
operably linked to a coding sequence are capable of effecting 
the expression of the coding sequence. The control sequences 
need not be contiguous with the coding sequence, so long as 
they function to direct the expression thereof. Thus, for 
example, intervening untranslated yet transcribed sequences 55 
can be present between a promoter sequence and the coding 
sequence and the promoter sequence can still be considered 
"operably linked" to the coding sequence. 
acid segments can be introduced into an organism using a 
wide array of nucleic acid manipulation techniques available 
to those skilled in the art. A recombinant cell can be a single 
enkaryotic cell, or a single prokaryotic cell, or a manimalian 
cell. The recombinant cell may harbor a vector that is extrage-
nomic. An extragenomic nucleic acid vector does not insert 
into the cell's genome. A recombinant cell may further harbor 
a vector or a portion thereof that is intragenomic. The term 
intragenomic defines a nucleic acid construct incorporated 
within the recombinant cell's genome. 
The term "transcription modulating system" as used herein 
refers to nucleotide sequences that are associated with a gene 60 
nucleic acid sequence and which regulate the transcriptional 
expression of the gene. Exemplary transcription regulatory 
sequences include enhancer elements, hormone response ele-
ments, steroid response elements, negative regulatory ele-
ments, and the like. The "transcription modulating system" 65 
may be isolated and incorporated into a vector nucleic acid to 
enable regulated transcription in appropriate cells of portions 
The terms "recombinant nucleic acid" and "recombinant 
DNA" as used herein refer to combinations of at least two 
nucleic acid sequences that are not naturally found in a 
enkaryotic or prokaryotic cell. The nucleic acid sequences 
include, but are not limited to, nucleic acid vectors, gene 
expression regulatory elements, origins of replication, suit-
able gene sequences that when expressed confer antibiotic 
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resistance, protein-encoding sequences, and the like. The 
term "recombinant polypeptide" is meant to include a 
polypeptide produced by recombinant DNA techniques such 
that it is distinct from a naturally occurring polypeptide either 
in its location, purity or structure. Generally, such a recom-
binant polypeptide will be present in a cell in an amount 
different from that normally observed in nature. 
12 
The term "polypeptides" includes proteins and fragments 
thereof. Polypeptides are disclosed herein as amino acid resi-
due sequences. Those sequences are written left to right in the 
direction from the amino to the carboxy terminus. In accor-
dance with standard nomenclature, amino acid residue 
sequences are denominated by either a three letter or a single 
letter code as indicated as follows: Alanine (Ala, A), Arginine 
(Arg, R), Asparagine (Asn, N), Aspartic Acid (Asp, D), Cys-
teine (Cys, C), Glutamine (Gin, Q), Glutamic Acid (Glu, E), 
The term "non-natural" means not typically found in 
nature including those items modified by man. Non-natural 
includes chemically modified subunits such as nucleotides as 
well as biopolymers having non-natural linkages, backbones, 
or substitutions. 
10 Glycine (Gly, G), Histidine (His, H), Isoleucine (Ile, I), Leu-
cine (Leu, L), Lysine (Lys, K), Methionine (Met, M), Pheny-
lalanine (Phe, F), Praline (Pro, P), Serine (Ser, S), Threonine 
(Thr, T), Tryptophan (Trp, W), Tyrosine (Tyr, Y), and Valine Oligonucleotides may also include nucleobase (often 
referred to in the art simply as "base") modifications or sub-
stitutions. As used herein, "urnnodified" or "natural" nucleo- 15 
bases include the purine bases adenine (A) and guanine (G), 
and the pyrimidine bases thymine (T), cytosine (C) and uracil 
(U). Modified nucleobases include other synthetic and natu-
(Val, V). 
"Variant" refers to a polypeptide or polynucleotide that 
differs from a reference polypeptide or polynucleotide, but 
retains essential properties. A typical variant of a polypeptide 
differs in amino acid sequence from another, reference 
polypeptide. Generally, differences are limited so that the ral nucleobases such as 5-methylcytosine (5-me-C), 5-hy-
droxymethyl cytosine, xanthine, hypoxanthine, 2-aminoad-
enine, 6-methyl and other alkyl derivatives of adenine and 
guanine, 2-propyl and other alkyl derivatives of adenine and 
guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 
5-halouracil and cytosine, 5-propynyl uracil and cytosine and 
other alkynyl derivatives of pyrimidine bases, 6-azo uracil, 
cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 
8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 
8-substituted adenines and guanines, 5-halo particularly 
5-bromo, 5-trifluoromethyl and other 5-substituted uracils 
and cytosines, 7-methylguanine and 7-methyladenine, 2-F-
adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 
7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 
3-deazaadenine. Further modified nucleobases include tricy-
clic pyrimidines such as phenoxazine cytidine(lH-pyrimido 
[5,4-b][l,4]benzoxazin-2(3H)-one), phenothiazine cytidine 
(lH-pyrimido[ 5,4-b] [ 1,4 ]benzothiazin-2(3H)-one ), 
20 sequences of the reference polypeptide and the variant are 
closely similar overall and, in many regions, identical. A 
variant and reference polypeptide may differ in amino acid 
sequence by one or more modifications (e.g., substitutions, 
additions, and/or deletions). A substituted or inserted amino 
25 acid residue may or may not be one encoded by the genetic 
code. A variant of a polypeptide may be naturally occurring 
such as an allelic variant, or it may be a variant that is not 
known to occur naturally. 
Modifications and changes can be made in the structure of 
30 the polypeptides of in disclosure and still obtain a molecule 
having similar characteristics as the polypeptide (e.g., a con-
servative amino acid substitution). For example, certain 
amino acids can be substituted for other amino acids in a 
sequence without appreciable loss of activity. Because it is the 
35 interactive capacity and nature of a polypeptide that defines 
that polypeptide's biological functional activity, certain 
amino acid sequence substitutions can be made in a polypep-
tide sequence and nevertheless obtain a polypeptide with like 
G-clamps such as a substituted phenoxazine cytidine (e.g., 
9-(2-aminoethoxy)-H-pyrimido[ 5,4-b] [ 1,4 ]benzoxazin-2 
(3H)-one ), carbazole cytidine (2H-pyrimido[ 4,5-b ]indol-2-
one ), pyridoindole cytidine (H-pyrido[3',':4,5]pyrrolo[2,3-d] 40 
pyrimidin-2-one). Modified nucleobases may also include 
those in which the purine or pyrimidine base is replaced with 
other heterocycles, for example 7-deaza-adenine, 7-deaza-
guanosine, 2-aminopyridine and 2-pyridone. Further nucleo-
bases include those disclosed in U.S. Pat. No. 3,687,808, 45 
those disclosed in The Concise Encyclopedia of Polymer 
Science and Engineering, pages 858-859, Kroschwitz, J. I., 
ed. John Wiley & Sons, 1990, those disclosed by Englisch et 
al., Angewandte Chemie, International Edition, 1991, 30, 
613, and those disclosed by Sanghvi, Y. S., Chapter 15, Anti- 50 
sense Research and Applications, pages 289-302, Crooke, S. 
T. and Lebleu, B., ed., CRC Press, 1993. Certain of these 
nucleobases may be particularly useful for increasing the 
binding affinity of the oligomeric compounds of the disclo-
sure. These include 5-substituted pyrimidines, 6-azapyrim- 55 
idines and N-2, N-6 and 0-6 substituted purines, including 
2-aminopropyladenine, 5-propynyluracil and 5-propynylcy-
tosine. 5-methylcytosine substitutions have been shown to 
increase nucleic acid duplex stability by 0.6-1.2° C. (Sanghvi, 
Y. S., Crooke, S. T. and Lebleu, B., eds., Antisense Research 60 
and Applications, CRC Press, Boca Raton, 1993, pp. 276-
278) and are presently preferred base substitutions, even 
more particularly when combined with 2'-0-methoxyethyl 
sugar modifications. 
The terms "including", "such as", "for example" and the 65 
like are intended to refer to exemplary embodiments and not 
to limit the scope of the present disclosure. 
properties. 
In making such changes, the hydropathic index of amino 
acids can be considered. The importance of the hydropathic 
amino acid index in conferring interactive biologic function 
on a polypeptide is generally understood in the art. It is known 
that certain amino acids can be substituted for other amino 
acids having a similar hydropathic index or score and still 
result in a polypeptide with similar biological activity. Each 
amino acid has been assigned a hydropathic index on the basis 
of its hydrophobicity and charge characteristics. Those indi-
ces are: isoleucine ( +4.5); valine ( +4.2); leucine ( +3.8); phe-
nylalanine ( +2.8); cysteine/cysteine ( +2.5); methionine 
(+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); 
serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); praline 
(-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); 
aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and argin-
ine (-4.5). 
It is believed that the relative hydropathic character of the 
amino acid determines the secondary structure of the result-
ant polypeptide, which in turn defines the interaction of the 
polypeptide with other molecules, such as enzymes, sub-
strates, receptors, antibodies, antigens, and the like. It is 
known in the art that an amino acid can be substituted by 
another amino acid having a similar hydropathic index and 
still obtain a functionally equivalent polypeptide. In such 
changes, the substitution of amino acids whose hydropathic 
indices are within ±2 is preferred, those within ±1 are par-
ticularly preferred, and those within ±0.5 are even more par-
ticularly preferred. 
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Substitution of like amino acids can also be made on the 
basis of hydrophilicity, particularly, where the biological 
functional equivalent polypeptide or peptide thereby created 
is intended for use in immunological embodiments. The fol-
lowing hydrophilicity values have been assigned to amino 
acid residues: arginine ( +3.0); lysine ( +3.0); aspartate 
(+3.0±1); glutamate (+3.0±1); serine (+0.3); asparagine 
14 
( +0.2); glutamine ( +0.2); glycine (O); pro line (-0.5±1 ); threo-
nine (-0.4); alanine (-0.5); histidine (-0.5); cysteine (-1.0); 
methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine 
(-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan 
(-3.4). It is understood that an amino acid can be substituted 
for another having a similar hydrophilicity value and still 
obtain a biologically equivalent, and in particular, an immu-
nologically equivalent polypeptide. In such changes, the sub-
stitution of amino acids whose hydrophilicity values are 
within ±2 is preferred, those within ±1 are particularly pre-
ferred, and those within ±0.5 are even more particularly pre-
ferred. 
the% identity is less than 100%. Such alterations are selected 
from: at least one amino acid deletion, substitution, including 
conservative and non-conservative substitution, or insertion, 
and wherein said alterations may occur at the amino- or 
carboxy-terminal positions of the reference polypeptide 
sequence or anywhere between those terminal positions, 
interspersed either individually among the amino acids in the 
reference sequence or in one or more contiguous groups 
within the reference sequence. The number of amino acid 
10 
alterations for a given% identity is determined by multiply-
ing the total number of amino acids in the reference polypep-
tide by the numerical percent of the respective percent iden-
tity (divided by 100) and then subtracting that product from 
15 said total number of amino acids in the reference polypeptide. 
As used herein, the term "transfection" refers to the intro-
duction of a nucleic acid sequence into the interior of a mem-
brane enclosed space of a living cell, including introduction 
of the nucleic acid sequence into the cytosol of a cell as well 
As outlined above, amino acid substitutions are generally 
based on the relative similarity of the amino acid side-chain 
substituents, for example, their hydrophobicity, hydrophilic-
ity, charge, size, and the like. Exemplary substitutions that 
take various of the foregoing characteristics into consider-
ation are well known to those of skill in the art and include 
(original residue: exemplary substitution): (Ala: Gly, Ser), 
(Arg: Lys), (Asn: Gin, His), (Asp: Glu, Cys, Ser), (Gln:Asn), 
(Glu: Asp), (Gly: Ala), (His: Asn, Gin), (Ile: Leu, Val), (Leu: 
20 as the interior space of a mitochondria, nucleus or chloro-
plast. The nucleic acid may be in the form of naked DNA or 
RNA, associated with various proteins or the nucleic acid 
may be incorporated into a vector. 
The term "selective agent" refers to a substance that is 
Ile, Val), (Lys: Arg), (Met: Leu, Tyr), (Ser: Thr), (Thr: Ser), 
(Tip: Tyr), (Tyr: Trp, Phe), and (Val: Ile, Leu). Embodiments 
of this disclosure thus contemplate functional or biological 
equivalents of a polypeptide as set forth above. In particular, 
embodiments of the polypeptides can include variants having 
about 50%, 60%, 70%, 80%, 90%, and 95% sequence identity 
to the polypeptide of interest. 
25 required for growth or for preventing growth of a cell or 
microorganism, for example cells or microorganisms that 
have been engineered to require a specific substance for 
growth or inhibit or reduce growth in the absence of a comple-
menting factor. Exemplary complementing factors include 
30 enzymes that degrade the selective agent, or enzymes that 
produce a selective agent. Generally, selective agents include, 
but are not limited to amino acids, antibiotics, nucleic acids, 
minerals, nutrients, etc. Selective media generally refers to 
culture media deficient in at least one substance, for example 
35 a selective agent, required for growth. The addition of a 
selective agent to selective media results in media sufficient 
for growth. 
"Identity," as known in the art, is a relationship between 
two or more polypeptide sequences, as determined by com-
paring the sequences. In the art, "identity" also means the 
degree of sequence relatedness between polypeptide as deter-
mined by the match between strings of such sequences. 40 
"Identity" and "similarity" can be readily calculated by 
known methods, including, but not limited to, those described 
in (Computational Molecular Biology, Lesk, A. M., Ed., 
Oxford University Press, New York, 1988; Biocomputing: 
Informatics and Genome Projects, Smith, D. W., Ed., Aca- 45 
demic Press, New York, 1993; Computer Analysis of 
Sequence Data, Part I, Griffin, A. M., and Griffin, H. G., Eds., 
Humana Press, New Jersey, 1994; Sequence Analysis in 
Molecular Biology, von Heinje, G., Academic Press, 1987; 
and Sequence Analysis Primer, Gribskov, M. and Devereux, 50 
J., Eds., M Stockton Press, New York, 1991; and Carillo, H., 
and Lipman, D., SIAM J Applied Math., 48: 1073 (1988). 
Preferred methods to determine identity are designed to 
give the largest match between the sequences tested. Methods 
to determine identity and similarity are codified in publicly 55 
available computer programs. The percent identity between 
two sequences can be determined by using analysis software 
(i.e., Sequence Analysis Software Package of the Genetics 
Computer Group, Madison Wis.) that incorporates the 
Needelman and Wunsch, (J. Mo!. Biol., 48: 443-453, 1970) 60 
algorithm (e.g., NBLAST, and XBLAST). The default 
parameters are used to determine the identity for the polypep-
tides of the present invention. 
By way of example, a polypeptide sequence may be iden-
tical to the reference sequence, that is be 100% identical, or it 65 
may include up to a certain integer number of amino acid 
alterations as compared to the reference sequence such that 
As used herein, the term "coregulator" refers to a transcrip-
tion modulator. 
"Polymerase chain reaction" or "PCR" refers to a ther-
mocyclic, polymerase-mediated, DNA amplification reac-
tion. A PCR typically includes template molecules, oligo-
nucleotide primers complementary to each strand of the 
template molecules, a thermostable DNA polymerase, and 
deoxyribonucleotides, and involves three distinct processes 
that are multiply repeated to effect the amplification of the 
original nucleic acid. The three processes ( denaturation, 
hybridization, and primer extension) are often performed at 
distinct temperatures, and in distinct temporal steps. In many 
embodiments, however, the hybridization and primer exten-
sion processes can be performed concurrently. The nucleotide 
sample to be analyzed may be PCR amplification products 
provided using the rapid cycling techniques described in U.S. 
Pat. Nos. 6,569,672; 6,569,627; 6,562,298; 6,556,940; 6,569, 
672; 6,569,627; 6,562,298; 6,556,940; 6,489,112; 6,482,615; 
6,472,156; 6,413,766; 6,387,621; 6,300,124; 6,270,723; 
6,245,514; 6,232,079; 6,228,634; 6,218,193; 6,210,882; 
6,197,520; 6,174,670; 6,132,996; 6,126,899; 6,124,138; 
6,074,868; 6,036,923; 5,985,651; 5,958,763; 5,942,432; 
5,935,522; 5,897,842; 5,882,918; 5,840,573; 5,795,784; 
5,795,547; 5,785,926; 5,783,439; 5,736,106; 5,720,923; 
5,720,406; 5,675,700; 5,616,301; 5,576,218 and 5,455,175, 
the disclosures of which are incorporated by reference in their 
entireties. Other methods of amplification include, without 
limitation, NASBR, SDA, 3SR, TSA and rolling circle repli-
cation. It is understood that, in any method for producing a 
polynucleotide containing given modified nucleotides, one or 
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several polymerases or amplification methods may be used. 
The selection of optimal polymerization conditions depends 
on the application. 
A "polymerase" is an enzyme that catalyzes the sequential 
addition of monomeric units to a polymeric chain, or links 
two or more monomeric units to initiate a polymeric chain. In 
advantageous embodiments of this invention, the "poly-
merase" will work by adding monomeric units whose identity 
is determined by and which is complementary to a template 
molecule of a specific sequence. For example, DNA poly- 10 
merases such as DNA pol 1 and Taq polymerase add deox-
yribonucleotides to the 3' end of a polynucleotide chain in a 
template-dependent manner, thereby synthesizing a nucleic 
acid that is complementary to the template molecule. Poly-
merases may be used either to extend a primer once or repeti- 15 
tively or to amplify a polynucleotide by repetitive priming of 
two complementary strands using two primers. 
A "restriction enzyme" refers to an endonuclease (an 
enzyme that cleaves phosphodiester bonds within a poly-
nucleotide chain) that cleaves DNA in response to a recogni- 20 
ti on site on the DNA. The recognition site (restriction site) 
consists of a specific sequence of nucleotides typically about 
4-8 nucleotides long. 
As used herein, a "template" refers to a target polynucle-
otide strand, for example, without limitation, an unmodified 25 
naturally-occurring DNA strand, which a polymerase uses as 
a means of recognizing which nucleotide it should next incor-
porate into a growing strand to polymerize the complement of 
the naturally-occurring strand. Such DNA strand may be 
single-stranded or it may be part of a double-stranded DNA 30 
template. In applications of the present invention requiring 
repeated cycles of polymerization, e.g., the polymerase chain 
reaction (PCR), the template strand itself may become modi-
fied by incorporation of modified nucleotides, yet still serve 
as a template for a polymerase to synthesize additional poly- 35 
nucleotides. 
A "thermocyclic reaction" is a multi-step reaction wherein 
at least two steps are accomplished by changing the tempera-
ture of the reaction. 
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tions may be made to the above-described embodiment(s) 
without departing substantially from the spirit and principles 
of the disclosure. All such modifications and variations are 
intended to be included herein within the scope of this dis-
closure and protected by the following claims. 
Description 
Methods and compositions for engineering proteins are 
provided, in particular, methods for engineering proteins that 
interact with a target compound. Embodiments of the disclo-
sure combine chemical complementation with genetic selec-
tion to engineer proteins, polypeptides, enzymes, cellular 
nuclear receptors, and the like. Typically, any protein or 
polypeptide that interacts with a small molecule can be engi-
neered or modified using the disclosed methods and systems. 
Exemplary proteins include, but are not limited to enzymes, 
antibodies, cell surface receptors, polypeptides involved in 
signal transduction pathways, intracellular polypeptides, 
secreted polypeptides, and transmembrane polypeptides. In 
some embodiments, the polypeptides interact with a small 
molecule that is produced naturally, such as an endogenously 
synthesized compound that may be converted to a ligand 
molecule that specifically interacts with a nuclear receptor 
ligand binding domain. Representative naturally produced 
small molecules include but are not limited to, neurotrans-
mitters, cAMP, cGMP, steroids, purines, pyrimidines, hetero-
cyclic compounds, ATP, DAG, IP3, inositol, calcium ions, 
magnesium ions, vitamins, minerals, and combinations 
thereof. Some embodiments provide methods and systems for 
engineering proteins, and in particular enzymes, that distin-
guish between optical isomers of a target compound. 
Other embodiments provide a more efficient manimalian 
model system in yeast for evaluating protein/ligand interac-
tions, and can be utilized in an array of applications including 
but not limited to, drug discovery. Nuclear receptors are 
implicated in diseases such as diabetes and various cancers. 
Agonists and antagonists for these nuclear receptors serve as 
drugs. With chemical complementation, libraries of com-
pounds can be screened as potential agonists, as described 
A "thermostable polymerase" refers to a DNA or RNA 
polymerase enzyme that can withstand extremely high tem-
peratures, such as those approaching 100° C. Often, thermo-
stable polymerases are derived from organisms that live in 
extreme temperatures, such as Thermus aquaticus. Examples 
40 herein. In some embodiments, antagonists can be identified 
with negative chemical complementation. Chemical comple-
mentation can also be extended to identify isotype-selective 
agonists and antagonists and used for the discovery of selec-
tive receptor modulators (e.g., SERMs). 
of thermostable polymerases include Taq, Tth, Pfu, Vent, 45 
deep vent, U!Tma, and variations and derivatives thereof. 
In addition to drug discovery, the increase in sensitivity of 
disclosed systems and methods also provides a method for 
engineering receptors to recognize small molecules. For 
example, libraries of engineered receptors can be transformed 
into yeast and plated onto media containing an exogenous 
The term "exogenous" as used herein refers to a compound 
that is introduced to the interior of a cell such as a yeast cell 
from the surrounding environment such as a culture medium 
and is not the product of a metabolic or enzymic reaction 
within the cell. 
The term "endogenous" as used herein refers to a com-
pound that is the product of a metabolic or enzymic reaction 
within the cell. 
Further definitions are provided in context below. Unless 
otherwise defined, all technical and scientific terms used 
herein have the same meaning as commonly understood by 
one of ordinary skill in the art of molecular biology. Although 
methods and materials similar or equivalent to those 
described herein can be used in the practice or testing of the 
present invention, suitable methods and materials are 
described herein. 
It should be emphasized that the embodiments of the 
present disclosure, particularly, any "preferred" embodi-
ments, are merely possible examples of implementations, 
merely set forth for a clear understanding of the principles of 
the disclosed subject matter. Many variations and modifica-
50 target ligand. These engineered receptors can be used for 
controlling transcription in mammalian cells, and potentially 
applied towards gene therapy. Furthermore, some embodi-
ments of the disclosed system can give insight into the general 
mechanism for understanding the fundamentals of protein 
55 structure and function. 
The addition of an adapter protein consisting of a human 
coactivator fused to a yeast transcriptional activator has now 
been shown to increase the sensitivity of chemical comple-
mentation with RXR 1000-fold, enhancing the system so that 
60 it is indistinguishable from activation by Gal4. Negative 
chemical complementation was performed in a different 
yeast strain, showing the versatility of the system, useful for 
performing chemical complementation with various select-
able markers. This system may be extended to other human or 
65 mammalian nuclear receptor proteins, plus nuclear receptors 
from other organisms, and the coactivators and corepressors 
with which they interact. 
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Embodiments of the present disclosure comprise chemical 
complementation systems focusing on a target ligand and 
utilize the power of genetic selection to reveal proteins within 
the library that bind and activate transcription in response to 
that small molecule. It is contemplated, for example, that 
functional receptors from a large pool of non-functional vari-
ants can be isolated, even from a non-optimized library. 
18 
tionarily closely related receptors (e.g., thyroid hormone 
receptor and retinoic acid receptor) bind different ligands, 
whereas some members of distant subfamilies (e.g., RXR and 
retinoic acid receptor) have affinity for the same ligand. This 
diversity of ligand-receptor interactions suggests that it 
should be possible to engineer LBDs with a large range of 
novel specificities. 
Chemical complementation is a method which links the 
proliferation of a yeast to the presence of a small molecule. 
This process allows high-throughput testing oflarge libraries. 
Hundreds of thousands to billions of variants can be assayed 
The crystal structure of RXR bound to 9cRA elucidates 
important hydrophobic and polar interactions in the LBD 
10 binding pocket. A subset of 20 hydrophobic and polar amino 
acids within 4.4 A of the bound 9cRA can be varied to make 
in one experiment without the spatial resolution necessary for 
traditional screening methods (e.g., no need for one colony 
per well). Cells expressing active variants will grow into 
colonies. Survivors can then be spatially resolved i.e. cloned 15 
(e.g. transferred to a microplate, one colony per well) for 
further characterization, decreasing the time and effort 
required to find new ligand-receptor pairs. 
A chemical complementation can identify a plurality of 
nuclear receptors with a variety of responses to a specific 20 
ligand. Nuclear receptors that activate transcription in 
response to a specific ligand and not to endogenous com-
pounds have several additional potential applications. The 
ability to switch a gene on and off in response to a desired 
compound can be used to build complex metabolic pathways, 25 
gene networks, and to create conditional knockouts and phe-
notypes in cell lines and animals. This ability can also be 
useful in gene therapy and in agriculture to control expression 
of therapeutic, pesticidal, or other genes. A variety of 
responses would be useful in engineering biosensor arrays: an 30 
array of receptors with differing activation profiles for a spe-
cific ligand could provide concentration measurements and 
increased accuracy of detection. 
The ability to engineer proteins that activate transcription 
in response to a desired compound with a variety of activation 35 
profiles provides a method of identifying enzymes. Receptors 
that bind the product of a desired enzymatic reaction can be 
used to select or screen for enzymes or modified enzymes that 
perform this reaction. The enzymes may be natural or engi-
neered. The stringency of the assay can be adjusted by using 40 
ligand-receptor pairs with lower or higher EC50 . 
The human retinoid X receptor (RXR) is a ligand-activated 
transcription factor of the nuclear receptor superfamily. RXR 
plays an important role in mammalian morphogenesis and 
differentiation and serves as a dimerization partner for other 45 
nuclear receptors. Like most nuclear receptors, RXR has two 
structural domains: the DNA binding domain (DBD) and the 
ligand binding domain (LBD), which are connected by a 
flexible hinge region. 
The DBD contains two zinc modules, which bind a 50 
sequence of six bases. The LBD has affinity for a small 
molecule ligand, including phytanic acid, docasahexaenoic 
acid and 9-cis retinoic acid (9cRA) with which it may bind, 
thereby activating transcription. 
RXR is a modular protein; with the DBD and LBD func- 55 
tioning independently. Therefore, the RXR LBD can be fused 
to a DBD from another source and retain functionality. A 
conformational change is induced in the LBD upon ligand 
binding, which initiates recruitment of coactivators and the 
basal transcription machinery resulting in transcription of the 60 
target gene. 
Nuclear receptors have evolved to bind and activate tran-
scription in response to a variety of small molecule ligands. 
The known ligands for nuclear receptors are chemically 
diverse, including, but not limited to, steroid and thyroid 65 
hormones, vitamin D, prostaglandins, fatty acids, leukot-
rienes, retinoids, antibiotics, and other xenobiotics. Evolu-
a library. These residues in RXR are good candidates for 
creating variants that can bind different ligands through site 
directed mutagenesis, because side chain atoms, not main 
chain atoms, contribute the majority of the ligand contacts. It 
is contemplated that a library ofRXR LBDs with all 20 amino 
acids at each of the 20 positions in the ligand-binding pocket, 
when screened against multiple compounds, could produce 
many new ligand-receptor pairs. It is further contemplated 
that other LBDs from other nuclear receptors can likewise be 
varied and screened against a target ligand. 
Codon randomization creates protein libraries with muta-
tions at specific sites. In one embodiment, a modified version 
of the Sauer codon randomization method to create a library 
of binding pocket variants of RXR is provided. This library 
allowed exploration of a vast quantity of sequence space in a 
minimal amount of time. 
Chemical complementation allows testing for the activa-
tion of protein variants by specific ligands using genetic 
selection. In one embodiment LG335, a synthetic retinoid-
like compound, was used as a model for the discovery of 
ligand-receptor pairs from large libraries using chemical 
complementation. LG335 was previously shown to selec-
tively activate an RXR variant and not activate wild-type 
RXR. Combining chemical complementation with a large 
library of protein variants decreases the time, effort, and 
resources necessary to find new ligand-receptor pairs. 
Enzyme Engineering 
The present disclosure encompasses methods and compo-
sitions for engineering a polypeptide or system of polypep-
tides, for example an enzyme( s ), to produce or interact with a 
desired molecule. Generally, a desired molecule of interest 
(or the reaction product) is selected, together with a suitable 
corresponding nuclear receptor. Modifications to the target 
nuclear receptor can be designed. For example, the X-ray 
structure of the target nuclear receptor can be loaded into a 
modeling program including, but not limited to, INSIGHT® 
or FLEXX®, along with the structure of the desired target 
molecule. Specific in silica interactions of the target receptor 
with the target molecule/ligand can be analyzed and those 
amino acids that may contribute to the ligand binding can be 
noted for modification. Generally, a nuclear receptor is 
selected that has at least a detectable amount of interaction 
with the target molecule or ligand or a binding pocket of a 
similar size and shape. The interaction can then be modulated 
as desired by creating a library of modified receptors. 
To create the library, site-specific codon randomization can 
be used. It will be appreciated that any process for generating 
a library of modified receptors can be used. Site-specific 
codon randomization involves modifying the amino acids 
identified through modeling as having or believed to have 
direct or indirect interactions with the ligand. When produc-
ing or designing the oligonucleotide, in place of those amino 
acids, there will be a degenerate code based on the combina-
tion of nucleotides that are desired. For example, if the modi-
fication can be a change from alanine to a cysteine, leucine, 
phenylalanine, isoleucine, threonine, serine, valine and 
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methionine. The nucleotide sequence for the alanine is GCC 
and to possibly incorporate all of the desired amino acids 
mentioned above, the following changes in each position 
must be made: 
G 
T 
A 
G 
c 
2 
T 
c 
c 
G 
c 
The oligonucleotide can be designed to have either a T, A, 
or Gin the first position, a T or C in the second position, and 
a G or C in the third position. For example, if a TTG (one of 
the combinations above) is in place of the GCC, a leucine 
would be incorporated instead of the alariiiie:-Therefore, 
when the oligos are synthesized, there would be the possibil-
ity of a T, A, or G in the first position, a T or C in the second 
position, and a G or C in the third position. The oligonucle-
otides may be designed to include insertions or deletions. The 
oligonucleotides have ends that are homologous to the vector 
in which the gene will be introduced to. 
To create a receptor library, the vector into which the gene 
will be incorporated will be cut with restriction enzymes, 
deleting a fragment of the wild-type gene. Oligonucleotides 
will be designed with homologous ends to the vector as men-
tioned above, but these oligonucleotides will also be designed 
such that they overlap each other. The overlapping ends will 
hybridize to each other, and using for example the enzyme 
Kienow, the ends are filed in. Then, using the polymerase 
chain reaction (PCR) the full gene or a fragment thereof will 
be amplified. The vector and gene can be introduced into 
yeast using transformation protocols, such as those of Gietz et 
al. ((2002) Meth. Enzymol. 350: 87-96). During transforma-
tion, the vector and gene or gene fragment will homologously 
recombine, and the various nuclear receptor mutants will be 
expressed. 
To select for variants that bind a desired small molecule, 
chemical complementation is be used. Chemical complemen-
tation is a general method of linking any small molecule to 
genetic selection. Chemical complementation is a derivative 
of the yeast two-hybrid system, where in a three-component 
system that in one embodiment comprises a human nuclear 
receptor protein, its coactivator protein, and a small molecule 
ligand, where the nuclear receptor and coactivator associate 
and activate transcription only in the presence of the ligand. 
An exemplary yeast strain contains a Gal4 response element 
fused to the ADE2 gene. It is contemplated, however, that a 
suitable transcription control element such as, but not limited 
to, Gal4 may be operably linked to any gene or gene cluster 
that can be expressed under the regulatory control of the 
transcription element. For example only, in place of ADE2, 
HIS3 may be used, allowing growth of the yeast host histidine 
auxotroph in the absence of an exogenous histidine supply. 
If adenine is not provided in the medium, the yeast will not 
be able to proliferate unless they are able to make their own, 
and to do that, expression ofADE2 needs to be activated. The 
following exemplary plasmids can be utilized: 1st plasmid 
encodes a fusion protein of the Gal4 DNA binding domain 
(Gal4 DBD) fused to the variant receptor ligand-binding 
domain (LBD); the other fusion protein comprises a human 
coactivator protein fused to the Gal4 activation domain. In the 
presence ofligand, the ligand will bind to the variant receptor 
ligand-binding domain and the Gal4 DNA binding domain 
20 
will bind to the Gal4 response element. This will cause the 
protein to undergo a conformational change, and will recruit 
the coactivator fused to the Gal4 activation domain. This, in 
turn, will result in RNA polymerase being recruited and acti-
vation of transcription of the downstream gene. 
The transformed yeast from above can be plated onto a 
culture medium containing the desired small molecule. 
Through chemical complementation, the variant receptor that 
is able to bind the desired molecule and activate the ADE2 
10 gene allows that yeast clone to grow. The plasmid from that 
colony will be rescued and sequenced and an engineered 
receptor will be identified and can be carried on to the next 
step. It will be appreciated that there may be many variant 
receptors that allow the yeast to grow without binding the 
15 targeted ligand. For example, they may be constitutively 
active or bind an endogenous small molecule ligand. These 
receptors may be identified through screening without the 
targeted ligand being present. Alternatively, they may be 
removed from the library by negative genetic selection on 
20 media without the targeted ligand, either before or after 
chemical complementation. Once an engineered receptor has 
been created, this gene can be integrated into the yeast 
genome, for example via homologous recombination. This 
will create a new strain useful in the following process. 
25 Once the receptor that can bind the small molecule has 
been identified, individual enzymes or a library of enzymes 
can be evaluated to generate a product of interest. Libraries of 
naturally occurring enzymes, for example expression cDNA 
libraries, may be evaluated. Also, libraries of enzymes can be 
30 created using a number of mutagenic protocols, such as DNA 
shuffling, RACHITT, Error-Prone PCR, to name a few. For 
example, an enzyme that is suspected of interacting with the 
target molecule can be selected and mutagenized with con-
ventional techniques. Alternatively, yeast or microorganisms 
35 can be randomly mutated. 
In one embodiment, chemical complementation is used to 
identify the engineered enzyme. In this embodiment the 
library of engineered enzymes will be introduced into the 
yeast strain transformed with a heterologous nucleic acid 
40 sequence encoding a modified nuclear receptor, as described 
above. This yeast strain will have a variant receptor integrated 
into its genome, and the variant receptor is able to bind the 
product molecule. Once the engineered enzymes have been 
transformed into the yeast strain, the yeast will be spread onto 
45 selective plates (for example, plates lacking adenine or histi-
dine) containing the reactants involved in the enzymatic reac-
tion that can be used to synthesize the missing product. The 
yeast will be able to take the reactants and if the yeast express 
an engineered enzyme that can convert the reactants to the 
50 reaction product, then the yeast will survive. In the alterna-
tive, the yeast cell engineered with a desired nuclear receptor 
LBD-DBD construct may be able to use an endogenous sub-
strate, i.e. a chemical compound not present in the culture 
medium, as the starting point for the conversion by the 
55 enzyme or enzyme system to a ligand molecule that has 
affinity for the target LBD. The yeast will survive because the 
reaction product will be able to bind to the variant receptor, 
and activate transcription oftheADE2 gene or other selection 
gene. The DNA from the yeast colony that grew will be 
60 rescued and sequenced. 
Target compounds that serve as ligands can be selected 
from any variety of natural or synthetic compounds. In one 
embodiment, natural products with agricultural or medicinal 
applications can be selected as target compounds. The search 
65 for natural products as potential agrochemical agents has 
increased due to the demand for crop protection chemicals. In 
1990, the world market value of pesticides totaled nearly $23 
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billion. Synthetic chemical pesticides are used to protect 
crops but several developments have triggered the search for 
alternative compounds. First, resistance has developed 
against synthetic chemical pesticides. Second, concern has 
arisen regarding potential human health risks. Third, there is 
22 
AmDH variants can be achieved through the action of a 
nuclear receptor activating transcription of an essential gene 
in response to the desired (R)-amine product. Whereas the 
first target is a model methyl arylalkyl ketone, the target in the 
second phase is an acetophenone derivative closer to desired 
applications. 
Conceptually, a concise and economical route to enantio-
merically pure products, for example amines, starts from the 
corresponding reactants, in this case ketones and uses ammo-
nium formate to generate the amine in up to 100% yield and 
selectivity with concomitant recycling of NAD(Pt to NAD 
(P)H using enzymes such as formate dehydrogenase (FDH). 
The starting enzyme is typically examined for, albeit small, 
levels of activity against a substrate, for example the ketone 
substrate in a high ammonia environment, either (i) in water/ 
liquid ammonia-mixtures, or (ii) in saturating concentrations 
of ammonium formate or animonium carbonate. A sensitive 
assay can be employed to check for NADH consumption such 
a growing awareness of environmental damage, such as con-
tamination of soil, water, and air. New environmentally 
friendly methods are being pursued to rectify these problems. 
The disclosed methods can be used to identify new prototype 
pesticides in natural products produced by microorganisms, 10 
for example, which are perceived as more environmentally 
friendly and acceptable. The natural products would be 
applied as the synthetic chemical pesticides have been or the 
biosynthetic genes would be expressed in transgenic plants. 
This strategy has been widely applied using the Bacillus 15 
thuringiensis toxin. In another embodiment, genes for toxins 
are delivered to target pest species using insect-specific 
viruses that leave beneficial insects unharmed. These 
"greener" technologies require not only identification of 
active natural products but also the genes for their biosynthe-
sis. With these applications in mind, and because of their 
availability, three compounds have been chosen as target 
ligands. Barbamide and jaspamide are relevant to the agricul-
tural industry. Resveratrol has antiviral, antimicrobial, and 
anticancer effects. 
20 as formation of formazan O'-max =450 nm). In this embodi-
ment, an (S)-amino acid dehydrogenase, either PheDH from 
Rhodococcus rhodocrous or LeuDH from Bacillus stearo-
thermophilus, an (R)-AmDH can be developed through 
change of substrate specificity. Diversity is generated within 
25 the respective gene through both random mutagenesis and 
recombination. Selection via binding of the product to a 
nuclear receptor with subsequent transcriptional control is 
chosen as the strategy to assay for successful variants. 
Barbamide is a natural product from the marine cyanobac-
terium, Lyngbya majuscula. From 295 g of algae, 258 mg of 
pure barbamide can be isolated. This chlorinated lipopeptide 
has potent mollucuscidal activity. The gene cluster for barba-
mide biosynthesis from L. majuscula has been cloned and 
analyzed. An approximately 26 kb region of DNA from this 
organism specifies the biosynthesis of barbamide. The gene 
cluster revealed 12 open reading frames and it is believed that 
barbamide is synthesized from acetate, L-phenylalanine, 
L-cysteine, and L-leucine. Polyketide synthase and non-ribo-
somal peptide synthetase modules accomplish biosynthesis. 
A trichloroleucine intermediate is involved, but an unre-
solved issue is its transfer between modules. The total syn-
thesis ofbarbamide has been reported. 
Jaspamide was isolated from various marine sponges and 
exhibits insecticidal (against Heliothis virescens) and fungi-
cidal activity (against Candida albicans). It is completely 
inactive against a series of Gram negative and Gram-positive 
bacteria. From 700 g of sponge tissue, 80 mg of pure jaspa-
mide was isolated. The biosynthetic pathway has not been 
elucidated, but its structure suggests polyketide synthase and 
non-ribosomal peptide synthetase modules. Since it is a fun-
gicide, a bacterial chemical complementation system for 
engineering nuclear receptors and discovering the genes 
involved in the biosynthesis of this compound would be used. 
Resveratrol is a stilbene phytoalexin that is produced in at 
least 72 plant species. Phytoalexins are low molecular weight 
antimicrobial metabolites that are produced by plants for 
protection against a wide range of pathogens. Some nuclear 
receptors are known to bind resveratrol, making the DNA 
shuffling approach to engineer a receptor highly relevant. 
This compound is commercially available on the gram scale. 
Development of an Amine Dehydrogenase (AmDH) 
Nuclear receptors PXR, BXR, and RAR can be used for 
30 engineering (R)-amine activated transcription with the dis-
closed methods and compositions. For example, these 
nuclear receptors can be engineered to activate the transcrip-
tion of the essential metabolic gene ADE2 in response to the 
(R)-amines in the modified Saccharomyces cerevisiae strain 
35 PJ69. PXR is chosen because ofits broad substrate specificity. 
BXR is chosen because it is already known to activate tran-
scription in response to amines. Random and structure-based 
approaches of creating libraries to engineer the nuclear recep-
tors for (R)-amine activated growth through genetic selection 
40 can be used. Receptors for multiple (R)-amines will be engi-
neered in parallel by selecting each library on multiple selec-
tive plates with the appropriate (R)-amine. Optionally, nega-
tive selection to genetically select libraries against enzymes 
that make an S-enantiomer product then select for the pro-
45 duction of the R-enantiomer (or vice-versa) can be used. A 
nuclear receptor library for the (R)-amine ligand can be syn-
thesized. Additionally, the (R)-amine ligand can be synthe-
sized in vivo by an expressedAmDH from the ketone precur-
sor supplemented within the growth medium. A mutant 
50 PheDH library can then be screened for in vivo synthesis of 
(R)-amines. In this overall scheme, the power of genetic 
selection is used to detect biocatalytic synthesis of amines. 
Utilizing genetic selection means that each member of the 
library does not need to be screened, only functional AmDH 
55 appear because they allow the microbe to grow and form a 
colony. Furthermore, catalysis is directly selected, as opposed 
to some related but indirect property (like transition state 
binding). Genetic selection coupled with the broad ligand 
specificity of nuclear receptors creates a process to rapidly Another embodiment provides methods and systems for 
engineering an enzyme, for example NAD+ -dependent amine 
dehydrogenase (AmDH) from an (S)-amino acid dehydroge-
nase (AADH) by changing its small pocket specificity. The 
enzyme can preferentially produce single optical isomer 
products, or use single optical isomer products as a substrate. 
Thus, the disclosure provides methods and compositions for 65 
generating polypeptides that can distinguish between optical 
isomers of a compound. Genetic selection of functional 
60 improve biocatalysts for more efficient synthesis of enantio-
merically pure compounds. 
Selected transformants can be optimized through succes-
sive rounds of directed evolution. Further mutant libraries of 
PheDH/LeuDH enzymes can be screened for in vivo synthe-
sis of (R)-amine. Mutant AmDH enzymes can be expressed 
and further studied for shifts in substrate specificity and 
changes in kinetic reaction rates. 
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FIG. 10 depicts another embodiment for the identification 
of selective receptor modulators (analogous to selective 
estrogen modulators). In this embodiment, the human nuclear 
receptor coactivator ACTR is fused to the Gal4 activation 
domain (ACTR:GAD). Additionally, the human nuclear 5 
receptor coactivator SRCl is fused to a yeast repression 
domain (SRCl :RD). In the presence of an agonist, these 
coactivator fusion proteins compete for expression of the 
HIS3 gene. The HIS3 gene encodes imidazoleglycerolphos-
phate dehydratase. In the presence of an agonist that recruits 10 
both coactivators equally, the yeast probably will produce 
enough histidine to survive. Adding the inhibitor 3-AT to the 
plates raises the threshold of enzyme that must be produced to 
permit growth. Compounds that selectively favor the RXR-
ACTR interaction over the RXR-SRC-1 interaction will 15 
yvitamin D2 as shown in FIG. 24. However, both compounds 
have affinity for, and can bind to the human vitamin D recep-
tor (VDR) ligand binding domain. Accordingly, in this 
experimental example, use was made of the yeast endogenous 
precursor ergesterol which was then converted to la,25-di-
hydroxyvitamin D2 by the heterologous cytochrome P450 
2Rl (vitamin D3 25-hydroxylase) and cytochrome P450 
27Bl (25-hydroxyvitamin D3 la-hydroxylase) enzyme sys-
tem 
In this embodiment, a recipient yeast cell such as, but not 
limited to strain PJ69-4A, can be transformed with a first 
heterologous nucleic acid expression system pGAD-BA-
ACTR, having the sequence SEQ ID NO.: 19 and encoding an 
ACTR:GAD fusion polypeptide, and a second heterologous 
nucleic acid system pVDR-wt (SEQ ID NO.: 20) encoding 
the GBD:VDR fusion polypeptide. Both of these fusion allow yeast to grow. 
FIG.11 is a diagram of another embodiment incorporating 
negative chemical selection. Human nuclear receptor coacti-
vator, ACTR is fused to the Gal4 activation domain (ACTR: 
GAD). The Gal4 DBD is fused to the nuclear receptor LBS 
(GBD:RXR). The Gal4 DBD binds to the Gal4 response 
element, regulating transcription to the URA3 gene. The 
URA3 gene codes for orotidine-5'-phosphate decarboxylase, 
an enzyme in the uracil biosynthetic pathway. This gene can 
be used for both positive and negative selection. For positive 
selection, yeast expressing this gene will survive in the 
absence of uracil in the media. For negative selection, 5-fluo-
roorotic acid (FOA) is added to the media. Expression of 
orotidine-5'-phosphate decarboxylase coverts FOA to the 
toxin 5'-fluorouracil, which kills the yeast. Libraries of small 
molecules can be screened in a high-throughput assay in 
wells containing an agonist and FOA. Antagonists will allow 
yeast to grow. 
FIG. 12 is a diagram illustrating still another embodiment 
comprising isotype specific nuclear receptor agonists are. 
Each isotype can be fused to a different DBD controlling 
expression of different genes. The isotype for which an ago-
nist is sought is fused to the Gal4 DBD to control expression 
of ADE2 (for positive chemical complementation). The iso-
type against which selectivity is desired, is fused to the GCN4 
DBD to control expression of the URA3 gene (for negative 
chemical complementation). Libraries of small molecules are 
screened in individual wells of a 384-well plate. Compounds 
that do no activate the receptor will no allow the yeast to grow. 
Compounds that agonize both isotypes will kill the yeast. 
Only compounds that agonize RXRa, and either do not bind 
or antagonize RXR~ will allow yeast to grow. 
FIG. 13 shows another embodiment in which a human 
nuclear receptor coactivator, ACTR, is fused to the Gal4 
activation domain (ACTR:GAD). The Gal4 DBD is fused to 
the nuclear receptor LBD (GBD:RXR). The Gal4 DBD binds 
to the Gal4 response element, regulating transcription of the 
ADE2 gene. Upon binding of the ligand, the LBD of the 
nuclear receptor undergoes a conformational change, which 
recruits theACTR:GAD fusion protein. This brings the Gal4 
AD and Gal4 DBD into close proximity activating transcrip-
tion of the ADE2 gene. For clarity only one ACTR:GAD 
protein is shown binding one GBD:RXR. Libraries of small 
molecules are screened in individual wells of a 384-well 
plate. Agonists will allow yeast to grow. 
FIG. 22 schematically illustrates another embodiment of 
the present disclosure, and as shown experimentally in FIG. 
23. In this embodiment, the nuclear receptor ligand binding 
domain is derived from the human vitamin D receptor. 
polypeptides may be expressed from their respective plas-
mids. The GBD:VDR polypeptide includes the ligand bind-
ing domain of the human vitamin D3 receptor and therefore is 
20 capable of selectively binding to the ligand molecules la,25-
dihydroxyvitamin D3 and la,25-dihydroxyvitamin D2 . The 
yeast strain PJ69-4A further incorporates the HIS3 genetic 
locus operably fused to the Gal4 promoter to which the GBD 
domains oftheACTR:GAD and GBD:VDR fusion polypep-
25 tides may bind, thereby leading to expression ofHIS3. 
The yeast strain PJ69-4A having the HIS3 genetic locus 
operably fused to the Gal4 promoter and further having the 
expressedACTR:GAD and GBD:VDR fusion polypeptides, 
however, is unable to grow on a selective medium lacking the 
30 amino acid histidine due to non-expression of the HIS3 gene. 
Expression of this gene requires activation of the operably 
linked to the Gal4 promoter. To achieve this expression, the 
embodiments of the system herein disclosed require that the 
GBD:VDR fusion polypeptide specifically bind its respective 
35 ligand, la,25-dihydroxyvitamin D3 , whereupon the fusion 
polypeptide can bind to the Gal4 promoter. 
In the system, as disclosed for example in FIG. 22, the 
nuclear receptor ligand la,25-dihydroxyvitamin D3 is not 
found or generated in wild-type yeast cells. Accordingly, to 
40 provide this ligand, the yeast strain now carrying the heter-
ologous nucleic acids encoding the ACTR:GAD and GBD: 
VDR fusion polypeptides can be further transformed with a 
third heterologous nucleic acid expression system that 
encodes enzymes necessary for the synthesis of the nuclear 
45 receptor ligand. In the example as shown in shown in FIG. 22, 
the third heterologous nucleic acid expression system com-
prised two plasmids transformed into the yeast. The first 
plasmid, p Y2653 (having the sequence according to SEQ ID 
NO.: 22) encodes for the expression product of the gene 
50 CYP2Rl, i.e. cytochrome P450 2Rl (vitamin D3 25-hy-
droxylase) that can convert the endogenous substrate chole-
calciferol to 25-hydroxyvitamin D3 . The second component 
of the thirdheterologous nucleic acid expression system is the 
plasmid pS0016 (having the nucleic acid sequence according 
55 to SEQ ID NO.: 21) that encodes forthe expression product of 
the gene CYP27Bl, i.e. cytochrome P450 27Bl (25-hydrox-
yvitamin D3 la-hydroxy lase) that can convert 25-hydroxyvi-
tamin D3 to the nuclear receptor ligand la,25-dihydroxyvi-
tamin D3. 
60 
Although the vertebrate metabolic pathway results in the 65 
formation of la,25-dihydroxyvitamin D3 , in yeast metabo-
lism of ergesterol results in the formation ofla,25-dihydrox-
When the recipient yeast strain includes all four of the 
transformed plasmids and expresses the heterologous prod-
ucts, the ACTR:GAD and GBD:VDR fusion polypeptides, 
the CYP2Rl gene product cytochrome P450 2Rl (vitamin D3 
25-hydroxylase), and the CYP27Bl gene product cyto-
chrome P450 27Bl (25-hydroxyvitamin D3 la-hydroxy-
lase) ), the yeast is able to grow on a selective medium lacking 
histidine, as shown in FIG. 23. It is also contemplated that the 
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systems of the disclosure are suitable for substituting the 
VDR region of the recombinant nuclear receptor fusion 
polypeptide with any receptor ligand binding region selected 
to respond to a selected ligand end-product of an enzyme 
synthesis pathway encoded by the third heterologous nucleic 
acid expression system. For example, but not intended to be 
limiting, suitable receptor ligand binding domains may be 
derived from such receptors as Thyroid hormone receptor-a, 
Thyroid hormone receptor-~, Retinoic acid receptor-a, Ret-
inoic acid receptor-~, Retinoic acid receptor-y, Peroxisome 
proliferator-activated receptor-a, Peroxisome proliferator-
activated receptor-~/11, Peroxisome proliferator-activated 
receptor-y, Rev-ErbAa, Rev-ErbAa, RAR-related orphan 
receptor-a, RAR-related orphan receptor-~, RAR-related 
orphan receptor-y, Liver X receptor-a, Liver X receptor-~, 
Famesoid X receptor, Vitamin D receptor, Pregnane X recep-
tor, Constitutive androstane receptor, Hepatocyte nuclear fac-
tor-4-a, Hepatocyte nuclear factor-4-y, Retinoid X receptor-
a, Retinoid X receptor-~, Retinoid X receptor-y, Testicular 
receptor 2, Testicular receptor 4, Homologue of the Droso-
phila tailless gene, Photoreceptor cell-specific nuclear recep-
tor, Chicken ovalbumin upstream promoter-transcription fac-
26 
Suitable selective methods include supplying a required 
nutrient such as, but not limited to, an amino acid (histidine 
for example). 
It is further contemplated that the systems and the methods 
of the present disclosure may be readily adapted to identify 
either an agonist or an antagonist of the heterologous enzyme 
system. In the case of an agonist or suspected agonist, an 
enzyme system that produces little or no nuclear receptor 
ligand that would allow the yeast strain to grow on a selective 
10 medium, may be enhanced to provide an effective amount of 
the nuclear receptor ligand. An antagonist will have the oppo-
site effect and result in the inhibition of the heterologous 
enzyme system by interacting with one or more of the 
enzymes thereof, thereby reducing the amount of the nuclear 
15 receptor ligand and reducing proliferation of the yeast. 
Additionally, the agonist or antagonist does not necessarily 
have to directly interact with at least one enzyme of the 
heterologous enzyme system. it is contemplated that a suspect 
agonist or antagonist may modulate the transcription of the 
20 one or more of the nucleic acid regions encoding an enzyme, 
leading to an increase or decrease in transcription and a cor-
responding change in the amount of an enzyme and in the 
overall activity of the heterologous enzyme system. 
Accordingly, the embodiments of the present disclosure 
25 provide a versatile system, and methods of using, that allow 
for the selection of variant nuclear receptor ligand binding 
domains, or for the selection of variant enzymes, or combi-
nations thereof, that may have an enhanced ability to synthe-
tor I, Chicken ovalbumin upstream promoter-transcription 
factor II, V-erbA-related, Estrogen receptor-a, Estrogen 
receptor-~, Estrogen-related receptor-a, Estrogen-related 
receptor-~Estrogen-related receptor-y, Glucocorticoid recep-
tor, Mineralocorticoid receptor, Progesterone receptor, 
Androgen receptor, Nerve Growth factor IB, Nuclear receptor 
related 1, Neuron-derived orphan receptor 1, Steroidogenic 30 
factor 1, Liver receptor hornolog-1, Germ cell nuclear factor, 
Dosage-sensitive sex reversal, adrenal hypoplasia critical 
region, onchromosomeX, gene 1, Smallheterodimerpartner, 
and the like. 
size a nuclear receptor ligand or a precursor thereof. 
One aspect of the present disclosure, therefore, encom-
passes embodiments of a yeast cell comprising: (i) a yeast 
transcription modulating system comprising a first heterolo-
gous nucleic acid expression system encoding a recombinant 
nuclear receptor polypeptide comprising a ligand-binding 
The third heterologous nucleic acid expression system may 
encode for any plurality of enzymes that operably cooperate 
to synthesize a nuclear receptor ligand molecule that may 
specifically bind to the selected nuclear receptor ligand bind-
ing domain. It is further contemplated, in the alternative, that 
the third heterologous nucleic acid expression system may 
encode for any plurality of enzymes that cooperate to synthe-
size a potential nuclear receptor ligand wherein the synthetic 
end-product may have a low affinity for the selected nuclear 
receptor expressed in the yeast cells (compared to the affinity 
of the natural ligand of the nuclear receptor). In this instance, 
it is contemplated that the third heterologous nucleic acid 
expression system may be mutated to provide a library of 
variant nuclear receptor ligand binding domains. The variant 
that has highest affinity for the synthesized ligand may then 
be selected by an elevated growth rate when compared to 
other yeast cells having a variant receptor ligand binding 
domain oflower affinity. It is also further contemplated that 
the third nucleic acid expression system may itself be mutated 
to provide variant enzymes that may more efficiently produce 
a receptor ligand having affinity for the targeted nuclear 
receptor LBD. 
35 domain operably linked to a DNA-binding domain and 
optionally to a flexible hinge domain, where the recombinant 
nuclear receptor polypeptide, when it is expressed in the yeast 
cell in the presence of a nuclear receptor ligand, specifically 
binds to the recombinant nuclear receptor polypeptide, 
40 thereby activating expression of a selective genetic locus; and 
a secondheterologous nucleic acid expression system encod-
ing an adapter polypeptide comprising a coactivator domain 
operably linked to a yeast transcriptional activator, and where 
the first heterologous nucleic acid expression system and the 
45 first heterologous nucleic acid expression system are each 
independently encoded by individual heterologous poly-
nucleotides or are encoded by the same heterologous poly-
nucleotide; (ii) a nuclear receptor ligand generating system 
comprising a third heterologous nucleic acid expression sys-
50 tern encoding a heterologous enzyme system for the genera-
tion of a nuclear receptor ligand from a substrate, where the 
nuclear receptor ligand is characterized as specifically bind-
ing to the recombinant nuclear receptor polypeptide; and (iii) 
a selective genetic locus expressed in the presence of the 
55 recombinant nuclear receptor polypeptide and a nuclear 
receptor ligand specifically bound to the recombinant nuclear 
receptor polypeptide. The examples of the present disclosure further include 
systems where the enzymes synthesizing the nuclear receptor 
ligand molecule may use an endogenous or an exogenous 
substrate for the biosynthetic pathway. In the case of an exog- 60 
enous substrate, the substrate should be transported into the 
cell via a transporter system or by passive diffusion. 
In embodiments of this aspect of the disclosure, the coregu-
lator domain can be SRC-1 or ACTR. 
In embodiments of this aspect of the disclosure, the third 
heterologous nucleic acid expression system may comprise a 
heterologous polynucleotide encoding a heterologous 
polypeptide, said heterologous polypeptide having an enzy-
mic activity characterized as generating a candidate nuclear 
The systems of the disclosure may use any suitable selec-
tive method that will allow for identification and selection of 
a yeast cell responding to the interaction of the synthesized 
nuclear receptor ligand with its target nuclear receptor ligand 
binding domain leading to the expression of a target gene. 
65 receptor ligand from a substrate. 
In other embodiments of this aspect of the disclosure, the 
third heterologous nucleic acid expression system may com-
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prise a heterologous polynucleotide encoding a plurality of 
heterologous polypeptides, where said heterologous 
polypeptides cooperate to generate a candidate nuclear recep-
tor ligand from a substrate. 
28 
In yet other embodiments of this aspect of the disclosure, 
the third heterologous nucleic acid expression system may 
comprise a plurality ofheterologous polynucleotides encod-
ing a plurality ofheterologous polypeptides, where said het-
erologous polypeptides cooperate to generate a candidate 
nuclear receptor ligand from a substrate. 
In embodiments of this aspect of the disclosure, the ligand-
binding domain of the recombinant nuclear receptor polypep-
tide can be derived from a ligand-binding domain of a human 
nuclear receptor polypeptide, or a variant thereof. 
enzyme system for the generation of a nuclear receptor ligand 
from a substrate, wherein the nuclear receptor ligand is char-
acterized as specifically binding to the recombinant nuclear 
receptor polypeptide; and (iii) a selective yeast genetic locus 
expressed in the presence of the recombinant nuclear receptor 
polypeptide and a nuclear receptor ligand specifically bound 
to the recombinant nuclear receptor polypeptide; and (2) cul-
turing the yeast cell under conditions allowing the yeast cell 
to synthesize a nuclear receptor ligand from a substrate, 
10 
whereupon the nuclear receptor ligand specifically binds to 
the recombinant nuclear receptor polypeptide, thereby induc-
ing transcription of the selective yeast genetic locus. 
In some embodiments of this aspect of the disclosure, the 
In embodiments of this aspect of the disclosure, the coac-
tivator domain of the adapter polypeptide can be derived from 
a coactivator domain of a human coactivator, or a variant 
thereof, where the coactivator binds to the ligand-binding 
domain of the recombinant nuclear receptor polypeptide in 
the presence of a ligand to activate expression of a genetic 
locus. 
15 step of providing a yeast cell or population of yeast cells may 
comprise delivering to a yeast cell or population of yeast cells 
a plurality of third heterologous nucleic acid expression sys-
tems encoding a plurality of enzyme systems suspected of 
generating from a substrate a nuclear receptor ligand specifi-
In embodiments of this aspect of the disclosure, expression 
of the genetic locus can allows proliferation of the yeast cell 
on a selective medium. 
20 cally binding the recombinant nuclear receptor polypeptide, 
and where the step of culturing the yeast cell under conditions 
allowing the yeast cell to synthesize a nuclear receptor ligand 
from a substrate identifies a third heterologous nucleic acid 
expression system encoding an enzyme system generating 
In embodiments of this aspect of the disclosure, expression 
of the genetic locus can inhibit proliferation of the yeast cell 
on a selective medium. 
25 the nuclear receptor ligand. 
In embodiments of this aspect of the disclosure, the heter-
ologous enzyme system for the generation of a nuclear recep-
tor ligand from a substrate can comprise a modified enzyme, 30 
where the modified enzyme catalyzes the formation of a 
receptor ligand characterized as binding to the recombinant 
receptor polypeptide. 
In embodiments of this aspect of the disclosure, the sub-
strate can be endogenous to the yeast cell. 
In other embodiments of this aspect of the disclosure, the 
substrate can be exogenous to the yeast cell. 
In embodiments of this aspect of the disclosure, the method 
may further comprise the step of modifying the first heterolo-
gous nucleic acid expression system encoding the recombi-
nant nuclear receptor polypeptide, thereby providing a vari-
ant recombinant nuclear receptor polypeptide specifically In some embodiments of this aspect of the disclosure, the 
heterologous enzyme system for the generation of a nuclear 
receptor ligand from a substrate comprises vitamin D3 25-hy-
droxylase and 25-hydroxyvitamin D3 la-hydroxylase, 
wherein said heterologous enzyme system catalyzes the for-
mation of la,25-dihydroxyvitamin D3 , and wherein the 
1 a,25-dihydroxyvitamin D3 binds to the recombinant nuclear 
receptor polypeptide comprising the ligand-binding domain 
of a vitamin D receptor, thereby inducing expression of a 
genetic locus allowing the yeast cell to proliferate on a culture 
medium not having histidine therein. 
35 binding to the nuclear receptor ligand. 
In embodiments of this aspect of the disclosure, the method 
may further comprise the step of modifying the third heter-
ologous nucleic acid expression system encoding the heter-
ologous enzyme system, thereby allowing the heterologous 
40 enzyme system to generate the nuclear receptor ligand from 
the substrate. 
Another aspect of the present disclosure provides methods 45 
of modulating the transcription of a gene of a yeast cell, the 
methods comprising (1) providing a yeast cell or population 
of yeast cells, wherein said yeast cell or population of yeast 
cells comprises: (i) a yeast transcription modulating system 
comprising a first heterologous nucleic acid expression sys- 50 
tern encoding a recombinant nuclear receptor polypeptide 
comprising a ligand-binding domain operably linked to a 
DNA-binding domain and optionally to a flexible hinge 
domain, where the recombinant nuclear receptor polypeptide, 
when expressed in the yeast cell in the presence of a nuclear 55 
receptor ligand specifically binding to the recombinant 
nuclear receptor polypeptide, activates expression of a 
genetic locus; and a second heterologous nucleic acid expres-
sion system encoding an adapter polypeptide, comprising a 
coactivator domain operably linked to a yeast transcriptional 60 
activator, and wherein the first heterologous nucleic acid 
expression system and the second heterologous nucleic acid 
expression system are each independently encoded by indi-
vidual heterologous polynucleotides or are encoded by the 
same heterologous polynucleotide; (ii) a nuclear receptor 65 
ligand generating system comprising a third heterologous 
nucleic acid expression system encoding a heterologous 
In other embodiments of this aspect of the disclosure, the 
third heterologous nucleic acid expression system may com-
prise a heterologous polynucleotide encoding a heterologous 
polypeptide, the heterologous polypeptide having an enzy-
mic activity characterized as generating a candidate nuclear 
receptor ligand from a substrate. 
In embodiments of this aspect of the disclosure, the third 
heterologous nucleic acid expression system may comprise a 
heterologous polynucleotide encoding a plurality ofheterolo-
gous polypeptides, where said heterologous polypeptides 
cooperate to generate a candidate nuclear receptor ligand 
from a substrate. 
In embodiments of this aspect of the disclosure, the third 
heterologous nucleic acid expression system may comprise a 
plurality ofheterologous polynucleotides encoding a plural-
ity of heterologous polypeptides, where said heterologous 
polypeptides cooperate to generate a candidate nuclear recep-
tor ligand from a substrate. 
In embodiments ofthis aspect of the disclosure, the ligand-
binding domain of the recombinant nuclear receptor polypep-
tide can be derived from a ligand-binding domain of a human 
nuclear receptor polypeptide, or a variant thereof. 
In embodiments of this aspect of the disclosure, the coac-
tivator domain of the adapter polypeptide may be derived 
from a coactivator domain of a human coactivator, or a variant 
thereof, and the coactivator binds to the ligand-binding 
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domain of the recombinant nuclear receptor polypeptide in 
the presence of a ligand to activate expression of a genetic 
locus. 
In embodiments of this aspect of the disclosure, transcrip-
tion of the yeast gene allows the yeast cell to proliferate on a 5 
selective culture medium. 
In other embodiments of this aspect of the disclosure, 
transcription of the yeast gene inhibits yeast cell proliferation 
on a selective culture medium. 
In embodiments of this aspect of the disclosure, the method 10 
may further comprise contacting the yeast cell with at least 
one compound suspected of modulating the activity of at least 
one enzyme of the heterologous enzyme system, thereby 
allowing the identification of the at least one compound as an 
activator or inhibitor of the at least one enzyme. 15 
In some embodiments of this aspect of the disclosure, the at 
least one compound can be suspected of enhancing the activ-
ity of at least one enzyme of the heterologous enzyme system. 
In embodiments of this aspect of the disclosure, the at least 
one compound can be suspected of inhibiting the activity of at 20 
least one enzyme of the heterologous enzyme system. 
In other embodiments of this aspect of the disclosure, the 
method may further comprise contacting the yeast cell with at 
least one compound suspected of modulating the transcrip-
tional activity of the third heterologous nucleic acid expres- 25 
sion system encoding a heterologous enzyme system, thereby 
allowing the identification of the at least one compound as an 
activator or inhibitor of the transcriptional activity of the third 
heterologous nucleic acid expression system. 
The specific examples below are to be construed as merely 30 
illustrative, and not limiting of the remainderof the disclosure 
in any way whatsoever. Without further elaboration, it is 
believed that one skilled in the art can, based on the descrip-
tion herein, utilize the present disclosure to its fullest extent. 
All publications recited herein are hereby incorporated by 35 
reference in their entirety. 
It should be emphasized that the embodiments of the 
present disclosure, particularly, any "preferred" embodi-
ments, are merely possible examples of the implementations, 
merely set forth for a clear understanding of the principles of 40 
the disclosure. Many variations and modifications may be 
made to the above-described embodiment(s) of the disclosure 
without departing substantially from the spirit and principles 
30 
not only the explicitly recited concentration of about 0.1 wt% 
to about 5 wt %, but also include individual concentrations 
(e.g., 1 %, 2%, 3%, and 4%) and the sub-ranges (e.g., 0.5%, 
1.1 %, 2.2%, 3.3%, and 4.4%) within the indicated range. The 
term "about" can include ±1 %, ±2%, ±3%, ±4%, ±5%, ±6%, 
±7%, ±8%, ±9%, or ±10%, or more of the numerical value(s) 
being modified. 
EXAMPLES 
Example 1 
Ligands 
9-cis retinoic acid (MW=304.44 g/mol) was purchased from 
ICN Biomedicals. 
LG335 Synthesis: 
3-(1-Carbonyl)propyl-5,5,8,8-tetramethyl-5,6,7,8-tetrahy-
dronapthylene: 
2,5-dimethyl-2,5,hexanediol (5.0 g, 34 mmol) was dissolved 
in anhydrous benzene (150 mL).AICl3 (5.0 g, 38 mmol) was 
added slowly while the mixture was stirred in an ice bath, 
followed by stirring at room temperature for 1 hour. Another 
portion of AICl3 (5.0 g, 38 mmol) was then added and the 
reaction was heated to 50° C. and stirred overnight. The 
brown solution was poured over iced 0.4 M HCI (50 mL) and 
extracted with ether (3x50 mL). The organic layer was then 
sequentially washed with water, saturated aqueous NaHC03 , 
and brine (80 mL each) and dried (MgS04 ). The solvent was 
removed in vacuo to yield 6.2 g of a yellow liquid. 
The crude product was then mixed with propionyl chloride 
(3 .2 mL, 3 7 mmol) and the resulting solution added dropwise 
to a mixture of AICl3 (5.0 g, 38 mmol) in dichloroethane (20 
mL) while maintaining the temperature between 20 and 25° 
C. The mixture was stirred for 2 hours at room temperature, at 
which point it was quenched by pouring carefully over ice. 
The reaction mixture was then extracted methylene chloride 
(3x10 mL). The organics layers were then combined, washed 
with water and saturated aqueous NaHC03 the volatiles 
removed by rotary evaporation. The product was purified by 
silica gel column chromatography eluting with hexanes:chlo-
roform ( 4: 1, then 1:1) to yield 6.9 g (28 mmol, 73%) of of the disclosure. All such modifications and variations are 
intended to be included herein within the scope of this dis-
closure, and the present disclosure and protected by the fol-
lowing claims. 
45 product as a yellow oil. 
3-Propyl-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronapthylene: 
The following examples are put forth so as to provide those 
of ordinary skill in the art with a complete disclosure and 
description of how to perform the methods and use the com-
positions and compounds disclosed and claimed herein. 
Efforts have been made to ensure accuracy with respect to 
numbers (e.g., amounts, temperature, etc.), but some errors 
and deviations should be accounted for. Unless indicated 
otherwise, parts are parts by weight, temperature is in ° C., 
and pressure is at or near atmospheric. Standard temperature 
and pressure are defined as 20° C. and 1 atmosphere. 
It should be noted that ratios, concentrations, amounts, and 
other numerical data may be expressed herein in a range 
format. It is to be understood that such a range format is used 
for convenience and brevity, and thus, should be interpreted in 
a flexible manner to include not only the numerical values 
explicitly recited as the limits of the range, but also to include 
all the individual numerical values or sub-ranges encom-
passed within that range as if each numerical value and sub-
range is explicitly recited. To illustrate, a concentration range 
of"about 0.1 % to about 5%" should be interpreted to include 
The 3-(1-carbonyl)propyl-5,5,8,8-tetramethyl-5,6, 7 ,8-tet-
rahydronapthylene (1.0 g, 4.1 mmol) inMeOH (lOmL), H2 0 
(1 mL), and cone. HCI (3 drops) was treated with 10% Pd/C 
50 (144 mg) and subjected to catalytic hydrogenation conditions 
at 60 psi while heating gently overnight. When the reaction 
was considered complete (Rf=O. 76, 5% EtOAc in hexanes) it 
was filtered through a celite pad and rinsed with MeOH (10 
mL) and hexane (50mL). Water(! mL) was thenadded to the 
55 filtrate and the organic phase separated and washed with brine 
(2x20 mL). The aqueous layer was washed with hexanes 
(2x20 mL). The organic layers were dried (Na2 S04 ), filtered 
and the volatiles removed by rotary evaporation to produce 
510 mg (2.2 mmol, 54%) of a colorless oil (5). 
60 4-[(3-Propyl-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naph-
tyl)carbonyl]benzoic Acid (LG335) 
3-Propyl-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronapthyl-
ene (2.2 g, 9.5 mmol) and chloromethyl terephthalate (2.0 g, 
10 mmol) were dissolved in dichloroethane (20 mL) and 
65 FeCl3 (80 mg, 490 µmo!) was added. The reaction mixture 
was stirred at 75° C. for 24 hours. The reaction was then 
cooled and MeOH (20 mL) added. The resulting slurry stirred 
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for 7 hours at room temperature, filtered and rinsed with cold 
MeOH (20 mL) to result in 2.1 g (5.5 mmol, 58%) of white 
crystals ( 6). 
32 
The crystals (I 07 mg, 280 µmo!) were stirred in MeOH (2 
mL), to which SN KOH (0.5 mL) was added. This mixture 5 
was refluxed for 30 minutes, cooled to room temperature and 
acidified with 20% aqueous HCI (0.5 mL). The MeOH was 
evaporated and the residue was extracted with EtOAc (2x5 
mL). The organic layers were combined and dried (MgS04 ) 
and filtered. The filtrate was treated with hexane (10 mL) and 10 
reduced in volume to 2 mL. After standing overnight the 
resulting crystals were collected to provide 39 mg (I 03 µmo!, 
37%) as a white powder (1). mp 250-252° C.; H1 NMR 
(CDCl3 ) ll 0.88 (t, 3H, -CH2CH2 CH3 ), 1.20 (s, 6H, CH3 ), 
1.32 (s, 6H, CH3 ), 1.55 (dt, 2H, --CH2 CH2CH3 ), 1.69 (s, 4H, 15 CH2 ), 2.65 (t, 2H, -CH2CH2 CH3), 7.20 (s, lH, Ar-CH) 
7.23 (s, lH, Ar-CH), 7.89 (d, 2H, Ar-CH), 8.18 (d, 2H, 
Ar-CH); MS (EI POS) m/z mass for C25H300 3 : Cale. 
378.2189. Found 378.2195. Anal. for C25H300 3 : Cale. C, 
Research, Orange, Calif.) spin columns, pGADIOBA was 
digested with Bp and Natl and ligated with both the ACTR 
and SRC-1 products. Ligations were transformed into 
Z-competent (Zymo Research, Orange, Calif.) XL I-Blue 
cells (Stratagene, La Jolla, Calif.). Transformants were res-
cued and sequenced. The final plasmids are called pGAD I 0-
BA-ACTR (SEQ ID NO.: 19) and pGADlO-BASRCl. 
Example 3 
Plasmid Construction 
The zero background plasmid, pGBDRXR:3Stop, was 
constructed using QuikChange Site-Directed Mutagenesis 
with pGBDRXRaL-SH-ME as the template and the 3Stop 
insert cassette (described below) as primers. 
The 3Stop insert cassette was synthesized using PCR from 
eight oligonucleotides (FIG. 16). All PCRs were done using 
2.5 U Pfu Polymerase (Stratagene, LaJolla, Calif.), lxPfu 79.33; H, 7.99. Found C, 79.10; H, 7.96. 
Example 2 
Expression Plasmids 
pGADlO-BA-ACTR (SEQ ID NO.: 19) (Chen et al., 
(1997) Cell 90: 569-580, incorporated herein by reference in 
its entirety), pGBT9Gal4, pGBDRXRa. (Azizi et al., (2003) 
Biochem. Biophys. Res. Comm. 306: 774-780, incorporated 
herein by reference in its entirety), pCMX-hRXR (Mangels-
dorf et al., (1990) Nature 345: 224-229, incorporated herein 
by reference in its entirety), and pCMX-~GAL (Peet et al., 
(1998) Chem. Biol. 5: 13-21, incorporated herein by reference 
in its entirety). pCMX-hRXR mutants were cloned from 
pGBDRXR vectors using Sall and Pstl restriction enzymes 
and ligated into similarly cut pCMX-hRXR vectors. pLuc_ 
CRBPII_MCS was constructed as below. All plasmids have 
been confirmed through sequencing. 
pGBDRXRa was cut with Smal and Neal, filled in, and 
blunt-end ligated to eliminate 153 amino acids of the RXR 
DBD. A HindIII site in the tryptophan selectable marker was 
silently deleted and the sole remaining HindIII site was cut, 
filled in, and blunt-end ligated to remove the restriction site. 
Unique HindIII and Sad sites were inserted into the RXR 
LBD gene and Mfel and EcoRI sites were removed from the 
plasmid using QuikChange Site-Directed Mutagenesis 
(Stratagene, La Jolla, Calif.) to create pGBDRXRaL-SH-
ME. 
pLuc_CRBPII_MCS was made by site-directed mutagen-
esis from pLucMCS (Stratagene, USA). Site-directed prim-
ers were designed to incorporate a CRBPII response element 
in the multiple cloning site (MCS), controlling transcription 
of the firefly luciferase gene. 
Plasmids expressing the fusion protein of the Gal4 activa-
tion domain with the coactivators are based on the commer-
cial plasmid pGADIO (Clontech, USA). ThepGADIOvector 
contains the Gal4 activation domain (residues 491-829) fused 
to a multiple cloning site (MCS) and uses a leucine marker. 
Additional restriction enzyme sites were added to the MCS of 
the plasmid via site directed mutagenesis. Primers were 
designed to add the following restriction enzymes: Ndel, 
Eagl, EcIXI, Natl, XmaIII, Xmal, and Smal, forming a new 
plasmid known as pGADIO-BA. (FIG.17) This plasmid was 
sequenced and used for specific interaction studies mentioned 
in the results. 
Both ACTR (residues 1-1413) and SRC-1 (residues 
54-1442) genes were amplified via PCR with primers that 
contained Bg!II and Natl sites. The PCR products were 
digested with the two restriction enzymes and cleaned using 
the Zymo "DNA Clean and Concentrator Kit" (Zymo 
20 buffer, 0.8 mM dNTPs, 50 ng ofpGBDRXRaL-SH-ME as a 
template, 125 ng of primers and sterile water to make 50 µL. 
First, four small cassettes were synthesized in reactions con-
taining the following primers: Cassette I, F (5'-CG-
GAATTTCCCATGGGC-3') (SEQ ID NO.: I), BPf (5'-
25 CTCGCCGAACGACCCGGTCACCGCATGCCACTAGT-
GG-3') (SEQ ID NO.: 2), and BPr (5'-CCGCTTGGC-
CCACTCCACTA GTGGCATGCGGTGACC-3') (SEQ ID 
NO.: 3); Cassette 2, BPf, BPr, SEf (5'-CGGGCAGGCTG-
GAATGAGCTCCTCGACGGAATTCTCC-3') (SEQ ID 
30 NO.: 4), andSEr(5'-CAGCCCGGTGGCCAGGAGAATTC-
CGTCGAGGAGCTC-3') (SEQ ID NO.: 5); Cassette 3, SEf, 
SEr, AMf (5'-CTCTGCGCTCCATCGGGCTTAAGTGC-
CCACCAATTGACAC-3') (SEQ ID NO.: 6), and AMr (5'-
CTCCAGCATCTCCATAAGGAAGGTGT-
35 CAATTGGTGGGCACTTAAGC-3') (SEQ ID NO.: 7); 
Cassette 4, AMf, AMr, and R (5'-CAAAGGATGGGCCG-
CAG-3') (SEQ ID NO.: 8). The cassettes were cleaned with 
either the DNA Clean and Concentrator-5 (Zymo Research, 
Orange, Calif.) or the Zymoclean Gel DNA Recovery Kit 
(Zymo Research, Orange, Calif.) depending on product 
40 purity. The four cassettes were used to make the final 3Stop 
insert cassette in a PCR that contained each cassette, primers 
F and R, dNTPs, Pfu Polymerase, and sterile water to a final 
volume of 50 µL. The 3Stop cassette was cleaned using the 
Zymoclean Gel DNA Recovery Kit. 
45 Insert Cassette Library Construction: The library of insert 
cassettes with randomized codons was constructed in a simi-
lar manner as above. The four cassettes (FBP, BPSE, SEAM 
andAMR) were made in the following ways. 
For the FBP cassette, oligos BPI (5'-GGCAAA-
50 CATGGGGCTGAACCCCAGCTCGCCGAACGACCCG 
GTCACC-3') (SEQ ID NO.: 9), BP2 (5'-GCCCACTCCAC-
TAGTGTGAAAAGCTGTTTGTC(A, C, or T)(A or G)(C or 
G)(A, C, or T)(A or G)(C or G)TTGGCA(A, C, or T)(A or 
G)(C or G)GTTGGTGACCGGGTCGTTCG-3') (SEQ ID 
55 NO.: 10), BP3 (5'-CTTTTCACACTAGTGGAGTGGGC-
CAAGCGGATCCCACACTTCTCAGAG-3') (SEQ ID NO.: 
11), and BP4 (5'-GGGGCAGCTCTGAGAAGTGTGG-
GATCCG-3') (SEQ ID NO.: 12) were mixed with TE con-
taining I 00 mM NaCl to bring the total volume to 50 µL. The 
mixture was heated to 95° C. for I minute, then slowly cooled 
60 to 10° C. The annealed mixture was combined with EcoPol 
Buffer, dNTPs, ATP, Kienow (NEB, Beverly, Mass.), T4 
DNA ligase (NEB, Beverly, Mass.) and sterile water to 200 
and kept at 25° C. for 45 min before heat inactivation at 7 5° C. 
for 20 minutes. The product was cleaned with DNA Clean and 
65 Concentrator-5 to make the BP cassette. Next, BP cassette 
was combined with Pfu Buffer, pGBDRXR:3Stop, oligo F, 
dNTPs, Pfu polymerase, and sterile water to make 50 µL for 
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a PCR. The final FBP product (300 bp) was purified using the 
Zymoclean Gel DNA Recovery Kit. 
BPSE was made in two consecutive PCRs. First, SE! (5'-
GCAGGCTGGAATGAGCTCCTC(A, G, or T)(C or T)(G or 
C)GCCTCC (A, G, or T)(C or T)(G or C)TCCCACCGCTC- 5 
CATC-3') (SEQ ID NO.: 13) and SE2 (5'-CCGGTGGCCAG-
GAGAATTCCGTCCTTCACGGCGATG-
GAGCGGTGGG-3') (SEQ ID NO.: 14) were combined with 
Pfu buffer, dNTPs, Pfu polymerase, and sterile water to make 
50 µL. After 5 PCR cycles, pGBDRXR:3Stop and BP were 10 
added to the reaction and the PCR was continued for 30 
cycles. The product (240 bp) was purified using the 
Zymoclean Gel DNA Recovery Kit. 
SEAM was constructed in a similar way to BPSE. SE! and 
SE2 were mixed with Pfu Buffer, dNTPs, Pfu polymerase, 15 
and sterile water to 25 µL. Simultaneously, AMI (5'-
GGCTCTGCGCTCCATCGGGCTTAAGTGC-
CTGGAACAT(A, G, or T)(C or T)(G or C)TTSCTTCT-
TCAAGCTCATCGGGG-3') (SEQ ID NO.: 15) and AM2 
(5'-GCATCTCAATAAGGAAGGTGTCAATTGT-
GTGTCCCCGATGAGCTTGAAGAA-3') (SEQ ID NO.: 20 
16) were combined with Pfu Buffer, dNTPs, Pfu polymerase, 
and sterile water to 25 µL. After 5 cycles, these two reactions 
were mixed and pGBDRXR:3Stop was added. The PCR was 
continued for 30 cycles. The PCR product ( 460 bp) was 
purified using the Zymoclean Gel DNA Recovery Kit. 25 
The AMR cassette was made similarly to FBP. AMI and 
AM2 were mixed with TE containing 100 mM NaCl to make 
50 µL, heated to 95° C. for 1 minute, then slowly cooled to 10° 
C. The annealed mixture was combined with EcoPol Buffer, 
dNTPs, Kienow, and sterile water to 200 µL, and kept at 25° 30 
C. for 45 min beforeheat inactivation at 75° C. for 20 minutes. 
The product (AM) was precipitated with isopropanol. Next, 
AM and R were combined with Pfu buffer, pGBDRXR: 
3Stop, dNTPs, Pfu Polymerase, and sterile water to make 50 
µL for a PCR. The product (140 bp) was purified using the 35 Zymoclean Gel DNA Recovery Kit. 
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(1 mL) was spread on each oflO large plates ofSC-Ade-Trp-
Leu media containing 10 µM LG335. The transformation 
mixture (2 and20 µL) was also spread on SC-Trp-Leumedia. 
These plates were grown for 4 days at 30° C. 
Example 5 
Molecular Modeling 
Docking of LG335 in to modified binding pockets was 
done using the InsightII module Affinity. The wild type RXR 
with 9cRA crystal structure (Egea et al., (2000) EMBO J. 19: 
2592-2601, incorporated herein by reference in its entirety) 
was modified using the Biopolymer module residue replace 
tool to make mutations in the binding pocket that corre-
sponded to the mutations in variants I268;I130A;F313A; 
L436F, I268V;A272V;I310L;F313M, and I268A;I310S; 
F313A;L436F. The ligand was placed in the binding pocket 
by superimposing the carboxylate carbon and two carbons in 
the tetrahydronapthalene ring of LG335 onto corresponding 
carbons of 9cRA in the crystal structure. A Monte Carlo 
simulation was performed first, followed by Simulated 
Annealing of the best docked conformations. 
Example 6 
Library Evaluation 
To evaluate the efficiency oflibrary creation and selection 
we take a binary approach-either the sequence is or is not a 
designed sequence. Eq. 1 is the relevant binomial distribution 
for statistical evaluation of the libraries. 
P- (N-1)! k 1- N-k 
- (k-l)!(N-k)!p ( p) 
(1) 
In Eq. 1 N is the number of sequenced plasmids; k is the 
number of background or designed plasmids; p is the fre-
quency of the occurrence of either background or designed 
The four cassettes (FBP, BPSE, SEAM, and AMR) were 
combined in a PCR to make the library of randomized insert 
cassettes (6mutIC). The library was cleaned using Bio-Spin 
30 columns (Bio-Rad Laboratories, Hercules, Calif.). 
Example 4 
Yeast Selection Plates and Transformation 
40 plasmid; and Pis the measure of certainty. Applying Eq. 1 to 
the libraries, there was 95% certainty that the unselected 
library was at least 72% background and the selected library 
was at least 78% designed sequences. 
Synthetic complete (SC) media and plates were made 45 
according to (Azizi et al., (2003) Biochem. Biophys. Res. 
Comm. 306: 77 4-780, incorporated herein by reference in its 
entirety). Selective plates were made without tryptophan 
(-Trp) and leucine (-Leu) or without adenine (-Ade), tryp-
tophan (-Trp) and leucine (-Leu). Ligands were added to the 50 
media after cooling to 50° C. 
Example 7 
Genotype Determination 
Plasmids were rescued using either the Powers method or 
the Zymoprepo Kit (Zymo Research, Orange, Calif.). The 
plasmids were then transformed into Z-competent (Zymo 
Research, Orange, Calif.) XLl-Blue cells (Stratagene, La 
Jolla, Calif.). The QIAprep Spin Miniprep Kit (Qiagen, 
Valencia, Calif.) was used to purify the DNA from the trans-
formants. These plasmids were sequenced. 
Example 8 
Quantitation Assays 
The randomized cassette library was homologously 
recombined into the pGBDRXR:3Stop plasmid using the 
following method. pGBDRXR:3Stop was first digested with 
BssHII and Eagl (NEB, Beverly, Mass.), and then treated 55 
with calf intestinal phosphatase (NEB, Beverly, Mass.), to 
make a vector cassette. Vector cassette (1 µg) and 6mutIC (9 
µg) were transformed according to Geitz's transformation 
protocol (Geitz& Woods (2002)Meths. Enzymol. 350: 87-96, 
incorporated herein by reference in its entirety) on a 1 Ox scale 
into the PJ69-4A yeast strain, which had previously been 
transformed with a plasmid (pGADlO-BA-ACTR) (manu-
script submitted) expressing the nuclear receptor coactivator 
ACTR fused to the yeast Gal4 activation domain. Homolo-
gous regions between the vector cassette and the insert cas-
sette allow the yeast to homologously recombine the insert 65 
cassette with the vector cassette forming a circular plasmid 
with a complete RXR LBD gene. The transformation mixture 
60 Solid Media: 
The rescued plasmids were transformed into PJ69-4A con-
taining the pGADlO BA-ACTR plasmid and plated on (SC)-
Trp-Leu media. These plates were grown for 2 days at 30° C. 
Colonies were streaked onto the following media: SC, 
SC-Trp-Leu, SC-Ade-Trp-Leu, SC-Ade-Trp-Leu plus 
increasing concentration ofLG335 or 9cRA from 1 nM to 10 
µM. 
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Liquid Media: The method used for quantitation was modi-
fied from a method developed by Miller and known in the art. 
Mammalian Luciferase Assay: Performed with HEK 293 
cells as previously described, and known in the art. 
Streaking cells onto adenine selective plates using PJ69-4A: 
Yeast transformants containing the plasmids were streaked 
onto the selective plates (SC-Ade) with different ligand con-
centrations using sterile toothpicks. Plates were divided into 
sectors for the samples and controls; the control sectors con-
tain pGBDMT and pGBT9Gal4. The same colony was used 
for streaking on all the plates, ending with a SC plate to 
confirm efficient transfer of the cells to each plate. Both 
selective and non-selective plates were incubated at 30° C. for 
two days. Each set of genetic selection plates was replicated 
at least once. 
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region to create this nonfunctional gene. The deletions corre-
spond to regions in the RXR gene where randomized codons 
are designed. This plasmid, pGBDRXR:3Stop, was co-trans-
formed into yeast with the library of insert cassettes contain-
5 ing full-length RXR LBD genes with randomized codons at 
positions 268, 271, 272, 310, 313, and 436. The insert cas-
settes and the plasmid contain homologous regions enabling 
the yeast to homologously recombine the cassette into the 
plasmid. Recombination repairs the deletions in the RXR: 
1 o 3 Stop gene to make full- length genes with mutations at the six 
specific sites. 
Example 10 
15 
Streaking cells onto FOA plates using MaVW3: Yeast trans-
formants containing the plasmids were streaked onto selec-
tive plates, SC-Leu-Trp, containing 5-fluororotic acid, FOA, 
and different ligand concentrations. Plates were also divided 
into sectors, with pGBT9Gal4 and pGBDMT as controls. The 20 
same procedure was used for streaking as for the adenine 
selection plates. Plates were incubated for two days. Each set 
Library Selection 
To limit the number of variants to be screened, the library 
was subjected to chemical complementation (FIG.1). Chemi-
cal complementation exploits the power of genetic selection 
to make the survival of yeast dependent on the presence of a 
small molecule. The PJ69-4A strain of S. cerevisiae has been of the genetic selection plates was replicated at least once. 
Example 9 
Library Design 
The binding pocket of the RXR LBD is composed of pri-
marily hydrophobic side chains plus several positively 
charged residues that stabilize the negatively charged car-
boxylate group of 9cRA. The target ligand, LG335, contains 
an analogous carboxylate group, so the positively charged 
residues were left unchanged. The binding affinity probably 
arises from hydrophobic contacts and that specificity arises 
from binding pocket size, shape, hydrogen bonding, and elec-
trostatics. The randomized amino acids were chosen based on 
their proximity to the bound 9cRA as observed in the crystal 
structure and the results of site directedmutagenesis (FIG. 14, 
(Egea et al., (2000) EMBO J. 19: 2592-2601; Doyle et al., 
(2001) J. Am. Chem. Soc. 123: 11367-11371, incorporated 
herein by reference in their entireties)). The electrostatic 
interactions were held constant while the size, shape, and 
potential hydrogen bonding interactions were varied to find 
optimum contacts for LG335 binding. A library ofRXRs with 
mutations at six positions was created. At three of the posi-
tions (1268, A271, and A272) are four possible amino acids 
engineered for use in yeast two-hybrid genetic selection and 
25 screening assays. For selection, PJ69-4A contains the ADE2 
gene under the control of a Gal4 response element. Plasmids 
created through homologous recombination in PJ69-4A 
express the Gal4 DBD fused with a variant RXR LBD (GBD: 
RXR). A plasmid expressing ACTR, a nuclear receptor coac-
30 tivator, fused with the Gal4 activation domain (ACTR:GAD), 
was also transformed into PJ69-4A. If a ligand causes a vari-
ant RXR LBD to associate with ACTR, transcription of the 
ADE2 gene is activated. Expression of ADE2 permits 
adenine biosynthesis and therefore, yeast survival on media 
35 lacking adenine. 
A small amount of the yeast library was plated onto media 
(SC-Leu-Trp) selecting only for the presence of the plasmids 
pGADlO-BA-ACTR (expressing ACTR:GAD and contain-
ing a leucine selective marker) and mutant pGBDRXR (ex-
40 pressing variant GBD:RXR and containing a tryptophan 
selective marker). The majority of the yeast cells transformed 
with the RXR library were plated directly onto SC-Leu-Trp-
Ade media containing 10 µM LG335, selecting for adenine 
production in response to the compound LG335. The trans-
formation efficiency of this library into yeast strain PJ69-4A 
45 
was 3.8x104 colonies per µg DNA. This number includes both 
the efficiency of transforming the DNA into the cells and the 
homologous recombination efficiency. Of the approximately 
380,000 transformants, approximately 300 grew on SC-Ade-
Trp-Leu+ 10 µM LG335 selective media. (L, V, A, and P) and at the other three positions (1310, F313, 
and L436) there are eight possible amino acids (L, I, V, F, M, 50 
S, A, and T). The combination of six positions and number of 
encoded amino acids allowed testing of the library construc-
tion while keeping the library size (32,768 amino acid com-
binations and about 3 million codon combinations) within 
reasonable limits. Praline was included in the library as a 55 
negative control. Residues 268, 271, and 272 are in the middle 
Example 11 
Library Characterization 
Twenty-one plasmids were rescued from yeast colonies: 
nine from non-selective plates (SC-Trp-Leu) and twelve from 
selective plates (SC-Ade-Trp-Leu+lO µM LG335). The rel-
evant portion of plasmid DNA from these colonies was 
sequenced to determine the genotype (Table 1 ). All nine of the 
plasmid sequences from the non-selective plates contained at 
least one deletion and are non-functional genes. Of the twelve 
plasmids that grew on the selective media, all contain full-
length RXR LBDs with designed mutations. With 95% cer-
tainty, we conclude that the unselected library is at least 72% 
background and the selected library is at least 78% designed 
sequences (supporting information). 
of helix 3, which would be disrupted by the inclusion of 
praline. Therefore, praline residues should appear at these 
positions only in unselected variants and not in the variants 
that activate in response to ligand. The substitutions at posi- 60 
tions 268, 271, and 272 were restricted to small amino acids 
allowing access to the positively charged residues at this end 
of the pocket. 
To eliminate contamination of the library with unmutated, 
wild-type RXR the gene was modified to create a non-func- 65 
tional gene, RXR:3Stop. Forty base pairs were deleted at 
three separate sites producing three stop codons in the coding 
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TABLE 1 
Genotypes of mutants from unselected and selected 
libraries 
Mutant 1268 A271 A272 1310 F313 L436 
Unselected library 
1 Deleted Deleted Deleted Deleted Deleted Deleted 
2 Deleted Deleted Deleted Deleted Deleted Deleted 
3 GTA(V) CCT(P) CCT(P) TCG(S) TCG(S) Deleted 
4 Deleted Deleted Deleted Deleted Deleted Deleted 
5 Deleted Deleted Deleted Deleted Deleted GCG(A) 
Deleted Deleted Deleted Deleted Deleted Deleted 
7 Deleted Deleted Deleted Deleted Deleted Deleted 
8 Deleted Deleted Deleted Deleted Deleted Deleted 
9 Deleted Deleted Deleted Deleted Deleted TTC(F) 
Selected library 
1 GTG(V) wtRXR GCA TTG(L) ATG(M) TTG 
2 GTG(V) wtRXR GCA GTG(V) TCC(S) TTG 
3 CTA(L) GCT GCA ATG(M) GTG(V) TTG 
4 GCG(A) wtRXR GCA TCC (S) GTG(V) TTC(F) 
5 GCT(A) GCT GCA GCC(A) GCG(A) TTC(F) 
GCT(A) GCT GTT(V) GCC(A) GCG(A) TTC(F) 
7 CTT(L) GCT GCT GTC(V) ATC(l) TTG 
8 CTG(L) GTG(V) GCG TTG(L) TTG(L) TTG 
9 GTG(V) GTG(V) GCG TTG(L) GTG(V) TTG 
10 GTA(V) wtRXR GTG(V) ATG(M) TCC(S) ATG(M) 
11 GCG(A) GCG GCA ATG(M) GCG(A) ACG(T) 
12 GCG(A) GCT GCG TCG(S) GTC(A) TTC(F) 
Sequences codons are followed by the encoded amino acid in 30 
parentheses. "wtRXR" indicates that the sequence corre-
sponds to the wild-type RXR codon. "Deleted" indicates the 
presence of an unmutated stop deletion background cassette. 
els at various concentration of ligand (FIGS. 2 and 3). The 
differences will be more fully discussed in a future publica-
tion. 
Three plasmids were used as controls in the screen and 
selection assays. The plasmids pGBDRXRa and 
Example 12 
Variant Characterization in Yeast 
35 pGBT9Gal4 were used as positive controls to which the acti-
vation level of the variants can be compared. pGBDRXRa 
expresses the gene for the "wild-type" GBD:RXR, which 
grows and is activated by 9cRA but not by LG335. 
pGBT9Gal4 expresses the gene for the ligand-independent 
The twelve plasmids rescued from the selective plates were 
retransformed into P J 69-4 A to confirm that their phenotype is 
plasmid linked. The strain PJ69-4A was engineered to con-
tain a Gal4 response element controlling expression of the 
Lacz gene, in addition to theADE2 gene. Both selection and 
screening were used to determine the activation level of each 
variant by 9cRA and LG335. The selection assay quantifies 
yeast growth occurring through transcriptional activation of 
the ADE2 gene, while the screen quantifies ~-galactosidase 
activity occurring though transcriptional activation of the 
Lacz gene. Although the selection assay (FIG. 2) is about 50 
10-fold more sensitive than the screen (FIG. 3), it does not 
quantify activation level (efficacy) as well as the screen. In the 
selection assay, there is either growth or no growth, whereas 
the screen more accurately quantifies different activation lev-
Variant 
WT 
40 
yeast transcription factor Gal4 (Johnston et al., (1986) Proc. 
Nat. Acad. Sci. USA 83: 6553-6557, incorporated herein by 
reference in its entirety), which is constitutively active in the 
presence or absence of either ligand. The plasmid pGB-
DRXR:3Stop serves as a negative control. pGBDRXR:3Stop 
carries a non-functional RXR LBD gene; therefore, yeast 
45 transformed with this plasmid does not grow in the selection 
assay nor show activity in the screen. This plasmid provides a 
measure of background noise in both the selection and screen 
assays. 
Both the selection and screen assays show that ten of the 
twelve variants are selectively activated by LG335. Results of 
these assays are shown in FIGS. 2 and 3. Table 2 summarizes 
the transcriptional activation profiles of all twelve variants in 
response to both 9cRA and LG335 compared to wild-type 
RXR. 
TABLE2 
EC,0 and efficacy in yeast and HEK 293 cells for RXR variants 
9CRA LG335 
Yeast HEK293 Yeast HEK293 
EC so Eff EC so Eff EC so Eff EC so Eff 
500 100 220 100 >10,000 10 300 10 
1268A; 1310A; F313A; L436F >10,000 0 >10,000 0 220 70 30 50 
1268V; A272V; 1310L; F313M >10,000 10 1,600 30 40 60 30 
1268A; 1310S; F313V; L436F >10,000 10 470 60 
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TABLE 2-continued 
EC,0 and efficacy in yeast and HEK 293 cells for RXR variants 
9CRA LG335 
Yeast HEK293 Yeast HEK293 
Variant EC so Eff EC so Eff EC so 
1268A; 1310S; F313V; L436F >10,000 0 >10,000 0 430 
1268V; A272V; 1310M; F313S; >10,000 10 >10,000 0 680 
L436M 
1268A; A272V; 1310A; F313A; >10,000 0 530 
L436F 
1268L; A271V;1310L; F313L >10,000 0 530 
1268A; 1310M; F313A; L436T >10,000 0 >10,000 0 610 
1268V; A271V;1310L; F313V >10,000 0 650 
1268L; 1310V; F3131 >10,000 0 >2000 
1268L; 1310M; F313V >10,000 20 610 
1268V; 1310V; F313S >10,000 0 440 
EC50 values (given in nm) represent the averages of two 
screen experiments in quadruplicate for yeast and in triplicate 
for HEK 293. Efficacy (Eff; given as a percent) is the maxi-
mum increase in activation relative to the increase in activa-
tion of wild type with 10 µM 9cRA. Values represent the 
averages of two screen experiments in quadruplicate for yeast 
and in triplicate in HEK 293. 
Five variants were chosen for testing in mammalian cell 
culture for comparison of the activation profiles (I268A; 
131 OA;F313A;L436F,I268V;A272V;l31 OL;F313M, I268A; 
131 OS;F313A;L436F, I268V;A272V;l31 OM;F313S;L436M, 
and I286A;l310M;F313A;L436T). The genes for these vari-
ants were removed from yeast expression plasmids and 
ligated into mammalian expression plasmids. 
Although I268L;l31 OM;F313V is constitutively active in 
the selection assay (FIG. 2n) and has high basal activity in the 
screen assay, both 9cRA and LG335 increase activity at 
micromolar concentrations (FIG. 3n ). This variant may be in 
an intermediate conformation, with weakly activated tran-
scription that can be improved by ligand binding. The high 
basal activation could also be due to a change in the confor-
mation equilibrium with a shift towards the active conforma-
tion when ligand is not present. 
I268V;l31 OV;F313S is constitutively active on solid media 
(data not shown), but shows no activation in the screen (0% 
Eff., Table 2, FIG. 3o) and only grows in the liquid media 
selection after two days (FIG. 2o ). The basal activation level 
may be below the threshold of detection for the liquid media 
assays. However, it is also possible that agar, which is not 
present in the liquid assays, contains some small molecule 
that activates the receptor. 
Activation levels and EC50s correlate in yeast and HEK 
293 cells (FIG. 4 and Table 2). For the majority of the variants 
9cRA shows little or no activation in yeast or manmialian 
cells. Variant I268V;A272V;l310L;F313M is activated 
slightly by 9cRA in yeast, but in mammalian cells is activated 
to the same level as with both 9cRA and LG335 (FIGS. 2, 3 
and 4). With one exception, all variants tested have EC50s 
within 10-fold in yeast and mammalian cells. However, the 
EC50s in mammalian cells are generally lower than in yeast. 
We speculate that this shift is due to increased penetration of 
LG335 into mammalian cells versus yeast. 
Subtle differences in binding pocket shape can have a 
drastic effect on specificity. For example, the I268V;A272V; 
l310L;F313M variant is activated to high levels by LG335 
(60% Eff. Table 2), and is only slightly activated by 10 µM 
9cRA in yeast (FIG. 3e), yet the amino acid changes are 
Eff EC so Eff 
50 690 20 
30 180 30 
30 
20 
10 140 20 
10 
10 
20 
10 
20 extremely conservative. The volume difference between phe-
nylalanine and methionine side chains is only about 4 A3 and 
their polarity difference is minimal (hydration potentials of 
the methionine and phenylalanine side chains are -0.76 kcal 
25 mo1-
1 and -1.48 kcal mo1- 1 , respectively). The other muta-
tions redistribute methyl groups within the binding pocket, 
with a net difference of one methyl group (about 18 A3 ). 
The LG335-I268V;A272V;l310L;F313M ligand receptor 
pair also represents a 25-fold improvement in EC50 over the 
30 previous best LG335 receptor, Q275C;l310M;F313I (40 nM 
vs. 1 µM in yeast). The Q275C;l310M;F313I variant was 
created using site directed mutagenesis. Subtle changes in the 
I268V;A272V;l310L;F313M variant produced a better 
ligand receptor pair than the Q275C;l310M;F313I variant. 
35 This conclusion is consistent with the observation that 
nuclear receptors bind ligands through an induced-fit mecha-
nism. With current knowledge about protein-ligand interac-
tions it is not possible to rationally design ligand-receptor 
pairs with specific activation profiles. Libraries and chemical 
40 complementation are a new way to circumvent this problem 
and obtain functional variants with a variety of activation 
profiles. 
Molecular modeling was used to generate hypotheses 
about the structural basis ofligand specificity for the variants 
45 discovered in the library. First, mutations to smaller or more 
flexible side chains at positions 310, and 313 are essential to 
provide space for the propyl group of LG335. All variants 
activated by LG335 have mutations at these two positions. 
Second, mutations to amino acids with larger side chains at 
50 position 436 sterically clash with the methyl group at the 9 
position of 9cRA. This interaction may prevent helix 12 from 
closing properly and therefore prevent activation by 9cRA. 
The only variant significantly activated by 9cRA (I268V; 
A272V;l310L;F313M) does not contain a mutation at posi-
55 tion 436. Third we hypothesize that tight packing in the bind-
ing pocket may lead to lower EC50s. The docking results for 
I268V;A272V;l310L;F313M with LG335 show that the 
methionine and leucine side chains pack tightly against the 
propyl group of LG335, which may result in tighter binding 
60 and consequently a lower EC50s. 
In the absence of functional data, chemical complementa-
tion may be used to test more hypotheses about the function of 
particular residues than would be possible through site 
directed mutagenesis. By making a library of changes at a 
65 single site, additional information could be obtained about the 
importance of side chain size, polarity, and charge over just 
the traditional mutation to alanine that is often used to explore 
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single residue importance. In the absence of structural infor-
mation, it is possible to make large libraries using error prone 
PCR or gene shuffling. Chemical complementation could 
also be used to select active variants from these types of 
libraries. 
Example 13 
Increasing the Sensitivity of Chemical 
Complementation with ACTR 
To increase the sensitivity of chemical complementation, 
10 
42 
with the Gal4 activation domain increases the sensitivity of 
chemical complementation 1000-fold, making this system 
more efficient for analysis of protein/ligand interactions. 
Example 14 
Increasing Sensitivity of Chemical Complementation 
Using SRC-1 
Another RXR coactivator was tested to increase the sensi-
tivity of chemical complementation. Residues 54 to 1442 of 
the human nuclear receptor coactivator, SRC-1, were fused to 
the Gal4 activation domain to construct the plasmid 
pGADlO-BASRCl. This plasmid, which expresses SRCl: 
an adapter protein was introduced to link the mammalian 
nuclear receptor function to the yeast transcription apparatus, 
thereby overcoming the evolutionary divergence between 
mammalian cells and yeast. The human nuclear receptor 
coactivator ACTR was fused to the yeast Gal4 activation 
domain This plasmid, pGADlO-BA-ACTR, expresses the 
ACTR:GAD fusion protein and contains a leucine marker. 
This plasmid was co-transformed into yeast with the plasmid 
pGBDRXR, which expresses the Gal4 DNA binding domain 
(DBD) fused to the RXR ligand binding domain (GBD:RXR) 
and contains a tryptophan marker. Transformants were 
selected on SC-Leu-Trp plates, and were streaked onto 
adenine selective plates (SC-Ade) containing 1o-5M9cRA, a 
known ligand for RXR (FIG. SG). Yeast containing just the 
pGBDRXR plasmid, the pGADlO-BA-ACTR plasmid, a 
plasmid with just the Gal4 DBD (pGBDMT), and a plasmid 
containing the Gal4 halo protein (pGBT9Gal4) were also 
streaked onto these plates as controls. 
15 GAD in yeast and contains a leucine marker was transformed 
with GBD:RXR; transformants selected from SC-Leu-Trp 
were streaked onto adenine selective plates (SC-Ade) with 
various concentrations of 9cRA (FIG. 6). Ligand-activated 
growth is observed only in the sector of the plate containing 
20 both GBD:RXR with SRCl :GAD, and the same trend is 
observed with SRC-I as the ACTR coactivator (FIG. 6). 
To verify that the increased sensitivity is from specific 
interactions between the coactivator and the active conforma-
tion of the receptor, a series of further controls was devised. 
25 pGADlO, a plasmid containing the Gal4 activation domain 
(GAD) without a coactivator domain was co-transformed 
with pGBDRXR. The plasmid was also transformed alone. 
pGADlO-BA-ACTR (SEQ ID NO.: 1), pGADlO-BASRCl, 
pGBT9Gal4, and pGBDMT were all transformed individu-
After two days of incubation, growth occurs on the sector 
of the plate containing ACTR:GAD with GBD:RXR and on 
the sector of the plate with Gal4; whereas no growth occurs on 
the sector of the plate with GBD:RXR alone (FIG. SG). The 
growth density produced by GBD:RXR and ACTR:GAD is 
the same as the growth produced by the halo Gal4. Impor-
tantly, GBD:RXR and ACTR:GAD produced no growth on 
plates without 9cRA. 
30 ally. These controls were streaked onto adenine selective 
plates (SC-Ade) with and without 9cRA. In the absence of 
ligand, only the entire Gal4 gene (pGBT9Gal4) grows as 
expected (data not shown). In the presence of 10-5 M 9cRA, 
growth occurs with the GBD:RXR with ACTR:GAD and 
35 GBD:RXR with SR Cl :GAD. The Gal4 AD only (without the 
coactivator domain) with GBD:RXR displays no growth. 
These results verify that the increase in chemical complemen-
tation is specifically due to the interaction of the coactivator 
Previous findings showed no growth was observed with 
RXR at 9cRA concentrations lower than 10-5 M. To deter- 40 
mine if the sensitivity of our system had increased with the 
introduction of the adapter fusion protein, a dose response 
was performed on adenine selective plates (SC-Ade) contain-
ing ligand concentrations ranging from 10-5 M to 10-9 M. 
After two days of incubation, a clear dose response occurs on 45 
the plates (FIG. 5). Without ligand, growth occurs only on the 
Gal4 sector of the plate, as expected At concentrations as low 
as 10-3 M 9cRA, ligand-activated growth occurs only on the 
sector of the plate containing both GBD:RXR with ACTR: 
GAD (FIG. SD). At concentrations of ligand above 10-3 M, 50 
higher density growth is observed on the sector of the plate 
containing GBD:RXR withACTR:GAD. No growth occurs 
with GBD:RXR alone as expected. In summary, the introduc-
tion of the fusion proteinACTR:GAD increases the sensitiv-
ity of chemical complementation. Growth occurs on adenine 55 
selective plates with 9cRA after two days ofincubation (FIG. 
5). Ligand-activated growth is observed at 9cRA concentra-
tions as low as 10-3 M 9cRA. With chemical complementa-
tion, an approximate EC50 value between 1 o-8 Mand 1o-7 M 
for wild-type RXR and 9cRA, which is comparable to the 60 
EC50 value measured for wild-type RXR in mammalian cell 
assays (about 10-7 M) (FIG. 5). The growth density and rate 
with the ACTR:GAD fusion protein is comparable to Gal4 
activated growth. The same results were obtained on adenine 
selective plates (SC-Ade-Trp and SC-Ade-Leu-Trp) and on 65 
histidine selective plates (data not shown). In summary, intro-
ducing an adapter fusion protein of the human coactivator 
fusion protein with the ligand-bound nuclear receptor. 
Example 15 
Chemical Complementation and Negative Selection 
Negative selection is the opposite of classical genetic 
complementation. Instead of allowing the microbe to survive, 
a functional gene kills the microbe; only cells containing 
non-functional genes survive and form colonies on selective 
plates. Negative selection is useful for finding mutations that 
disrupt the function of a protein. 
For negative selection in yeast, others have generated yeast 
strains that contain Gal4 response elements (REs) fused to the 
URA3 gene. The URA3 gene codes for or orotidine-5'-phos-
phate decarboxylase, an enzyme in the uracil biosynthetic 
pathway. This gene can be used for both positive and negative 
selection. For positive selection, yeast expressing this gene 
will survive in the absence of uracil in the media. For negative 
selection, uracil and 5-fluoroorotic acid (FOA) is added to the 
media. Expression of orotidine-5'-phosphate decarboxylase 
coverts FOA to the toxin 5-fluorouracil, which kills the yeast. 
As used herein, the term "negative chemical complementa-
tion" refers to negative selection that occurs due to the pres-
ence of a small molecule. 
Plasmids pGBDRXR and pGADlO-BA-ACTR were indi-
vidually transformed and co-transformed into MaV103. 
Transformants were streaked onto uracil selective plates (SC-
Ura-Trp) with 9cRA for positive selection. The same trend 
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was seen with the ACTR:GAD with GBD:RXR in the 
MaV103 strain as seen previously with the PJ69-4A strain. 
The same transformants were streaked onto selective plates 
(SC-Leu-Trp) with FOA for negative chemical complemen-
tation. Varying concentrations of9cRA were also added to the 5 
plates, ranging from 10-5 M to 1 o-8 M. In the absence of 
ligand (FIG. 7B), yeast grow on the sector of the plate con-
taining ACTR:GAD with GBD:RXR as expected. This is 
expected because uracil is provided, and in the absence of 
ligand RXR maintains its inactive conformation, preventing 10 
ACTR:GAD from binding and transcription does not occur. 
Without expression of the URA3 gene, 5-fluorouracil is not 
produced and the yeast survive. However, as the concentra-
tion ofligand increases (FIG. 7B-7F), less growth occurs and 
at the highest concentration of ligand, 10-5 M, very little 15 
growth occurs. The small amount of growth that is observed 
is due to background growth associated with negative selec-
tion in this strain. 
Negative chemical complementation is advantageous for 
engineering receptors for new small molecules for several 20 
reasons. First, mutant receptor libraries may contain consti-
tutively active receptors or receptors that activate transcrip-
tion in response to endogenous small molecules. These unde-
sirable receptors can be removed from the library with 
negative selection. Second, in some cases it will be desirable 25 
to remove members of the library that activate in response to 
certain small molecules, e.g. the natural ligands. Negative 
chemical complementation will remove these members of the 
library. The remaining library can then be put through chemi-
44 
Gal4, but growth also occurs on the sectorof the plate with the 
two mutants F313I and F313I;F 439L, This could be a result of 
the mutations causing a structural modification to the binding 
pocket that is favorable for the binding of an endogenous 
small molecule in yeast. At 10-5 M 9cRA, growth occurs on 
the sectors of the plate with the single mutants, C432G, 
Q275C, I268F, I310M, V342F, andF439L, as well as some of 
the triple mutants I310M;F313I;F439L and Q275C;F313I; 
V342F. As the concentration of ligand decreases, some 
mutants no longer show ligand-activated growth. At 10-7 M 
9cRA, growth is observed with the F439L mutant as well as 
wild-type RXR (FIG. 8). At the lowest concentration of 
ligand, 10-8M 9cRA, growth is observed in the Gal4 and 
F313I sectors of the plates. For the synthetic ligand LG335, 
growth is observed with several of the single, double and 
triple mutants at 10-5 M (FIG. 8). At lower concentrations of 
ligand, the single mutants do not show much growth. How-
ever, several of the double and triple mutants I310M;F313I; 
F439L, Q275C;F313I, and I310M;F313I display ligand-ac-
tivated growth at 10-7M LG335. At 10-3 M LG335, some 
growth is still observed in the I310M;F313I;F439L sector of 
the plate. 
A correlation is apparent between yeast growth and tran-
scriptional activation in mammalian cells when quantitating 
these results and comparing them with results from cell cul-
ture assays (Table 3 ). The I268F, Q27 SC, C432G, 131 OM, and 
I310M; F313I; F439L mutations which had previously not 
shown any growth with chemical complementation, grow 
with theACTR:GAD fusion protein (FIG. 8). The more direct 
correlation between chemical complementation and mamma-
lian cell assays shows that the coactivator fusion protein 
(ACTR:GAD) serves to bridge millions of years of evolution 
by adapting mammalian nuclear receptor function to the yeast 
transcription machinery. 
Example 17 
Experimental Procedure for Enzyme-Linked Yeast 
Growth 
cal complementation with the small molecule of interest. 30 
Third, for enzyme engineering negative chemical comple-
mentation can remove library members that produce a par-
ticular small molecule, e.g. an enantiomer of the compound of 
interest. The remaining mutant enzyme library can then be 
put through chemical complementation to find those capable 35 
of producing the small molecule of interest. Fourth, for drug 
discovery, chemical libraries can be efficiently evaluated for 
antagonists of nuclear receptors by their ability to allow the 
yeast to survive negative chemical complementation. An endogenous yeast compound was converted by two 
40 enzymes to a VDR-specific ligand allowing the yeast strain to 
survive and grow on a culture medium lacking histidine. Example 16 
Chemical Complementation with RXR Mutants 
Several RXR mutants previously tested in both mamma-
lian cell assays and with chemical complementation in yeast 
(without the coactivator fusion protein) showed a general, but 
less than complete correlation. Without the coactivator fusion 
protein, ligand-activated growth was observed only with 
wild-type RXR and the F439L mutant after five days of 
incubation; none of the other mutants showed ligand-acti-
vated growth. The variation in the transcription machinery 
could lead to the different patterns in activation. To test 
whether the adapter fusion protein could overcome the dif-
ferences and show a more direct correlation, all the mutants in 
Table 3 were cloned into pGBD vectors and co-transformed 
into yeast with pGADlO-BA-ACTR. Again, transformants 
were selected from SC-Leu-Trp plates and then streaked onto 
adenine selective plates (SC-Ade-Trp ). These mutants were 
tested with 9cRA and LG335 (a near-drug, a synthetic com-
pound structurally similar to an RXR agonist but that does not 
activate wild-type RXR) (Table 3). 
The transcriptional activation patterns of these mutants in 
chemical complementation with the addition of ACTR:GAD 
was observed on dose response plates containing both 9cRA 
and the synthetic ligand, LG335 (FIG. 8). On the plate with-
out ligand, growth occurs on the sector of the plate containing 
The yeast strain PJ69-4A (James et al., (1996) Genetics 
144:1425-1436, incorporated herein in its entirety) was trans-
formed using standard yeast transformation protocols accord-
45 ing to Gietz et al., (2002) Methods Enzymol. 350:87-96, 
incorporated herein in its entirety, with various combinations 
of four plasmids: pVDR-wt (SEQ ID NO.: 20), expressing the 
GDB:VDR fusion protein; pGAD-BA-ACTR (SEQ ID NO.: 
19), expressing the ACTR:GAD fusion protein; pY2653 
50 (SEQ ID NO.: 22), expressing the CYP2Rl gene (encoding 
the P450 2Rl enzyme); and pS0016 (SEQ ID NO.: 21), 
expressing the CYP27Bl gene (encoding the P450 27Bl 
enzyme). 
The endogenous yeast compound is proposed to be vitamin 
55 D2 ( ergocalciferol). Vitamin D2 (which is not a VDR ligand) 
is converted by the enzyme P450 2Rl to 25-hydroxyvitamin 
D2 (also not a VDR ligand) (Cheng et al., (2003) J. Biol. 
Chem. 278:38084-38093). The 25-hydroxyvitamin D2 is con-
verted by the P450 27B2 enzyme to la,25-dihydroxyvitamin 
60 D2 (Takeyama et al., (1997) Science 277: 1827-1830), which 
is a VDR ligand. la,25-dihydroxyvitamin D2 binds and acti-
vates VDR, expressing the HIS3 gene, allowing the yeast to 
survive and grow on media lacking histidine. FIG. 22 illus-
trates schematically the conversion of the endogenous sub-
65 strate to the VDR ligand la,25-dihydroxyvitamin D2 . FIG. 
23 illustrates digital images of the growth results of the four 
types oftransformants on His-culture medium. 
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SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 22 
<210> SEQ ID NO 1 
<211> LENGTH, 17 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer 
<400> SEQUENCE, 1 
cggaatttcc catgggc 
<210> SEQ ID NO 2 
<211> LENGTH, 37 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer 
<400> SEQUENCE, 2 
ctcgccgaac gacccggtca ccgcatgcca ctagtgg 
<210> SEQ ID NO 3 
<211> LENGTH, 36 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer 
<400> SEQUENCE, 3 
ccgcttggcc cactccacta gtggcatgcg gtgacc 
<210> SEQ ID NO 4 
<211> LENGTH, 37 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer 
<400> SEQUENCE, 4 
cgggcaggct ggaatgagct cctcgacgga attctcc 
<210> SEQ ID NO 5 
<211> LENGTH, 36 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer 
<400> SEQUENCE, 5 
cagcccggtg gccaggagaa ttccgtcgag gagctc 
<210> SEQ ID NO 6 
<211> LENGTH, 40 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer 
<400> SEQUENCE, 
ctctgcgctc catcgggctt aagtgcccac caattgacac 
<210> SEQ ID NO 7 
<211> LENGTH, 46 
<212> TYPE, DNA 
46 
17 
37 
36 
37 
36 
40 
47 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer 
<400> SEQUENCE, 7 
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ctccagcatc tccataagga aggtgtcaat tggtgggcac ttaagc 
<210> SEQ ID NO 8 
<211> LENGTH, 17 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer 
<400> SEQUENCE, 8 
caaaggatgg gccgcag 
<210> SEQ ID NO 9 
<211> LENGTH, 46 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer 
<400> SEQUENCE, 9 
ggcaaacatg gggctgaacc ccagctcgcc gaacgacccg gtcacc 
<210> SEQ ID NO 10 
<211> LENGTH, 66 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (33) .. (38) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (45) .. (46) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<400> SEQUENCE, 10 
46 
17 
46 
gcccactcca ctagtgtgaa aagctgtttg tcnnnnnntt ggcanngttg gtgaccgggt 60 
cgttcg 66 
<210> SEQ ID NO 11 
<211> LENGTH, 48 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer 
<400> SEQUENCE, 11 
cttttcacac tagtggagtg ggccaagcgg atcccacact tctcagag 
<210> SEQ ID NO 12 
<211> LENGTH, 28 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer 
<400> SEQUENCE, 12 
ggggcagctc tgagaagtgt gggatccg 
<210> SEQ ID NO 13 
48 
28 
48 
<211> LENGTH, 48 
<212> TYPE, DNA 
49 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (22) .. (24) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (31) .. (33) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<400> SEQUENCE, 13 
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gcaggctgga atgagctcct cnnngcctcc nnntcccacc gctccatc 
<210> SEQ ID NO 14 
<211> LENGTH, 46 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer 
<400> SEQUENCE, 14 
ccggtggcca ggagaattcc gtccttcacg gcgatggagc ggtggg 
<210> SEQ ID NO 15 
<211> LENGTH, 63 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, AMl 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (38) .. (40) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<400> SEQUENCE, 15 
48 
46 
ggctctgcgc tccatcgggc ttaagtgcct ggaacatnnn ttscttcttc aagctcatcg 60 
ggg 63 
<210> SEQ ID NO 16 
<211> LENGTH, 51 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, AM2 
<400> SEQUENCE, 16 
gcatctcaat aaggaaggtg tcaattgtgt gtccccgatg agcttgaaga a 
<210> SEQ ID NO 17 
<211> LENGTH, 12414 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Artificial vector 
<400> SEQUENCE, 17 
gcttgcatgc aacttctttt cttttttttt cttttctctc 
atatccgcaa tgacaaaaaa aatgatggaa gacactaaag 
cagcaccaac agatgtcgtt gttccagagc tgatgagggg 
tttttccttc cttcattcac gcacactact ctctaatgag 
tccagttact tgaatttgaa ataaaaaaag tttgccgctt 
tcccccgttg ttgtctcacc 
gaaaaaatta acgacaaaga 
tatcttcgaa cacacgaaac 
caacggtata cggccttcct 
tgctatcaag tataaataga 
51 
60 
120 
180 
240 
300 
50 
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cctgcaatta ttaatctttt gtttcctcgt cattgttctc gttccctttc ttccttgttt 
ctttttctgc acaatatttc aagctatacc aagcatacaa tcaactccaa gctttgcaaa 
gatggataaa gcggaattaa ttcccgagcc tccaaaaaag aagagaaagg tcgaattggg 
taccgccgcc aattttaatc aaagtgggaa tattgctgat agctcattgt ccttcacttt 
cactaacagt agcaacggtc cgaacctcat aacaactcaa acaaattctc aagcgctttc 
acaaccaatt gcctcctcta acgttcatga taacttcatg aataatgaaa tcacggctag 
taaaattgat gatggtaata attcaaaacc actgtcacct ggttggacgg accaaactgc 
gtataacgcg tttggaatca ctacagggat gtttaatacc actacaatgg atgatgtata 
taactatcta ttcgatgatg aagatacccc accaaaccca aaaaaagaga tctttatgag 
tggattagga gaaaacttgg atccactggc cagtgattca cgaaaacgca aattgccatg 
tgatactcca ggacaaggtc ttacctgcag tggtgaaaaa cggagacggg agcaggaaag 
taaatatatt gaagaattgg ctgagctgat atctgccaat cttagtgata ttgacaattt 
caatgtcaaa ccagataaat gtgcgatttt aaaggaaaca gtaagacaga tacgtcaaat 
aaaagagcaa ggaaaaacta tttccaatga tgatgatgtt caaaaagccg atgtatcttc 
tacagggcag ggagttattg ataaagactc cttaggaccg cttttacttc aggcattgga 
tggtttccta tttgtggtga atcgagacgg aaacattgta tttgtatcag aaaatgtcac 
acaatacctg caatataagc aagaggacct ggttaacaca agtgtttaca atatcttaca 
tgaagaagac agaaaggatt ttcttaagaa tttaccaaaa tctacagtta atggagtttc 
ctggacaaat gagacccaaa gacaaaaaag ccatacattt aattgccgta tgttgatgaa 
aacaccacat gatattctgg aagacataaa cgccagtcct gaaatgcgcc agagatatga 
aacaatgcag tgctttgccc tgtctcagcc acgagctatg atggaggaag gggaagattt 
gcaatcttgt atgatctgtg tggcacgccg cattactaca ggagaaagaa catttccatc 
aaaccctgag agctttatta ccagacatga tctttcagga aaggttgtca atatagatac 
aaattcactg agatcctcca tgaggcctgg ctttgaagat ataatccgaa ggtgtattca 
gagatttttt agtctaaatg atgggcagtc atggtcccag aaacgtcact atcaagaagt 
taccagtgat gggatatttt ccccaacagc ttatcttaat ggccatgcag aaaccccagt 
atatcgattc tcgttggctg atggaactat agtgactgca cagacaaaaa gcaaactctt 
ccgaaatcct gtaacaaatg atcgacatgg ctttgtctca acccacttcc ttcagagaga 
acagaatgga tatagaccaa acccaaatcc tgttggacaa gggattagac cacctatggc 
tggatgcaac agttcggtag gcggcatgag tatgtcgcca aaccaaggct tacagatgcc 
gagcagcagg gcctatggct tggcagaccc tagcaccaca gggcagatga gtggagctag 
gtatgggggt tccagtaaca tagcttcatt gacccctggg ccaggcatgc aatcaccatc 
ttcctaccag aacaacaact ataggctcaa catgagtagc cccccacatg ggagtcctgg 
tcttgcccca aaccagcaga atatcatgat ttctcctcgt aatcgtggga gtccaaagat 
agcctcacat cagttttctc ctgttgcagg tgtgcactct cccatggcat cttctggcaa 
tactgggaac cacagctttt ccagcagctc tctcagtgcc ctgcaagcca tcagtgaagg 
tgtggggact tcccttttat ctactctgtc atcaccaggc cccaaattgg ataactctcc 
caatatgaat attacccaac caagtaaagt aagcaatcag gattccaaga gtcctctggg 
cttttattgc gaccaaaatc cagtggagag ttcaatgtgt cagtcaaata gcagagatca 
cctcagtgac aaagaaagta aggagagcag tgttgagggg gcagagaatc aaaggggtcc 
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tttggaaagc aaaggtcata aaaaattact gcagttactt acctgttctt ctgatgaccg 
gggtcattcc tccttgacca actcccccct agattcaagt tgtaaagaat cttctgttag 
tgtcaccagc ccctctggag tctcctcctc tacatctgga ggagtatcct ctacatccaa 
tatgcatggg tcactgttac aagagaagca ccggattttg cacaagttgc tgcagaatgg 
gaattcacca gctgaggtag ccaagattac tgcagaagcc actgggaaag acaccagcag 
tataacttct tgtggggacg gaaatgttgt caagcaggag cagctaagtc ctaagaagaa 
ggagaataat gcacttctta gatacctgct ggacagggat gatcctagtg atgcactctc 
taaagaacta cagccccaag tggaaggagt ggataataaa atgagtcagt gcaccagctc 
caccattcct agctcaagtc aagagaaaga ccctaaaatt aagacagaga caagtgaaga 
gggatctgga gacttggata atctagatgc tattcttggt gatctgacta gttctgactt 
ttacaataat tccatatcct caaatggtag tcatctgggg actaagcaac aggtgtttca 
aggaactaat tctctgggtt tgaaaagttc acagtctgtg cagtctattc gtcctccata 
taaccgagca gtgtctctgg atagccctgt ttctgttggc tcaagtcctc cagtaaaaaa 
tatcagtgct ttccccatgt taccaaagca acccatgttg ggtgggaatc caagaatgat 
ggatagtcag gaaaattatg gctcaagtat gggagactgg ggcttaccaa actcaaaggc 
cggcagaatg gaacctatga attcaaactc catgggaaga ccaggaggag attataatac 
ttctttaccc agacctgcac tgggtggctc tattcccaca ttgcctcttc ggtctaatag 
cataccaggt gcgagaccag tattgcaaca gcagcagcag atgcttcaaa tgaggcctgg 
tgaaatcccc atgggaatgg gggctaatcc ctatggccaa gcagcagcat ctaaccaact 
gggttcctgg cccgatggca tgttgtccat ggaacaagtt tctcatggca ctcaaaatag 
gcctcttctt aggaattccc tggatgatct tgttgggcca ccttccaacc tggaaggcca 
gagtgacgaa agagcattat tggaccagct gcacactctt ctcagcaaca cagatgccac 
aggcctggaa gaaattgaca gagctttggg cattcctgaa cttgtcaatc agggacaggc 
attagagccc aaacaggatg ctttccaagg ccaagaagca gcagtaatga tggatcagaa 
ggcaggatta tatggacaga catacccagc acaggggcct ccaatgcaag gaggctttca 
tcttcaggga caatcaccat cttttaactc tatgatgaat cagatgaacc agcaaggcaa 
ttttcctctc caaggaatgc acccacgagc caacatcatg agaccccgga caaacacccc 
caagcaactt agaatgcagc ttcagcagag gctgcagggc cagcagtttt tgaatcagag 
ccgacaggca cttgaattga aaatggaaaa ccctactgct ggtggtgctg cggtgatgag 
gcctatgatg cagccccagc agggttttct taatgctcaa atggtcgccc aacgcagcag 
agagctgcta agtcatcact tccgacaaca gagggtggct atgatgatgc agcagcagca 
acagcagcag cagcagcagc agcagcagca acagcaacag caacagcaac agcagcaaca 
gcagcaaacc caggccttca gcccacctcc taatgtgact gcttccccca gcatggatgg 
gcttttggca ggacccacaa tgccacaagc tcctccgcaa cagtttccat atcaaccaaa 
ttatggaatg ggacaacaac cagatccagc ctttggtcga gtgtctagtc ctcccaatgc 
aatgatgtcg tcaagaatgg gtccctccca gaatcccatg atgcaacacc cgcaggctgc 
atccatctat cagtcctcag aaatgaaggg ctggccatca ggaaatttgg ccaggaacag 
ctccttttcc cagcagcagt ttgcccacca ggggaatcct gcagtgtata gtatggtgca 
catgaatggc agcagtggtc acatgggaca gatgaacatg aaccccatgc ccatgtctgg 
catgcctatg ggtcctgatc agaaatactg ctgacatctc tgcaccagga cctcttaagg 
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aaaccactgt acaaatgaca ctgcactagg attattggga aggaatcatt gttccaggca 
tccatcttgg aagaaaggac cagctttgag ctccatcaag ggtattttaa gtgatgtcat 
ttgagcagga ctggatttta agccgaaggg caatatctac gtgtttttcc cccctccttc 
tgctgtgtat catggtgttc aaaacagaaa tgttttttgg cattccacct cctagggata 
taattctgga gacatggagt gttactgatc ataaaacttt tgtgtcactt ttttctgcct 
tgctagccaa aatctcttaa atacacgtag gtgggccaga gaacattgga agaatcaaga 
gagattagaa tatctggttt ctctagttgc agtattggac aaagagcata gtcccagcct 
tcaggtgtag tagttctgtg ttgacccttt gtccagtgga attggtgatt ctgaattgtc 
ctttactaat ggtgttgagt tgctctgtcc ctattatttg ccctaggctt tctcctaatg 
aaggttttca tttgccattc atgtcctgta atacttcacc tccaggaact gtcatggatg 
tccaaatggc tttgcagaaa ggaaatgaga tgacagtatt taatcgcagc agtagcaaac 
ttttcacatg ctaatgtgca gctgagtgca ctttatttaa aaagaatgga taaatgcaat 
attcttgagg tcttgaggga atagtgaaac acattcctgg tttttgccta cacttacgtg 
ttagacaaga actatgattt ttttttttaa agtactggtg tcaccctttg cctatatggt 
agagcaataa tgctttttaa aaataaactt ctgaaaaccc aaggccaggt actgcattct 
gaatcagaat ctcgcagtgt ttctgtgaat agattttttt gtaaatatga cctttaagat 
attgtattat gtaaaatatg tatatacctt tttttgtagg tcacaacaac tcatttttac 
agagtttgtg aagctaaata tttaacattg ttgatttcag taagctgtgt ggtgaggcta 
ccagtggaag agacatccct tgacttttgt ggcctggggg aggggtagtg caccacagct 
tttccttccc caccccccag ccttagatgc ctcgctcttt tcaatctctt aatctaaatg 
ctttttaaag agattatttg tttagatgta ggcattttaa ttttttaaaa attcctctac 
cagaactaag cactttgtta atttgggggg aaagaataga tatggggaaa taaacttaaa 
aaaaaatcag gaatttaaaa aaaacgagca atttgaagag aatcttttgg attttaagca 
gtccgaaata atagcaattc atgggctgtg tgtgtgtgtg tatgtgtgtg tgtgtgtgtg 
tatgtttaat tatgttacct tttcatcccc tttaggagcg ttttcagatt ttggttcgta 
agacctgaat cccgcggccg ccccgggcgt agatactgaa aaaccccgca agttcacttc 
aactgtgcat cgtgcaccat ctcaatttct ttcatttata catcgttttg ccttctttta 
tgtaactata ctcctctaag tttcaatctt ggccatgtaa cctctgatct atagaatttt 
ttaaatgact agaattaatg cccatctttt ttttggacct aaattcttca tgaaaatata 
ttacgagggc ttattcagaa gctttggact tcttcgccag aggtttggtc aagtctccaa 
tcaaggttgt cggcttgtct accttgccag aaatttacga aaagatggaa aagggtcaaa 
tcgttggtag atacgttgtt gacacttcta aataagcgaa tttcttatga tttatgattt 
ttattattaa ataagttata aaaaaaataa gtgtatacaa attttaaagt gactcttagg 
ttttaaaacg aaaattcttg ttcttgagta actctttcct gtaggtcagg ttgctttctc 
aggtatagca tgaggtcgct cttattgacc acacctctac cggcatgccc gaaattcccc 
taccctatga acatattcca ttttgtaatt tcgtgtcgtt tctattatga atttcattta 
taaagtttat gtacaaatat cataaaaaaa gagaatcttt ttaagcaagg attttcttaa 
cttcttcggc gacagcatca ccgacttcgg tggtactgtt ggaaccacct aaatcaccag 
ttctgatacc tgcatccaaa acctttttaa ctgcatcttc aatggcctta ccttcttcag 
gcaagttcaa tgacaatttc aacatcattg cagcagacaa gatagtggcg atagggtcaa 
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ccttattctt tggcaaatct ggagcagaac cgtggcatgg ttcgtacaaa ccaaatgcgg 
tgttcttgtc tggcaaagag gccaaggacg cagatggcaa caaacccaag gaacctggga 
taacggaggc ttcatcggag atgatatcac caaacatgtt gctggtgatt ataataccat 
ttaggtgggt tgggttctta actaggatca tggcggcaga atcaatcaat tgatgttgaa 
ccttcaatgt aggaaattcg ttcttgatgg tttcctccac agtttttctc cataatcttg 
aagaggccaa aacattagct ttatccaagg accaaatagg caatggtggc tcatgttgta 
gggccatgaa agcggccatt cttgtgattc tttgcacttc tggaacggtg tattgttcac 
tatcccaagc gacaccatca ccatcgtctt cctttctctt accaaagtaa atacctccca 
ctaattctct gacaacaacg aagtcagtac ctttagcaaa ttgtggcttg attggagata 
agtctaaaag agagtcggat gcaaagttac atggtcttaa gttggcgtac aattgaagtt 
ctttacggat ttttagtaaa ccttgttcag gtctaacact acctgtaccc catttaggac 
cacccacagc acctaacaaa acggcatcaa ccttcttgga ggcttccagc gcctcatctg 
gaagtgggac acctgtagca tcgatagcag caccaccaat taaatgattt tcgaaatcga 
acttgacatt ggaacgaaca tcagaaatag ctttaagaac cttaatggct tcggctgtga 
tttcttgacc aacgtggtca cctggcaaaa cgacgatctt cttaggggca gacattagaa 
tggtatatcc ttgaaatata tatatatatt gctgaaatgt aaaaggtaag aaaagttaga 
aagtaagacg attgctaacc acctattgga aaaaacaata ggtccttaaa taatattgtc 
aacttcaagt attgtgatgc aagcatttag tcatgaacgc ttctctattc tatatgaaaa 
gccggttccg gcctctcacc tttccttttt ctcccaattt ttcagttgaa aaaggtatat 
gcgtcaggcg acctctgaaa ttaacaaaaa atttccagtc atcgaatttg attctgtgcg 
atagcgcccc tgtgtgttct cgttatgttg aggaaaaaaa taatggttgc taagagattc 
gaactcttgc atcttacgat acctgagtat tcccacagtt ggggatctcg actctagcta 
gaggatcaat tcgtaatcat ggtcatagct gtttcctgtg tgaaattgtt atccgctcac 
aattccacac aacatacgag ccggaagcat aaagtgtaaa gcctggggtg cctaatgagt 
gaggtaactc acattaattg cgttgcgctc actgcccgct ttccagtcgg gaaacctgtc 
gtgccagctg gattaatgaa tcggccaacg cgcggggaga ggcggtttgc gtattgggcg 
ctcttccgct tcctcgctca ctgactcgct gcgctcggtc gttcggctgc ggcgagcggt 
atcagctcac tcaaaggcgg taatacggtt atccacagaa tcaggggata acgcaggaaa 
gaacatgtga gcaaaaggcc agcaaaaggc caggaaccgt aaaaaggccg cgttgctggc 
gtttttccat aggctccgcc cccctgacga gcatcacaaa aatcgacgct caagtcagag 
gtggcgaaac ccgacaggac tataaagata ccaggcgttt ccccctggaa gctccctcgt 
gcgctctcct gttccgaccc tgccgcttac cggatacctg tccgcctttc tcccttcggg 
aagcgtggcg ctttctcata gctcacgctg taggtatctc agttcggtgt aggtcgttcg 
ctccaagctg ggctgtgtgc acgaaccccc cgttcagccc gaccgctgcg ccttatccgg 
taactatcgt cttgagtcca acccggtaag acacgactta tcgccactgg cagcagccac 
tggtaacagg attagcagag cgaggtatgt aggcggtgct acagagttct tgaagtggtg 
gcctaactac ggctacacta gaaggacagt atttggtatc tgcgctctgc tgaagccagt 
taccttcgga aaaagagttg gtagctcttg atccggcaaa caaaccaccg ctggtagcgg 
tggttttttt gtttgcaagc agcagattac gcgcagaaaa aaaggatctc aagaagatcc 
tttgatcttt tctacggggt ctgacgctca gtggaacgaa aactcacgtt aagggatttt 
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ggtcatgaga ttatcaaaaa ggatcttcac ctagatcctt ttaaattaaa aatgaagttt 9960 
taaatcaatc taaagtatat atgagtaaac ttggtctgac agttaccaat gcttaatcag 10020 
tgaggcacct atctcagcga tctgtctatt tcgttcatcc atagttgcct gactccccgt 10080 
cgtgtagata actacgatac gggagggctt accatctggc cccagtgctg caatgatacc 10140 
gcgagaccca cgctcaccgg ctccagattt atcagcaata aaccagccag ccggaagggc 10200 
cgagcgcaga agtggtcctg caactttatc cgcctccatc cagtctatta attgttgccg 10260 
ggaagctaga gtaagtagtt cgccagttaa tagtttgcgc aacgttgttg ccattgctac 10320 
aggcatcgtg gtgtcacgct cgtcgtttgg tatggcttca ttcagctccg gttcccaacg 10380 
atcaaggcga gttacatgat cccccatgtt gtgcaaaaaa gcggttagct ccttcggtcc 10440 
tccgatcgtt gtcagaagta agttggccgc agtgttatca ctcatggtta tggcagcact 10500 
gcataattct cttactgtca tgccatccgt aagatgcttt tctgtgactg gtgagtactc 10560 
aaccaagtca ttctgagaat agtgtatgcg gcgaccgagt tgctcttgcc cggcgtcaat 10620 
acgggataat accgcgccac atagcagaac tttaaaagtg ctcatcattg gaaaacgttc 10680 
ttcggggcga aaactctcaa ggatcttacc gctgttgaga tccagttcga tgtaacccac 10740 
tcgtgcaccc aactgatctt cagcatcttt tactttcacc agcgtttctg ggtgagcaaa 10800 
aacaggaagg caaaatgccg caaaaaaggg aataagggcg acacggaaat gttgaatact 10860 
catactcttc ctttttcaat attattgaag catttatcag ggttattgtc tcatgagcgg 10920 
atacatattt gaatgtattt agaaaaataa acaaataggg gttccgcgca catttccccg 10980 
aaaagtgcca cctgacgtct aagaaaccat tattatcatg acattaacct ataaaaatag 11040 
gcgtatcacg aggccctttc gtctcgcgcg tttcggtgat gacggtgaaa acctctgaca 11100 
catgcagctc ccggagacgg tcacagcttg tctgtaagcg gatgccggga gcagacaagc 11160 
ccgtcagggc gcgtcagcgg gtgttggcgg gtgtcggggc tggcttaact atgcggcatc 11220 
agagcagatt gtactgagag tgcaccataa cgcatttaag cataaacacg cactatgccg 11280 
ttcttctcat gtatatatat atacaggcaa cacgcagata taggtgcgac gtgaacagtg 11340 
agctgtatgt gcgcagctcg cgttgcattt tcggaagcgc tcgttttcgg aaacgctttg 11400 
aagttcctat tccgaagttc ctattctcta gctagaaagt ataggaactt cagagcgctt 11460 
ttgaaaacca aaagcgctct gaagacgcac tttcaaaaaa ccaaaaacgc accggactgt 11520 
aacgagctac taaaatattg cgaataccgc ttccacaaac attgctcaaa agtatctctt 11580 
tgctatatat ctctgtgcta tatccctata taacctaccc atccaccttt cgctccttga 11640 
acttgcatct aaactcgacc tctacatttt ttatgtttat ctctagtatt actctttaga 11700 
caaaaaaatt gtagtaagaa ctattcatag agtgaatcga aaacaatacg aaaatgtaaa 11760 
catttcctat acgtagtata tagagacaaa atagaagaaa ccgttcataa ttttctgacc 11820 
aatgaagaat catcaacgct atcactttct gttcacaaag tatgcgcaat ccacatcggt 11880 
atagaatata atcggggatg cctttatctt gaaaaaatgc acccgcagct tcgctagtaa 11940 
tcagtaaacg cgggaagtgg agtcaggctt tttttatgga agagaaaata gacaccaaag 12000 
tagccttctt ctaaccttaa cggacctaca gtgcaaaaag ttatcaagag actgcattat 12060 
agagcgcaca aaggagaaaa aaagtaatct aagatgcttt gttagaaaaa tagcgctctc 12120 
gggatgcatt tttgtagaac aaaaaagaag tatagattct ttgttggtaa aatagcgctc 12180 
tcgcgttgca tttctgttct gtaaaaatgc agctcagatt ctttgtttga aaaattagcg 12240 
ctctcgcgtt gcatttttgt tttacaaaaa tgaagcacag attcttcgtt ggtaaaatag 12300 
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cgctttcgcg ttgcatttct gttctgtaaa aatgcagctc agattctttg tttgaaaaat 12360 
tagcgctctc gcgttgcatt tttgttctac aaaatgaagc acagatgctt cgtt 12414 
<210> SEQ ID NO 18 
<211> LENGTH, 7254 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Artificial vector 
<400> SEQUENCE, 18 
gcttgcatgc aacttctttt cttttttttt cttttctctc tcccccgttg ttgtctcacc 
atatccgcaa tgacaaaaaa aatgatggaa gacactaaag gaaaaaatta acgacaaaga 
cagcaccaac agatgtcgtt gttccagagc tgatgagggg tatcttcgaa cacacgaaac 
tttttccttc cttcattcac gcacactact ctctaatgag caacggtata cggccttcct 
tccagttact tgaatttgaa ataaaaaaag tttgccgctt tgctatcaag tataaataga 
cctgcaatta ttaatctttt gtttcctcgt cattgttctc gttccctttc ttccttgttt 
ctttttctgc acaatatttc aagctatacc aagcatacaa tcaactccaa gcttgaagca 
agcctcctga aagatgaagc tactgtcttc tatcgaacaa gcatgcgata tttgccgact 
taaaaagctc aagtgctcca aagaaaaacc gaagtgcgcc aagtgtctga agaacaactg 
ggagtgtcgc tactctccca aaaccaaaag gtctccgctg actagggcac atctgacaga 
agtggaatca aggctagaaa gactggaaca gctatttcta ctgatttttc ctcgagaaga 
ccttgacatg attttgaaaa tggattcttt acaggatata aaagcattgt taacaggatt 
atttgtacaa gataatgtga ataaagatgc cgtcacagat agattggctt cagtggagac 
tgatatgcct ctaacattga gacagcatag aataagtgcg acatcatcat cggaagagag 
tagtaacaaa ggtcaaagac agttgactgt atcgccggaa ttcccgggac agctgcattc 
tcccatcagc accctgagct cccccatcaa cggcatgggc ccgcctttct cggtcatcag 
ctcccccatg ggcccccact ccatgtcggt gcccaccaca cccaccctgg gcttcagcac 
tggcagcccc cagctcagct cacctatgaa ccccgtcagc agcagcgagg acatcaagcc 
ccccctgggc ctcaatggcg tcctcaaggt ccccgcccac ccctcaggaa acatggcttc 
cttcaccaag cacatctgcg ccatctgcgg ggaccgctcc tcaggcaagc actatggagt 
gtacagctgc gaggggtgca agggcttctt caagcggacg gtgcgcaagg acctgaccta 
cacctgccgc gacaacaagg actgcctgat tgacaagcgg cagcggaacc ggtgccagta 
ctgccgctac cagaagtgcc tggccatggg catgaagcgg gaagccgtgc aggaggagcg 
gcagcgtggc aaggaccgga acgagaatga ggtggagtcg accagcagcg ccaacgagga 
catgccggtg gagaggatcc tggaggctga gctggccgtg gagcccaaga ccgagaccta 
cgtggaggca aacatggggc tgaaccccag ctcgccgaac gaccctgtca ccaacatttg 
ccaagcagcc gacaaacagc ttttcaccct ggtggagtgg gccaagcgga tcccacactt 
ctcagagctg cccctggacg accaggtcat cctgctgcgg gcaggctgga atgagctgct 
catcgcctcc ttctcccacc gctccatcgc cgtgaaggac gggatcctcc tggccaccgg 
gctgcacgtc caccggaaca gcgcccacag cgcaggggtg ggcgccatct ttgacagggt 
gctgacggag cttgtgtcca agatgcggga catgcagatg gacaagacgg agctgggctg 
cctgcgcgcc atcgtcctct ttaaccctga ctccaagggg ctctcgaacc cggccgaggt 
ggaggcgctg agggagaagg tctatgcgtc cttggaggcc tactgcaagc acaagtaccc 
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agagcagccg ggaaggttcg ctaagctctt gctccgcctg ccggctctgc gctccatcgg 
gctcaaatgc ctggaacatc tcttcttctt caagctcatc ggggacacac ccattgacac 
cttccttatg gagatgctgg aggcgccgca ccaaatgact taggcctgcg ggcccatcct 
ttgtgcccac ccgttctggc caccctgcct ggacgccagc tgttcttctc agcctgagcc 
ctgtccctgc ccttctctgc ctggcctgtt tggactttgg ggcacagcct gtcactgctc 
tgcctaagag atgtgttgtc accctcctta tttctgttac tacttgtctg tggcccaggg 
cagtggcttt cctgagcagc agccttcgtg gcaagaacta gcgtgagccc agccaggcgc 
ctccccaccg ggctctcagg acgccctgcc acacccacgg ggcttgggcg actacagggt 
cttcggcccc agccctggag ctgcagccaa gctaattccg ggcgaatttc ttatgattta 
tgatttttat tattaaataa gttataaaaa aaataagtgt atacaaattt taaagtgact 
cttaggtttt aaaacgaaaa ttcttgttct tgagtaactc tttcctgtag gtcaggttgc 
tttctcaggt atagcatgag gtcgctctta ttgaccacac ctctaccggc atgccggcaa 
gtgcacaaac aatacttaaa taaatactac tcagtaataa cctatttctt agcatttttg 
acgaaatttg ctattttgtt agagtctttt acaccatttg tctccacacc tccgcttaca 
tcaacaccaa taacgccatt taatctaagc gcatcaccaa cattttctgg cgtcagtcca 
ccagctaaca taaaatgtaa gctttcgggg ctctcttgcc ttccaaccca gtcagaaatc 
gagttccaat ccaaaagttc acctgtccca cctgcttctg aatcaaacaa gggaataaac 
gaatgaggtt tctgtgaagc tgcactgagt agtatgttgc agtcttttgg aaatacgagt 
cttttaataa ctggccttac tccaaagaca cttcgacgtg actcatcata caacgtcaga 
aaacctttat gctcagaaaa ttattgaccg aaaccgagga actcttggta ttcttgccac 
gactcatctc catgcagttg gacgatatca atgccgtaat cattgaccag agccaaaaca 
tcctccttag gttgattacg aaacacgcca accaagtatt tcggagtgcc tgaactattt 
ttatatgctt ttacaagact tgaaattttc cttgcaataa ccgggtcaat tgttctcttt 
ctattgggca cacatataat acccagcaag tcagcatcgg aatctagagc acattctgcg 
gcctctgtgc tctgcaagcc gcaaactttc accaatggac cagaactacc tgtgaaatta 
ataacagaca tactccaagc tgcctttgtg tgcttaatca cgtatactca cgtgctcaat 
agtcaccaat gccctccctc ttggccctct ccttttcttt tttcgaccga attaattcgt 
aatcatggtc atagctgttt cctgtgtgaa attgttatcc gctcacaatt ccacacaaca 
tacgagccgg aagcataaag tgtaaagcct ggggtgccta atgagtgagg taactcacat 
taattgcgtt gcgctcactg cccgctttcc agtcgggaaa cctgtcgtgc cagctggatt 
aatgaatcgg ccaacgcgcg gggagaggcg gtttgcgtat tgggcgctct tccgcttcct 
cgctcactga ctcgctgcgc tcggtcgttc ggctgcggcg agcggtatca gctcactcaa 
aggcggtaat acggttatcc acagaatcag gggataacgc aggaaagaac atgtgagcaa 
aaggccagca aaaggccagg aaccgtaaaa aggccgcgtt gctggcgttt ttccataggc 
tccgcccccc tgacgagcat cacaaaaatc gacgctcaag tcagaggtgg cgaaacccga 
caggactata aagataccag gcgtttcccc ctggaagctc cctcgtgcgc tctcctgttc 
cgaccctgcc gcttaccgga tacctgtccg cctttctccc ttcgggaagc gtggcgcttt 
ctcatagctc acgctgtagg tatctcagtt cggtgtaggt cgttcgctcc aagctgggct 
gtgtgcacga accccccgtt cagcccgacc gctgcgcctt atccggtaac tatcgtcttg 
agtccaaccc ggtaagacac gacttatcgc cactggcagc agccactggt aacaggatta 
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gcagagcgag gtatgtaggc ggtgctacag agttcttgaa gtggtggcct aactacggct 
acactagaag gacagtattt ggtatctgcg ctctgctgaa gccagttacc ttcggaaaaa 
gagttggtag ctcttgatcc ggcaaacaaa ccaccgctgg tagcggtggt ttttttgttt 
gcaagcagca gattacgcgc agaaaaaaag gatctcaaga agatcctttg atcttttcta 
cggggtctga cgctcagtgg aacgaaaact cacgttaagg gattttggtc atgagattat 
caaaaaggat cttcacctag atccttttaa attaaaaatg aagttttaaa tcaatctaaa 
gtatatatga gtaaacttgg tctgacagtt accaatgctt aatcagtgag gcacctatct 
cagcgatctg tctatttcgt tcatccatag ttgcctgact ccccgtcgtg tagataacta 
cgatacggga gggcttacca tctggcccca gtgctgcaat gataccgcga gacccacgct 
caccggctcc agatttatca gcaataaacc agccagccgg aagggccgag cgcagaagtg 
gtcctgcaac tttatccgcc tccatccagt ctattaattg ttgccgggaa gctagagtaa 
gtagttcgcc agttaatagt ttgcgcaacg ttgttgccat tgctacaggc atcgtggtgt 
cacgctcgtc gtttggtatg gcttcattca gctccggttc ccaacgatca aggcgagtta 
catgatcccc catgttgtgc aaaaaagcgg ttagctcctt cggtcctccg atcgttgtca 
gaagtaagtt ggccgcagtg ttatcactca tggttatggc agcactgcat aattctctta 
ctgtcatgcc atccgtaaga tgcttttctg tgactggtga gtactcaacc aagtcattct 
gagaatagtg tatgcggcga ccgagttgct cttgcccggc gtcaatacgg gataataccg 
cgccacatag cagaacttta aaagtgctca tcattggaaa acgttcttcg gggcgaaaac 
tctcaaggat cttaccgctg ttgagatcca gttcgatgta acccactcgt gcacccaact 
gatcttcagc atcttttact ttcaccagcg tttctgggtg agcaaaaaca ggaaggcaaa 
atgccgcaaa aaagggaata agggcgacac ggaaatgttg aatactcata ctcttccttt 
ttcaatatta ttgaagcatt tatcagggtt attgtctcat gagcggatac atatttgaat 
gtatttagaa aaataaacaa ataggggttc cgcgcacatt tccccgaaaa gtgccacctg 
acgtctaaga aaccattatt atcatgacat taacctataa aaataggcgt atcacgaggc 
cctttcgtct cgcgcgtttc ggtgatgacg gtgaaaacct ctgacacatg cagctcccgg 
agacggtcac agcttgtctg taagcggatg ccgggagcag acaagcccgt cagggcgcgt 
cagcgggtgt tggcgggtgt cggggctggc ttaactatgc ggcatcagag cagattgtac 
tgagagtgca ccataacgca tttaagcata aacacgcact atgccgttct tctcatgtat 
atatatatac aggcaacacg cagatatagg tgcgacgtga acagtgagct gtatgtgcgc 
agctcgcgtt gcattttcgg aagcgctcgt tttcggaaac gctttgaagt tcctattccg 
aagttcctat tctctagcta gaaagtatag gaacttcaga gcgcttttga aaaccaaaag 
cgctctgaag acgcactttc aaaaaaccaa aaacgcaccg gactgtaacg agctactaaa 
aaacttttgg ttttcgcgag acttctgcgt gaaagttttt tggtttttgc gtggcctgac 
attgctcgat gatttatatt gcgaataccg cttccacaaa cattgctcaa aagtatctct 
ttgctatata tctctgtgct atatccctat ataacctacc catccacctt tcgctccttg 
aacttgcatc taaactcgac ctctacattt tttatgttta tctctagtat tactctttag 
acaaaaaaat tgtagtaaga actattcata gagtgaatcg aaaacaatac gaaaatgtaa 
acatttccta tacgtagtat atagagacaa aatagaagaa accgttcata attttctgac 
caatgaagaa tcatcaacgc tatcactttc tgttcacaaa gtatgcgcaa tccacatcgg 
tatagaatat aatcggggat gcctttatct tgaaaaaatg cacccgcagc ttcgctagta 
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atcagtaaac gcgggaagtg gagtcaggct ttttttatgg aagagaaaat agacaccaaa 
gtagccttct tctaacctta acggacctac agtgcaaaaa gttatcaaga gactgcatta 
tagagcgcac aaaggagaaa aaaagtaatc taagatgctt tgttagaaaa atagcgctct 
cgggatgcat ttttgtagaa caaaaaagaa gtatagattc tttgttggta aaatagcgct 
ctcgcgttgc atttctgttc tgtaaaaatg cagctcagat tctttgtttg aaaaattagc 
gctctcgcgt tgcatttttg ttttacaaaa atgaagcaca gattcttcgt tggtaaaata 
gcgctttcgc gttgcatttc tgttctgtaa aaatgcagct cagattcttt gtttgaaaaa 
ttagcgctct cgcgttgcat ttttgttcta caaaatgaag cacagatgct tcgt 
<210> SEQ ID NO 19 
<211> LENGTH, 12315 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Plasmid pGAD-BA-ACTR 
<400> SEQUENCE, 19 
gcttgcatgc aacttctttt cttttttttt cttttctctc tcccccgttg ttgtctcacc 
atatccgcaa tgacaaaaaa aatgatggaa gacactaaag gaaaaaatta acgacaaaga 
cagcaccaac agatgtcgtt gttccagagc tgatgagggg tatcttcgaa cacacgaaac 
tttttccttc cttcattcac gcacactact ctctaatgag caacggtata cggccttcct 
tccagttact tgaatttgaa ataaaaaaag tttgccgctt tgctatcaag tataaataga 
cctgcaatta ttaatctttt gtttcctcgt cattgttctc gttccctttc ttccttgttt 
ctttttctgc acaatatttc aagctatacc aagcatacaa tcaactccaa gctttgcaaa 
gatggataaa gcggaattaa ttcccgagcc tccaaaaaag aagagaaagg tcgaattggg 
taccgccgcc aattttaatc aaagtgggaa tattgctgat agctcattgt ccttcacttt 
cactaacagt agcaacggtc cgaacctcat aacaactcaa acaaattctc aagcgctttc 
acaaccaatt gcctcctcta acgttcatga taacttcatg aataatgaaa tcacggctag 
taaaattgat gatggtaata attcaaaacc actgtcacct ggttggacgg accaaactgc 
gtataacgcg tttggaatca ctacagggat gtttaatacc actacaatgg atgatgtata 
taactatcta ttcgatgatg aagatacccc accaaaccca aaaaaagaga tctttatgag 
tggattagga gaaaacttgg atccactggc cagtgattca cgaaaacgca aattgccatg 
tgatactcca ggacaaggtc ttacctgcag tggtgaaaaa cggagacggg agcaggaaag 
taaatatatt gaagaattgg ctgagctgat atctgccaat cttagtgata ttgacaattt 
caatgtcaaa ccagataaat gtgcgatttt aaaggaaaca gtaagacaga tacgtcaaat 
aaaagagcaa ggaaaaacta tttccaatga tgatgatgtt caaaaagccg atgtatcttc 
tacagggcag ggagttattg ataaagactc cttaggaccg cttttacttc aggcattgga 
tggtttccta tttgtggtga atcgagacgg aaacattgta tttgtatcag aaaatgtcac 
acaatacctg caatataagc aagaggacct ggttaacaca agtgtttaca atatcttaca 
tgaagaagac agaaaggatt ttcttaagaa tttaccaaaa tctacagtta atggagtttc 
ctggacaaat gagacccaaa gacaaaaaag ccatacattt aattgccgta tgttgatgaa 
aacaccacat gatattctgg aagacataaa cgccagtcct gaaatgcgcc agagatatga 
aacaatgcag tgctttgccc tgtctcagcc acgagctatg atggaggaag gggaagattt 
gcaatcttgt atgatctgtg tggcacgccg cattactaca ggagaaagaa catttccatc 
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aaaccctgag agctttatta ccagacatga tctttcagga aaggttgtca atatagatac 
aaattcactg agatcctcca tgaggcctgg ctttgaagat ataatccgaa ggtgtattca 
gagatttttt agtctaaatg atgggcagtc atggtcccag aaacgtcact atcaagaagt 
taccagtgat gggatatttt ccccaacagc ttatcttaat ggccatgcag aaaccccagt 
atatcgattc tcgttggctg atggaactat agtgactgca cagacaaaaa gcaaactctt 
ccgaaatcct gtaacaaatg atcgacatgg ctttgtctca acccacttcc ttcagagaga 
acagaatgga tatagaccaa acccaaatcc tgttggacaa gggattagac cacctatggc 
tggatgcaac agttcggtag gcggcatgag tatgtcgcca aaccaaggct tacagatgcc 
gagcagcagg gcctatggct tggcagaccc tagcaccaca gggcagatga gtggagctag 
gtatgggggt tccagtaaca tagcttcatt gacccctggg ccaggcatgc aatcaccatc 
ttcctaccag aacaacaact ataggctcaa catgagtagc cccccacatg ggagtcctgg 
tcttgcccca aaccagcaga atatcatgat ttctcctcgt aatcgtggga gtccaaagat 
agcctcacat cagttttctc ctgttgcagg tgtgcactct cccatggcat cttctggcaa 
tactgggaac cacagctttt ccagcagctc tctcagtgcc ctgcaagcca tcagtgaagg 
tgtggggact tcccttttat ctactctgtc atcaccaggc cccaaattgg ataactctcc 
caatatgaat attacccaac caagtaaagt aagcaatcag gattccaaga gtcctctggg 
cttttattgc gaccaaaatc cagtggagag ttcaatgtgt cagtcaaata gcagagatca 
cctcagtgac aaagaaagta aggagagcag tgttgagggg gcagagaatc aaaggggtcc 
tttggaaagc aaaggtcata aaaaattact gcagttactt acctgttctt ctgatgaccg 
gggtcattcc tccttgacca actcccccct agattcaagt tgtaaagaat cttctgttag 
tgtcaccagc ccctctggag tctcctcctc tacatctgga ggagtatcct ctacatccaa 
tatgcatggg tcactgttac aagagaagca ccggattttg cacaagttgc tgcagaatgg 
gaattcacca gctgaggtag ccaagattac tgcagaagcc actgggaaag acaccagcag 
tataacttct tgtggggacg gaaatgttgt caagcaggag cagctaagtc ctaagaagaa 
ggagaataat gcacttctta gatacctgct ggacagggat gatcctagtg atgcactctc 
taaagaacta cagccccaag tggaaggagt ggataataaa atgagtcagt gcaccagctc 
caccattcct agctcaagtc aagagaaaga ccctaaaatt aagacagaga caagtgaaga 
gggatctgga gacttggata atctagatgc tattcttggt gatctgacta gttctgactt 
ttacaataat tccatatcct caaatggtag tcatctgggg actaagcaac aggtgtttca 
aggaactaat tctctgggtt tgaaaagttc acagtctgtg cagtctattc gtcctccata 
taaccgagca gtgtctctgg atagccctgt ttctgttggc tcaagtcctc cagtaaaaaa 
tatcagtgct ttccccatgt taccaaagca acccatgttg ggtgggaatc caagaatgat 
ggatagtcag gaaaattatg gctcaagtat gggagactgg ggcttaccaa actcaaaggc 
cggcagaatg gaacctatga attcaaactc catgggaaga ccaggaggag attataatac 
ttctttaccc agacctgcac tgggtggctc tattcccaca ttgcctcttc ggtctaatag 
cataccaggt gcgagaccag tattgcaaca gcagcagcag atgcttcaaa tgaggcctgg 
tgaaatcccc atgggaatgg gggctaatcc ctatggccaa gcagcagcat ctaaccaact 
gggttcctgg cccgatggca tgttgtccat ggaacaagtt tctcatggca ctcaaaatag 
gcctcttctt aggaattccc tggatgatct tgttgggcca ccttccaacc tggaaggcca 
gagtgacgaa agagcattat tggaccagct gcacactctt ctcagcaaca cagatgccac 
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aggcctggaa gaaattgaca gagctttggg cattcctgaa cttgtcaatc agggacaggc 
attagagccc aaacaggatg ctttccaagg ccaagaagca gcagtaatga tggatcagaa 
ggcaggatta tatggacaga catacccagc acaggggcct ccaatgcaag gaggctttca 
tcttcaggga caatcaccat cttttaactc tatgatgaat cagatgaacc agcaaggcaa 
ttttcctctc caaggaatgc acccacgagc caacatcatg agaccccgga caaacacccc 
caagcaactt agaatgcagc ttcagcagag gctgcagggc cagcagtttt tgaatcagag 
ccgacaggca cttgaattga aaatggaaaa ccctactgct ggtggtgctg cggtgatgag 
gcctatgatg cagccccagc agggttttct taatgctcaa atggtcgccc aacgcagcag 
agagctgcta agtcatcact tccgacaaca gagggtggct atgatgatgc agcagcagca 
acagcagcag cagcagcagc agcagcagca acagcaacag caacagcaac agcagcaaca 
gcagcaaacc caggccttca gcccacctcc taatgtgact gcttccccca gcatggatgg 
gcttttggca ggacccacaa tgccacaagc tcctccgcaa cagtttccat atcaaccaaa 
ttatggaatg ggacaacaac cagatccagc ctttggtcga gtgtctagtc ctcccaatgc 
aatgatgtcg tcaagaatgg gtccctccca gaatcccatg atgcaacacc cgcaggctgc 
atccatctat cagtcctcag aaatgaaggg ctggccatca ggaaatttgg ccaggaacag 
ctccttttcc cagcagcagt ttgcccacca ggggaatcct gcagtgtata gtatggtgca 
catgaatggc agcagtggtc acatgggaca gatgaacatg aaccccatgc ccatgtctgg 
catgcctatg ggtcctgatc agaaatactg ctgacatctc tgcaccagga cctcttaagg 
aaaccactgt acaaatgaca ctgcactagg attattggga aggaatcatt gttccaggca 
tccatcttgg aagaaaggac cagctttgag ctccatcaag ggtattttaa gtgatgtcat 
ttgagcagga ctggatttta agccgaaggg caatatctac gtgtttttcc cccctccttc 
tgctgtgtat catggtgttc aaaacagaaa tgttttttgg cattccacct cctagggata 
taattctgga gacatggagt gttactgatc ataaaacttt tgtgtcactt ttttctgcct 
tgctagccaa aatctcttaa atacacgtag gtgggccaga gaacattgga agaatcaaga 
gagattagaa tatctggttt ctctagttgc agtattggac aaagagcata gtcccagcct 
tcaggtgtag tagttctgtg ttgacccttt gtccagtgga attggtgatt ctgaattgtc 
ctttactaat ggtgttgagt tgctctgtcc ctattatttg ccctaggctt tctcctaatg 
aaggttttca tttgccattc atgtcctgta atacttcacc tccaggaact gtcatggatg 
tccaaatggc tttgcagaaa ggaaatgaga tgacagtatt taatcgcagc agtagcaaac 
ttttcacatg ctaatgtgca gctgagtgca ctttatttaa aaagaatgga taaatgcaat 
attcttgagg tcttgaggga atagtgaaac acattcctgg tttttgccta cacttacgtg 
ttagacaaga actatgattt ttttttttaa agtactggtg tcaccctttg cctatatggt 
agagcaataa tgctttttaa aaataaactt ctgaaaaccc aaggccaggt actgcattct 
gaatcagaat ctcgcagtgt ttctgtgaat agattttttt gtaaatatga cctttaagat 
attgtattat gtaaaatatg tatatacctt tttttgtagg tcacaacaac tcatttttac 
agagtttgtg aagctaaata tttaacattg ttgatttcag taagctgtgt ggtgaggcta 
ccagtggaag agacatccct tgacttttgt ggcctggggg aggggtagtg caccacagct 
tttccttccc caccccccag ccttagatgc ctcgctcttt tcaatctctt aatctaaatg 
ctttttaaag agattatttg tttagatgta ggcattttaa ttttttaaaa attcctctac 
cagaactaag cactttgtta atttgggggg aaagaataga tatggggaaa taaacttaaa 
4080 
4140 
4200 
4260 
4320 
4380 
4440 
4500 
4560 
4620 
4680 
4740 
4800 
4860 
4920 
4980 
5040 
5100 
5160 
5220 
5280 
5340 
5400 
5460 
5520 
5580 
5640 
5700 
5760 
5820 
5880 
5940 
6000 
6060 
6120 
6180 
6240 
6300 
6360 
6420 
72 
US 8,492,088 B2 
73 
-continued 
aaaaaatcag gaatttaaaa aaaacgagca atttgaagag aatcttttgg attttaagca 
gtccgaaata atagcaattc atgggctgtg tgtgtgtgtg tatgtgtgtg tgtgtgtgtg 
tatgtttaat tatgttacct tttcatcccc tttaggagcg ttttcagatt ttggttcgta 
agacctgaat cccgcggccg ccccgggcgt agatactgaa aaaccccgca agttcacttc 
aactgtgcat cgtgcaccat ctcaatttct ttcatttata catcgttttg ccttctttta 
tgtaactata ctcctctaag tttcaatctt ggccatgtaa cctctgatct atagaatttt 
ttaaatgact agaattaatg cccatctttt ttttggacct aaattcttca tgaaaatata 
ttacgagggc ttattcagaa gctttggact tcttcgccag aggtttggtc aagtctccaa 
tcaaggttgt cggcttgtct accttgccag aaatttacga aaagatggaa aagggtcaaa 
tcgttggtag atacgttgtt gacacttcta aataagcgaa tttcttatga tttatgattt 
ttattattaa ataagttata aaaaaaataa gtgtatacaa attttaaagt gactcttagg 
ttttaaaacg aaaattcttg ttcttgagta actctttcct gtaggtcagg ttgctttctc 
aggtatagca tgaggtcgct cttattgacc acacctctac cggcatgccc gaaattcccc 
taccctatga acatattcca ttttgtaatt tcgtgtcgtt tctattatga atttcattta 
taaagtttat gtacaaatat cataaaaaaa gagaatcttt ttaagcaagg attttcttaa 
cttcttcggc gacagcatca ccgacttcgg tggtactgtt ggaaccacct aaatcaccag 
ttctgatacc tgcatccaaa acctttttaa ctgcatcttc aatggcctta ccttcttcag 
gcaagttcaa tgacaatttc aacatcattg cagcagacaa gatagtggcg atagggtcaa 
ccttattctt tggcaaatct ggagcagaac cgtggcatgg ttcgtacaaa ccaaatgcgg 
tgttcttgtc tggcaaagag gccaaggacg cagatggcaa caaacccaag gaacctggga 
taacggaggc ttcatcggag atgatatcac caaacatgtt gctggtgatt ataataccat 
ttaggtgggt tgggttctta actaggatca tggcggcaga atcaatcaat tgatgttgaa 
ccttcaatgt aggaaattcg ttcttgatgg tttcctccac agtttttctc cataatcttg 
aagaggccaa aacattagct ttatccaagg accaaatagg caatggtggc tcatgttgta 
gggccatgaa agcggccatt cttgtgattc tttgcacttc tggaacggtg tattgttcac 
tatcccaagc gacaccatca ccatcgtctt cctttctctt accaaagtaa atacctccca 
ctaattctct gacaacaacg aagtcagtac ctttagcaaa ttgtggcttg attggagata 
agtctaaaag agagtcggat gcaaagttac atggtcttaa gttggcgtac aattgaagtt 
ctttacggat ttttagtaaa ccttgttcag gtctaacact acctgtaccc catttaggac 
cacccacagc acctaacaaa acggcatcaa ccttcttgga ggcttccagc gcctcatctg 
gaagtgggac acctgtagca tcgatagcag caccaccaat taaatgattt tcgaaatcga 
acttgacatt ggaacgaaca tcagaaatag ctttaagaac cttaatggct tcggctgtga 
tttcttgacc aacgtggtca cctggcaaaa cgacgatctt cttaggggca gacattagaa 
tggtatatcc ttgaaatata tatatatatt gctgaaatgt aaaaggtaag aaaagttaga 
aagtaagacg attgctaacc acctattgga aaaaacaata ggtccttaaa taatattgtc 
aacttcaagt attgtgatgc aagcatttag tcatgaacgc ttctctattc tatatgaaaa 
gccggttccg gcctctcacc tttccttttt ctcccaattt ttcagttgaa aaaggtatat 
gcgtcaggcg acctctgaaa ttaacaaaaa atttccagtc atcgaatttg attctgtgcg 
atagcgcccc tgtgtgttct cgttatgttg aggaaaaaaa taatggttgc taagagattc 
gaactcttgc atcttacgat acctgagtat tcccacagtt ggggatctcg actctagcta 
6480 
6540 
6600 
6660 
6720 
6780 
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gaggatcaat tcgtaatcat ggtcatagct gtttcctgtg tgaaattgtt atccgctcac 8880 
aattccacac aacatacgag ccggaagcat aaagtgtaaa gcctggggtg cctaatgagt 8940 
gaggtaactc acattaattg cgttgcgctc actgccggat taatgaatcg gccaacgcgc 9000 
ggggagaggc ggtttgcgta ttgggcgctc ttccgcttcc tcgctcactg actcgctgcg 9060 
ctcggtcgtt cggctgcggc gagcggtatc agctcactca aaggcggtaa tacggttatc 9120 
cacagaatca ggggataacg caggaaagaa catgtgagca aaaggccagc aaaaggccag 9180 
gaaccgtaaa aaggccgcgt tgctggcgtt tttccatagg ctccgccccc ctgacgagca 9240 
tcacaaaaat cgacgctcaa gtcagaggtg gcgaaacccg acaggactat aaagatacca 9300 
ggcgtttccc cctggaagct ccctcgtgcg ctctcctgtt ccgaccctgc cgcttaccgg 9360 
atacctgtcc gcctttctcc cttcgggaag cgtggcgctt tctcatagct cacgctgtag 9420 
gtatctcagt tcggtgtagg tcgttcgctc caagctgggc tgtgtgcacg aaccccccgt 9480 
tcagcccgac cgctgcgcct tatccggtaa ctatcgtctt gagtccaacc cggtaagaca 9540 
cgacttatcg ccactggcag cagccactgg taacaggatt agcagagcga ggtatgtagg 9600 
cggtgctaca gagttcttga agtggtggcc taactacggc tacactagaa ggacagtatt 9660 
tggtatctgc gctctgctga agccagttac cttcggaaaa agagttggta gctcttgatc 9720 
cggcaaacaa accaccgctg gtagcggtgg tttttttgtt tgcaagcagc agattacgcg 9780 
cagaaaaaaa ggatctcaag aagatccttt gatcttttct acggggtctg acgctcagtg 9840 
gaacgaaaac tcacgttaag ggattttggt catgagatta tcaaaaagga tcttcaccta 9900 
gatcctttta aattaaaaat gaagttttaa atcaatctaa agtatatatg agtaaacttg 9960 
gtctgacagt taccaatgct taatcagtga ggcacctatc tcagcgatct gtctatttcg 10020 
ttcatccata gttgcctgac tccccgtcgt gtagataact acgatacggg agggcttacc 10080 
atctggcccc agtgctgcaa tgataccgcg agacccacgc tcaccggctc cagatttatc 10140 
agcaataaac cagccagccg gaagggccga gcgcagaagt ggtcctgcaa ctttatccgc 10200 
ctccatccag tctattaatt gttgccggga agctagagta agtagttcgc cagttaatag 10260 
tttgcgcaac gttgttgcca ttgctacagg catcgtggtg tcacgctcgt cgtttggtat 10320 
ggcttcattc agctccggtt cccaacgatc aaggcgagtt acatgatccc ccatgttgtg 10380 
caaaaaagcg gttagctcct tcggtcctcc gatcgttgtc agaagtaagt tggccgcagt 10440 
gttatcactc atggttatgg cagcactgca taattctctt actgtcatgc catccgtaag 10500 
atgcttttct gtgactggtg agtactcaac caagtcattc tgagaatagt gtatgcggcg 10560 
accgagttgc tcttgcccgg cgtcaatacg ggataatacc gcgccacata gcagaacttt 10620 
aaaagtgctc atcattggaa aacgttcttc ggggcgaaaa ctctcaagga tcttaccgct 10680 
gttgagatcc agttcgatgt aacccactcg tgcacccaac tgatcttcag catcttttac 10740 
tttcaccagc gtttctgggt gagcaaaaac aggaaggcaa aatgccgcaa aaaagggaat 10800 
aagggcgaca cggaaatgtt gaatactcat actcttcctt tttcaatatt attgaagcat 10860 
ttatcagggt tattgtctca tgagcggata catatttgaa tgtatttaga aaaataaaca 10920 
aataggggtt ccgcgcacat ttccccgaaa agtgccacct gacgtctaag aaaccattat 10980 
tatcatgaca ttaacctata aaaataggcg tatcacgagg ccctttcgtc tcgcgcgttt 11040 
cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca cagcttgtct 11100 
gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg ttggcgggtg 11160 
tcggggctgg cttaactatg cggcatcaga gcagattgta ctgagagtgc accataacgc 11220 
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atttaagcat aaacacgcac tatgccgttc ttctcatgta tatatatata caggcaacac 11280 
gcagatatag gtgcgacgtg aacagtgagc tgtatgtgcg cagctcgcgt tgcattttcg 11340 
gaagcgctcg ttttcggaaa cgctttgaag ttcctattcc gaagttccta ttctctagct 11400 
agaaagtata ggaacttcag agcgcttttg aaaaccaaaa gcgctctgaa gacgcacttt 11460 
caaaaaacca aaaacgcacc ggactgtaac gagctactaa aatattgcga ataccgcttc 11520 
cacaaacatt gctcaaaagt atctctttgc tatatatctc tgtgctatat ccctatataa 11580 
cctacccatc cacctttcgc tccttgaact tgcatcctag tattactctt tagacaaaaa 11640 
aattgtagta agaactattc atagagtgaa tcgaaaacaa tacgaaaatg taaacatttc 11700 
ctatacgtag tatatagaga caaaatagaa gaaaccgttc ataattttct gaccaatgaa 11760 
gaatcatcaa cgctatcact ttctgttcac aaagtatgcg caatccacat cggtatagaa 11820 
tataatcggg gatgccttta tcttgaaaaa atgcacccgc agcttcgcta gtaatcagta 11880 
aacgcgggaa gtggagtcag gcttttttta tggaagagaa aatagacacc aaagtagcct 11940 
tcttctaacc ttaacggacc tacagtgcaa aaagttatca agagactgca ttatagagcg 12000 
cacaaaggag aaaaaaagta atctaagatg ctttgttaga aaaatagcgc tctcgggatg 12060 
catttttgta gaacaaaaaa gaagtataga ttctttgttg gtaaaatagc gctctcgcgt 12120 
tgcatttctg ttctgtaaaa atgcagctca gattctttgt ttgaaaaatt agcgctctcg 12180 
cgttgcattt ttgttttaca aaaatgaagc acagattctt cgttggtaaa atagcgcttt 12240 
cgcgttgcat ttctgttctg taaaaatgca gctcaggcat ttttgttcta caaaatgaag 12300 
cacagatgct tcgtt 12315 
<210> SEQ ID NO 20 
<211> LENGTH, 7280 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, pVDR-wt 
<400> SEQUENCE, 20 
gcttgcatgc aacttctttt cttttttttt cttttctctc tcccccgttg ttgtctcacc 60 
atatccgcaa tgacaaaaaa aatgatggaa gacactaaag gaaaaaatta acgacaaaga 120 
cagcaccaac agatgtcgtt gttccagagc tgatgagggg tatcttcgaa cacacgaaac 180 
tttttccttc cttcattcac gcacactact ctctaatgag caacggtata cggccttcct 240 
tccagttact tgaatttgaa ataaaaaaag tttgccgctt tgctatcaag tataaataga 300 
cctgcaatta ttaatctttt gtttcctcgt cattgttctc gttccctttc ttccttgttt 360 
ctttttctgc acaatatttc aagctatacc aagcatacaa tcaactccaa gcttgaagca 420 
agcctcctga aagatgaagc tactgtcttc tatcgaacaa gcatgcgata tttgccgact 480 
taaaaagctc aagtgctcca aagaaaaacc gaagtgcgcc aagtgtctga agaacaactg 540 
ggagtgtcgc tactctccca aaaccaaaag gtctccgctg actagggcac atctgacaga 600 
agtggaatca aggctagaaa gactggaaca gctatttcta ctgatttttc ctcgagaaga 660 
ccttgacatg attttgaaaa tggattcttt acaggatata aaagcattgt taacaggatt 720 
atttgtacaa gataatgtga ataaagatgc cgtcacagat agattggctt cagtggagac 780 
tgatatgcct ctaacattga gacagcatag aataagtgcg acatcatcat cggaagagag 840 
tagtaacaaa ggtcaaagac agttgactgt atcgccggct agcgaattca tggaggcaat 900 
ggcggccagc acttccctgc ctgaccctgg agactttgac cggaacgtgc cccggatctg 960 
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tggggtgtgt ggagaccgag ccactggctt tcacttcaat gctatgacct gtgaaggctg 
caaaggcttc ttcaggcgaa gcatgaagcg gaaggcacta ttcacctgcc ccttcaacgg 
ggactgccgc atcaccaagg acaaccgacg ccactgccag gcctgccggc tcaaacgctg 
tgtggacatc ggcatgatga aggagttcat tctgacagat gaggaagtgc agaggaagcg 
ggagatgatc ctgaagcgga aggaggagga ggccttgaag gacagtctgc ggcccaagct 
gtctgaggag cagcagcgca tcattgccat actgctggac gcccaccata agacctacga 
ccccacctac tccgacttct gccagttccg gcctccagtt cgtgtgaatg atggtggagg 
gagccatcct tccaggccca actccagaca cactcccagc ttctctgggg actcctcctc 
ctcctgctca gatcactgta tcacctcttc agacatgatg gactcgtcca gcttctccaa 
tctggatctg agtgaagaag attcagatga cccttctgtg accctagagc tgtcccagct 
ctccatgctg ccccacctgg ctgacctggt cagttacagc atccaaaagg tcattggctt 
tgctaagatg ataccaggat tcagagacct cacctctgag gaccagatcg tactgctgaa 
gtcaagtgcc attgaggtca tcatgttgcg ctccaatgag tccttcacca tggacgacat 
gtcctggacc tgtggcaacc aagactacaa gtaccgcgtc agtgacgtga ccaaagccgg 
acacagcctg gagctgattg agcccctcat caagttccag gtgggactga agaagctgaa 
cttgcatgag gaggagcatg tcctgctcat ggccatctgc atcgtctccc cagatcgtcc 
tggggtgcag gacgccgcgc tgattgaggc catccaggac cgcctgtcca acacactgca 
gacgtacatc cgctgccgcc acccgccccc gggcagccac ctgctctatg ccaagatgat 
ccagaagcta gccgacctgc gcagcctcaa tgaggagcac tccaagcagt accgctgcct 
ctccttccag cctgagtgca gcatgaagct aacgcccctt gtgctcgaag tgtttggcaa 
tgagatctcc tgaactagtc catcctttgt gcccacccgt tctggccacc ctgcctggac 
gccagctgtt cttctcagcc tgagccctgt ccctgccctt ctctgcctgg cctgtttgga 
ctttggggca cagcctgtca ctgctctgcc taagagatgt gttgtcaccc tccttatttc 
tgttactact tgtctgtggc ccagggcagt ggctttcctg agcagcagcc ttcgtggcaa 
gaactagcgt gagcccagcc aggcgcctcc ccaccgggct ctcaggacgc cctgccacac 
ccacggggct tgggcgacta cagggtcttc ggccccagcc ctggagctgc agccaagcta 
attccgggcg aatttcttat gatttatgat ttttattatt aaataagtta taaaaaaaat 
aagtgtatac aaattttaaa gtgactctta ggttttaaaa cgaaaattct tgttcttgag 
taactctttc ctgtaggtca ggttgctttc tcaggtatag catgaggtcg ctcttattga 
ccacacctct accggcatgc cggcaagtgc acaaacaata cttaaataaa tactactcag 
taataaccta tttcttagca tttttgacga aatttgctat tttgttagag tcttttacac 
catttgtctc cacacctccg cttacatcaa caccaataac gccatttaat ctaagcgcat 
caccaacatt ttctggcgtc agtccaccag ctaacataaa atgtaagctt tcggggctct 
cttgccttcc aacccagtca gaaatcgagt tccaatccaa aagttcacct gtcccacctg 
cttctgaatc aaacaaggga ataaacgaat gaggtttctg tgaagctgca ctgagtagta 
tgttgcagtc ttttggaaat acgagtcttt taataactgg ccttactcca aagacacttc 
gacgtgactc atcatacaac gtcagaaaac ctttatgctc agaaaattat tgaccgaaac 
cgaggaactc ttggtattct tgccacgact catctccatg cagttggacg atatcaatgc 
cgtaatcatt gaccagagcc aaaacatcct ccttaggttg attacgaaac acgccaacca 
agtatttcgg agtgcctgaa ctatttttat atgcttttac aagacttgaa attttccttg 
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caataaccgg gtcaattgtt ctctttctat tgggcacaca tataataccc agcaagtcag 
catcggaatc tagagcacat tctgcggcct ctgtgctctg caagccgcaa actttcacca 
atggaccaga actacctgtg aaattaataa cagacatact ccaagctgcc tttgtgtgct 
taatcacgta tactcacgtg ctcaatagtc accaatgccc tccctcttgg ccctctcctt 
ttcttttttc gaccgaatta attcgtaatc atggtcatag ctgtttcctg tgtgaaattg 
ttatccgctc acaattccac acaacatacg agccggaagc ataaagtgta aagcctgggg 
tgcctaatga gtgaggtaac tcacattaat tgcgttgcgc tcactgcccg ctttccagtc 
gggaaacctg tcgtgccagc tggattaatg aatcggccaa cgcgcgggga gaggcggttt 
gcgtattggg cgctcttccg cttcctcgct cactgactcg ctgcgctcgg tcgttcggct 
gcggcgagcg gtatcagctc actcaaaggc ggtaatacgg ttatccacag aatcagggga 
taacgcagga aagaacatgt gagcaaaagg ccagcaaaag gccaggaacc gtaaaaaggc 
cgcgttgctg gcgtttttcc ataggctccg cccccctgac gagcatcaca aaaatcgacg 
ctcaagtcag aggtggcgaa acccgacagg actataaaga taccaggcgt ttccccctgg 
aagctccctc gtgcgctctc ctgttccgac cctgccgctt accggatacc tgtccgcctt 
tctcccttcg ggaagcgtgg cgctttctca tagctcacgc tgtaggtatc tcagttcggt 
gtaggtcgtt cgctccaagc tgggctgtgt gcacgaaccc cccgttcagc ccgaccgctg 
cgccttatcc ggtaactatc gtcttgagtc caacccggta agacacgact tatcgccact 
ggcagcagcc actggtaaca ggattagcag agcgaggtat gtaggcggtg ctacagagtt 
cttgaagtgg tggcctaact acggctacac tagaaggaca gtatttggta tctgcgctct 
gctgaagcca gttaccttcg gaaaaagagt tggtagctct tgatccggca aacaaaccac 
cgctggtagc ggtggttttt ttgtttgcaa gcagcagatt acgcgcagaa aaaaaggatc 
tcaagaagat cctttgatct tttctacggg gtctgacgct cagtggaacg aaaactcacg 
ttaagggatt ttggtcatga gattatcaaa aaggatcttc acctagatcc ttttaaatta 
aaaatgaagt tttaaatcaa tctaaagtat atatgagtaa acttggtctg acagttacca 
atgcttaatc agtgaggcac ctatctcagc gatctgtcta tttcgttcat ccatagttgc 
ctgactcccc gtcgtgtaga taactacgat acgggagggc ttaccatctg gccccagtgc 
tgcaatgata ccgcgagacc cacgctcacc ggctccagat ttatcagcaa taaaccagcc 
agccggaagg gccgagcgca gaagtggtcc tgcaacttta tccgcctcca tccagtctat 
taattgttgc cgggaagcta gagtaagtag ttcgccagtt aatagtttgc gcaacgttgt 
tgccattgct acaggcatcg tggtgtcacg ctcgtcgttt ggtatggctt cattcagctc 
cggttcccaa cgatcaaggc gagttacatg atcccccatg ttgtgcaaaa aagcggttag 
ctccttcggt cctccgatcg ttgtcagaag taagttggcc gcagtgttat cactcatggt 
tatggcagca ctgcataatt ctcttactgt catgccatcc gtaagatgct tttctgtgac 
tggtgagtac tcaaccaagt cattctgaga atagtgtatg cggcgaccga gttgctcttg 
cccggcgtca atacgggata ataccgcgcc acatagcaga actttaaaag tgctcatcat 
tggaaaacgt tcttcggggc gaaaactctc aaggatctta ccgctgttga gatccagttc 
gatgtaaccc actcgtgcac ccaactgatc ttcagcatct tttactttca ccagcgtttc 
tgggtgagca aaaacaggaa ggcaaaatgc cgcaaaaaag ggaataaggg cgacacggaa 
atgttgaata ctcatactct tcctttttca atattattga agcatttatc agggttattg 
tctcatgagc ggatacatat ttgaatgtat ttagaaaaat aaacaaatag gggttccgcg 
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cacatttccc cgaaaagtgc cacctgacgt ctaagaaacc attattatca tgacattaac 
ctataaaaat aggcgtatca cgaggccctt tcgtctcgcg cgtttcggtg atgacggtga 
aaacctctga cacatgcagc tcccggagac ggtcacagct tgtctgtaag cggatgccgg 
gagcagacaa gcccgtcagg gcgcgtcagc gggtgttggc gggtgtcggg gctggcttaa 
ctatgcggca tcagagcaga ttgtactgag agtgcaccat aacgcattta agcataaaca 
cgcactatgc cgttcttctc atgtatatat atatacaggc aacacgcaga tataggtgcg 
acgtgaacag tgagctgtat gtgcgcagct cgcgttgcat tttcggaagc gctcgttttc 
ggaaacgctt tgaagttcct attccgaagt tcctattctc tagctagaaa gtataggaac 
ttcagagcgc ttttgaaaac caaaagcgct ctgaagacgc actttcaaaa aaccaaaaac 
gcaccggact gtaacgagct actaaaaaac ttttggtttt cgcgagactt ctgcgtgaaa 
gttttttggt ttttgcgtgg cctgacattg ctcgatgatt tatattgcga ataccgcttc 
cacaaacatt gctcaaaagt atctctttgc tatatatctc tgtgctatat ccctatataa 
cctacccatc cacctttcgc tccttgaact tgcatctaaa ctcgacctct acatttttta 
tgtttatctc tagtattact ctttagacaa aaaaattgta gtaagaacta ttcatagagt 
gaatcgaaaa caatacgaaa atgtaaacat ttcctatacg tagtatatag agacaaaata 
gaagaaaccg ttcataattt tctgaccaat gaagaatcat caacgctatc actttctgtt 
cacaaagtat gcgcaatcca catcggtata gaatataatc ggggatgcct ttatcttgaa 
aaaatgcacc cgcagcttcg ctagtaatca gtaaacgcgg gaagtggagt caggcttttt 
ttatggaaga gaaaatagac accaaagtag ccttcttcta accttaacgg acctacagtg 
caaaaagtta tcaagagact gcattataga gcgcacaaag gagaaaaaaa gtaatctaag 
atgctttgtt agaaaaatag cgctctcggg atgcattttt gtagaacaaa aaagaagtat 
agattctttg ttggtaaaat agcgctctcg cgttgcattt ctgttctgta aaaatgcagc 
tcagattctt tgtttgaaaa attagcgctc tcgcgttgca tttttgtttt acaaaaatga 
agcacagatt cttcgttggt aaaatagcgc tttcgcgttg catttctgtt ctgtaaaaat 
gcagctcaga ttctttgttt gaaaaattag cgctctcgcg ttgcattttt gttctacaaa 
atgaagcaca gatgcttcgt 
<210> SEQ ID NO 21 
<211> LENGTH, 7460 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Plasmid pS0016 
<400> SEQUENCE, 21 
5820 
5880 
5940 
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tacggtcatt ctagagggcc cttcgaaggt aagcctatcc ctaaccctct cctcggtctc 60 
gattctacgc gtaccggtca tcatcaccat caccattgag tttaaacccg ctgatcctag 120 
agggccgcat catgtaatta gttatgtcac gcttacattc acgccctccc cccacatccg 180 
ctctaaccga aaaggaagga gttagacaac ctgaagtcta ggtccctatt tattttttta 240 
tagttatgtt agtattaaga acgttattta tatttcaaat ttttcttttt tttctgtaca 300 
gacgcgtgta cgcatgtaac attatactga aaaccttgct tgagaaggtt ttgggacgct 360 
cgaaggcttt aatttgcaag ctgcggccct gcattaatga atcggccaac gcgcggggag 420 
aggcggtttg cgtattgggc gctcttccgc ttcctcgctc actgactcgc tgcgctcggt 480 
cgttcggctg cggcgagcgg tatcagctca ctcaaaggcg gtaatacggt tatccacaga 540 
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atcaggggat aacgcaggaa agaacatgtg agcaaaaggc cagcaaaagc ccaggaaccg 
taaaaaggcc gcgttgctgg cgtttttcca taggctccgc ccccctgacg agcatcacaa 
aaatcgatgc tcaagtcaga ggtggcgaaa cccgacagga ctataaagat accaggcgtt 
tccccctgga agctccctcg tgcgctctcc tgttccgacc ctgccgctta ccggatacct 
gtccgccttt ctcccttcgg gaagcgtggc gctttctcat agctcacgct gtaggtatct 
cagttcggtg taggtcgttc gctccaagct gggctgtgtg cacgaacccc ccgttcagcc 
cgaccgctgc gccttatccg gtaactatcg tcttgagtcc aacccggtaa gacacgactt 
atcgccactg gcagcagcca ctggtaacag gattagcaga gcgaggtatg taggcggtgc 
tacagagttc ttgaagtggt ggcctaacta cggctacact agaaggacag tatttggtat 
ctgcgctctg ctgaagccag ttaccttcgg aaaaagagtt ggtagctctt gatccggcaa 
acaaaccacc gctggtagcg gtggtttttt tgtttgcaag cagcagatta cgcgcagaaa 
aaaaggatct caagaagatc ctttgatctt ttctacgggg tctgacgctc agtggaacga 
aaactcacgt taagggattt tggtcatgag attatcaaaa aggatcttca cctagatcct 
tttaaattaa aaatgaagtt ttaaatcaat ctaaagtata tatgagtaaa cttggtctga 
cagttaccaa tgcttaatca gtgaggcacc tatctcagcg atctgtctat ttcgttcatc 
catagttgcc tgactccccg tcgtgtagat aactacgata cgggagcgct taccatctgg 
ccccagtgct gcaatgatac cgcgagaccc acgctcaccg gctccagatt tatcagcaat 
aaaccagcca gccggaaggg ccgagcgcag aagtggtcct gcaactttat ccgcctccat 
ccagtctatt aattgttgcc gggaagctag agtaagtagt tcgccagtta atagtttgcg 
caacgttgtt ggcattgcta caggcatcgt ggtgtcactc tcgtcgtttg gtatggcttc 
attcagctcc ggttcccaac gatcaaggcg agttacatga tcccccatgt tgtgcaaaaa 
agcggttagc tccttcggtc ctccgatcgt tgtcagaagt aagttggccg cagtgttatc 
actcatggtt atggcagcac tgcataattc tcttactgtc atgccatccg taagatgctt 
ttctgtgact ggtgagtact caaccaagtc attctgagaa tagtgtatgc ggcgaccgag 
ttgctcttgc ccggcgtcaa tacgggataa tagtgtatca catagcagaa ctttaaaagt 
gctcatcatt ggaaaacgtt cttcggggcg aaaactctca aggatcttac cgctgttgag 
atccagttcg atgtaaccca ctcgtgcacc caactgatct tcagcatctt ttactttcac 
cagcgtttct gggtgagcaa aaacaggaag gcaaaatgcc gcaaaaaagg gaataagggc 
gacacggaaa tgttgaatac tcatactctt cctttttcaa tgggtaataa ctgatataat 
taaattgaag ctctaatttg tgagtttagt atacatgcat ttacttataa tacagttttt 
tagttttgct ggccgcatct tctcaaatat gcttcccagc ctgcttttct gtaacgttca 
ccctctacct tagcatccct tccctttgca aatagtcctc ttccaacaat aataatgtca 
gatcctgtag agaccacatc atccacggtt ctatactgtt gacccaatgc gtctcccttg 
tcatctaaac ccacaccggg tgtcataatc aaccaatcgt aaccttcatc tcttccaccc 
atgtctcttt gagcaataaa gccgataaca aaatctttgt cgctcttcgc aatgtcaaca 
gtacccttag tatattctcc agtagatagg gagcccttgc atgacaattc tgctaacatc 
aaaaggcctc taggttcctt tgttacttct tctgccgcct gcttcaaacc gctaacaata 
cctgggccca ccacaccgtg tgcattcgta atgtctgccc attctgctat tctgtataca 
cccgcagagt actgcaattt gactgtatta ccaatgtcag caaattttct gtcttcgaag 
agtaaaaaat tgtacttggc ggataatgcc tttagcggct taactgtgcc ctccatggaa 
600 
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780 
840 
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aaatcagtca agatatccac atgtgttttt agtaaacaaa ttttgggacc taatgcttca 
actaactcca gtaattcctt ggtggtacga acatccaatg aagcacacaa gtttgtttgc 
ttttcgtgca tgatattaaa tagcttggca gcaacaggac taggatgagt agcagcacgt 
tccttatatg tagctttcga catgatttat cttcgtttcc tgcaggtttt tgttctgtgc 
agttgggtta agaatactgg gcaatttcat gtttcttcaa cactacatat gcgtatatat 
accaatctaa gtctgtgctc cttccttcgt tcttccttct gttcggagat taccgaatca 
aaaaaatttc aaagaaaccg aaatcaaaaa aaagaataaa aaaaaaatga tgaattgaat 
tgaaaagcta gcttatcgat gataagctgt caaagatgag aattaattcc acggactata 
gactatacta gatactccgt ctactgtacg atacacttcc gctcaggtcc ttgtccttta 
acgaggcctt accactcttt tgttactcta ttgatccagc tcagcaaagg cagtgtgatc 
taagattcta tcttcgcgat gtagtaaaac tagctagacc gagaaagaga ctagaaatgc 
aaaaggcact tctacaatgg ctgccatcat tattatccga tgtgacgctg cagcttctca 
atgatattcg aatacgcttt gaggagatac agcctaatat ccgacaaact gttttacaga 
tttacgatcg tacttgttac ccatcattga attttgaaca tccgaacctg ggagttttcc 
ctgaaacaga tagtatattt gaacctgtat aataatatat agtctagcgc tttacggaag 
acaatgtatg tatttcggtt cctggagaaa ctattgcatc tattgcatag gtaatcttgc 
acgtcgcatc cccggttcat tttctgcgtt tccatcttgc acttcaatag catatctttg 
ttaacgaagc atctgtgctt cattttgtag aacaaaaatg caacgcgaga gcgctaattt 
ttcaaacaaa gaatctgagc tgcattttta cagaacagaa atgcaacgcg aaagcgctat 
tttaccaacg aagaatctgt gcttcatttt tgtaaaacaa aaatgcaacg cgacgagagc 
gctaattttt caaacaaaga atctgagctg catttttaca gaacagaaat gcaacgcgag 
agcgctattt taccaacaaa gaatctatac ttcttttttg ttctacaaaa atgcatcccg 
agagcgctat ttttctaaca aagcatctta gattactttt tttctccttt gtgcgctcta 
taatgcagtc tcttgataac tttttgcact gtaggtccgt taaggttaga agaaggctac 
tttggtgtct attttctctt ccataaaaaa agcctgactc cacttcccgc gtttactgat 
tactagcgaa gctgcgggtg cattttttca agataaaggc atccccgatt atattctata 
ccgatgtgga ttgcgcatac tttgtgaaca gaaagtgata gcgttgatga ttcttcattg 
gtcagaaaat tatgaacggt ttcttctatt ttgtctctat atactacgta taggaaatgt 
ttacattttc gtattgtttt cgattcactc tatgaatagt tcttactaca atttttttgt 
ctaaagagta atactagaga taaacataaa aaatgtagag gtcgagttta gatgcaagtt 
caaggagcga aaggtggatg ggtaggttat atagggatat agcacagaga tatatagcaa 
agagatactt ttgagcaatg tttgtggaag cggtattcgc aatgggaagc tccaccccgg 
ttgataatca gaaaagcccc aaaaacagga agattgtata agcaaatatt taaattgtaa 
acgttaatat tttgttaaaa ttcgcgttaa atttttgtta aatcagctca ttttttaacg 
aatagcccga aatcggcaaa atcccttata aatcaaaaga atagaccgag atagggttga 
gtgttgttcc agtttccaac aagagtccac tattaaagaa cgtggactcc aacctcaaag 
ggcgaaaaag ggtctatcag ggcgatggcc cactacgtga accatcaccc taatcaagtt 
ttttggggtc gaggtgccgt aaagcagtaa atcggaaggg taaacggatg cccccattta 
gagcttgacg gggaaagccg gcgaacgtgg cgagaaagga agggaagaaa gcgaaaggag 
cgggggctag ggcggtggga agtgtagggg tcacgctggg cgtaaccacc acacccgccg 
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cgcttaatgg ggcgctacag ggcgcgtggg gatgatccac tagtacggat tagaagccgc 
cgagcgggtg acagccctcc gaaggaagac tctcctccgt gcgtcctcgt cttcaccggt 
cgcgttcctg aaacgcagat gtgcctcgcg ccgcactgct ccgaacaata aagattctac 
aatactagct tttatggtta tgaagaggaa aaattggcag taacctggcc ccacaaacct 
tcaaatgaac gaatcaaatt aacaaccata ggatgataat gcgattagtt ttttagcctt 
atttctgggg taattaatca gcgaagcgat gatttttgat ctattaacag atatataaat 
gcaaaaactg cataaccact ttaactaata ctttcaacat tttcggtttg tattacttct 
tattcaaatg taataaaagt atcaacaaaa aattgttaat atacctctat actttaacgt 
caaggagaaa aaaccccgga tcggactact agcagctgta atacgactca ctatagggaa 
tattaagcta tcaaacaagt ttgtacaaaa aagcaggctt ggaaggagtt cgaaccatga 
cccagaccct caagtacgcc tccagagtgt tccatcgcgt ccgctgggcg cccgagttgg 
gcgcctccct aggctaccga gagtaccact cagcacgccg gagcttggca gacatcccag 
gcccctctac gcccagcttt ctggccgaac ttttctgcaa gggggggctg tcgaggctac 
acgagctgca ggtgcagggc gccgcgcact tcgggccggt gtggctagcc agctttggga 
cagtgcgcac cgtgtacgtg gctgcccctg cactcgtcga ggagctgctg cgacaggagg 
gaccccggcc cgagcgctgc agcttctcgc cctggacgga gcaccgccgc tgccgccagc 
gggcttgcgg actgctcact gcggaaggcg aagaatggca aaggctccgc agtctcctgg 
ccccgctcct cctccggcct caagcggccg cccgctacgc cggaaccctg aacaacgtag 
tctgcgacct tgtgcggcgt ctgaggcgcc agcggggacg tggcacgggg ccgcccgccc 
tggttcggga cgtggcgggg gaattttaca agttcggact ggaaggcatc gccgcggttc 
tgctcggctc gcgcttgggc tgcctggagg ctcaagtgcc acccgacacg gagaccttca 
tccgcgctgt gggctcggtg tttgtgtcca cgctgttgac catggcgatg ccccactggc 
tgcgccacct tgtgcctggg ccctggggcc gcctctgccg agactgggac cagatgtttg 
catttgctca gaggcacgtg gagcggcgag aggcagaggc agccatgagg aacggaggac 
agcccgagaa ggacctggag tctggggcgc acctgaccca cttcctgttc cgggaagagt 
tgcctgccca gtccatcctg ggaaatgtga cagagttgct attggcggga gtggacacgg 
tgtccaacac gctctcttgg gctctgtatg agctctcccg gcaccccgaa gtccagacag 
cactccactc agagatcaca gctgccctga gccctggctc cagtgcctac ccctcagcca 
ctgttctgtc ccagctgccc ctgctgaagg cggtggtcaa ggaagtgcta agactgtacc 
ctgtggtacc tggaaattct cgtgtcccag acaaagacat tcatgtgggt gactatatta 
tccccaaaaa tacgctggtc actctgtgtc actatgccac ttcaagggac cctgcccagt 
tcccagagcc aaattctttt cgtccagctc gctggctggg ggagggtccc accccccacc 
catttgcatc tcttcccttt ggctttggca agcgcagctg tatggggaga cgcctggcag 
agcttgaatt gcaaatggct ttggcccaga tcctaacaca ttttgaggtg cagcctgagc 
caggtgcggc cccagttaga cccaagaccc ggactgtcct ggtacctgaa aggagcatca 
acctacagtt tttggacaga 
<210> SEQ ID NO 22 
<211> LENGTH, 7458 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Plasmid pY2653 
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<400> SEQUENCE, 22 
cccagctttc ttgtacaaag tggttcgatc tagagggccc ttcgaaggta agcctatccc 
taaccctctc ctcggtctcg attctacgcg taccggtcat catcaccatc accattgagt 
ttaaacccgc tgatcctaga gggccgcatc atgtaattag ttatgtcacg cttacattca 
cgccctcccc ccacatccgc tctaaccgaa aaggaaggag ttagacaacc tgaagtctag 
gtccctattt atttttttat agttatgtta gtattaagaa cgttatttat atttcaaatt 
tttctttttt ttctgtacag acgcgtgtac gcatgtaaca ttatactgaa aaccttgctt 
gagaaggttt tgggacgctc gaaggcttta atttgcaagc tgcggccctg cattaatgaa 
tcggccaacg cgcggggaga ggcggtttgc gtattgggcg ctcttccgct tcctcgctca 
ctgactcgct gcgctcggtc gttcggctgc ggcgagcggt atcagctcac tcaaaggcgg 
taatacggtt atccacagaa tcaggggata acgcaggaaa gaacatgtga gcaaaaggcc 
agcaaaagcc caggaaccgt aaaaaggccg cgttgctggc gtttttccat aggctccgcc 
cccctgacga gcatcacaaa aatcgacgct caagtcagag gtggcgaaac ccgacaggac 
tataaagata ccaggcgttt ccccctggaa gctccctcgt gcgctctcct gttccgaccc 
tgccgcttac cggatacctg tccgcctttc tcccttcggg aagcgtggcg ctttctcata 
gctcacgctg taggtatctc agttcggtgt aggtcgttcg ctccaagctg ggctgtgtgc 
acgaaccccc cgttcagccc gaccgctgcg ccttatccgg taactatcgt cttgagtcca 
acccggtaag acacgactta tcgccactgg cagcagccac tggtaacagg attagcagag 
cgaggtatgt aggcggtgct acagagttct tgaagtggtg gcctaactac ggctacacta 
gaaggacagt atttggtatc tgcgctctgc tgaagccagt taccttcgga aaaagagttg 
gtagctcttg atccggcaaa caaaccaccg ctggtagcgg tggttttttt gtttgcaagc 
agcagattac gcgcagaaaa aaaggatctc aagaagatcc tttgatcttt tctacggggt 
ctgacgctca gtggaacgaa aactcacgtt aagggatttt ggtcatgaga ttatcaaaaa 
ggatcttcac ctagatcctt ttaaattaaa aatgaagttt taaatcaatc taaagtatat 
atgagtaaac ttggtctgac agttaccaat gcttaatcag tgaggcacct atctcagcga 
tctgtctatt tcgttcatcc atagttgcct gactccccgt cgtgtagata actacgatac 
gggagcgctt accatctggc cccagtgctg caatgatacc gcgagaccca cgctcaccgg 
ctccagattt atcagcaata aaccagccag ccggaagggc cgagcgcaga agtggtcctg 
caactttatc cgcctccatc cagtctatta attgttgccg ggaagctaga gtaagtagtt 
cgccagttaa tagtttgcgc aacgttgttg gcattgctac aggcatcgtg gtgtcactct 
cgtcgtttgg tatggcttca ttcagctccg gttcccaacg atcaaggcga gttacatgat 
cccccatgtt gtgcaaaaaa gcggttagct ccttcggtcc tccgatcgtt gtcagaagta 
agttggccgc agtgttatca ctcatggtta tggcagcact gcataattct cttactgtca 
tgccatccgt aagatgcttt tctgtgactg gtgagtactc aaccaagtca ttctgagaat 
agtgtatgcg gcgaccgagt tgctcttgcc cggcgtcaat acgggataat agtgtatcac 
atagcagaac tttaaaagtg ctcatcattg gaaaacgttc ttcggggcga aaactctcaa 
ggatcttacc gctgttgaga tccagttcga tgtaacccac tcgtgcaccc aactgatctt 
cagcatcttt tactttcacc agcgtttctg ggtgagcaaa aacaggaagg caaaatgccg 
caaaaaaggg aataagggcg acacggaaat gttgaatact catactcttc ctttttcaat 
gggtaataac tgatataatt aaattgaagc tctaatttgt gagtttagta tacatgcatt 
60 
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tacttataat acagtttttt agttttgctg gccgcatctt ctcaaatatg cttcccagcc 
tgcttttctg taacgttcac cctctacctt agcatccctt ccctttgcaa atagtcctct 
tccaacaata ataatgtcag atcctgtaga gaccacatca tccacggttc tatactgttg 
acccaatgcg tctcccttgt catctaaacc cacaccgggt gtcataatca accaatcgta 
accttcatct cttccaccca tgtctctttg agcaataaag ccgataacaa aatctttgtc 
gctcttcgca atgtcaacag tacccttagt atattctcca gtagataggg agcccttgca 
tgacaattct gctaacatca aaaggcctct aggttccttt gttacttctt ctgccgcctg 
cttcaaaccg ctaacaatac ctgggcccac cacaccgtgt gcattcgtaa tgtctgccca 
ttctgctatt ctgtatacac ccgcagagta ctgcaatttg actgtattac caatgtcagc 
aaattttctg tcttcgaaga gtaaaaaatt gtacttggcg gataatgcct ttagcggctt 
aactgtgccc tccatggaaa aatcagtcaa gatatccaca tgtgttttta gtaaacaaat 
tttgggacct aatgcttcaa ctaactccag taattccttg gtggtacgaa catccaatga 
agcacacaag tttgtttgct tttcgtgcat gatattaaat agcttggcag caacaggact 
aggatgagta gcagcacgtt ccttatatgt agctttcgac atgatttatc ttcgtttcct 
gcaggttttt gttctgtgca gttgggttaa gaatactggg caatttcatg tttcttcaac 
actacatatg cgtatatata ccaatctaag tctgtgctcc ttccttcgtt cttccttctg 
ttcggagatt accgaatcaa aaaaatttca aagaaaccga aatcaaaaaa aagaataaaa 
aaaaaatgat gaattgaatt gaaaagctag cttatcgatg ataagctgtc aaagatgaga 
attaattcca cggactatag actatactag atactccgtc tactgtacga tacacttccg 
ctcaggtcct tgtcctttaa cgaggcctta ccactctttt gttactctat tgatccagct 
cagcaaaggc agtgtgatct aagattctat cttcgcgatg tagtaaaact agctagaccg 
agaaagagac tagaaatgca aaaggcactt ctacaatggc tgccatcatt attatccgat 
gtgacgctgc agcttctcaa tgatattcga atacgctttg aggagataca gcctaatatc 
cgacaaactg ttttacagat ttacgatcgt acttgttacc catcattgaa ttttgaacat 
ccgaacctgg gagttttccc tgaaacagat agtatatttg aacctgtata ataatatata 
gtctagcgct ttacggaaga caatgtatgt atttcggttc ctggagaaac tattgcatct 
attgcatagg taatcttgca cgtcgcatcc ccggttcatt ttctgcgttt ccatcttgca 
cttcaatagc atatctttgt taacgaagca tctgtgcttc attttgtaga acaaaaatgc 
aacgcgagag cgctaatttt tcaaacaaag aatctgagct gcatttttac agaacagaaa 
tgcaacgcga aagcgctatt ttaccaacga agaatctgtg cttcattttt gtaaaacaaa 
aatgcaacgc gacgagagcg ctaatttttc aaacaaagaa tctgagctgc atttttacag 
aacagaaatg caacgcgaga gcgctatttt accaacaaag aatctatact tcttttttgt 
tctacaaaaa tgcatcccga gagcgctatt tttctaacaa agcatcttag attacttttt 
ttctcctttg tgcgctctat aatgcagtct cttgataact ttttgcactg taggtccgtt 
aaggttagaa gaaggctact ttggtgtcta ttttctcttc cataaaaaaa gcctgactcc 
acttcccgcg tttactgatt actagcgaag ctgcgggtgc attttttcaa gataaaggca 
tccccgatta tattctatac cgatgtggat tgcgcatact ttgtgaacag aaagtgatag 
cgttgatgat tcttcattgg tcagaaaatt atgaacggtt tcttctattt tgtctctata 
tactacgtat aggaaatgtt tacattttcg tattgttttc gattcactct atgaatagtt 
cttactacaa tttttttgtc taaagagtaa tactagagat aaacataaaa aatgtagagg 
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tcgagtttag atgcaagttc aaggagcgaa aggtggatgg gtaggttata tagggatata 
gcacagagat atatagcaaa gagatacttt tgagcaatgt ttgtggaagc ggtattcgca 
atgggaagct ccaccccggt tgataatcag aaaagcccca aaaacaggaa gattgtataa 
gcaaatattt aaattgtaaa cgttaatatt ttgttaaaat tcgcgttaaa tttttgttaa 
atcagctcat tttttaacga atagcccgaa atcggcaaaa tcccttataa atcaaaagaa 
tagaccgaga tagggttgag tgttgttcca gtttccaaca agagtccact attaaagaac 
gtggactcca acgtcaaagg gcgaaaaagg gtctatcagg gcgatggccc actacgtgaa 
ccatcaccct aatcaagttt tttggggtcg aggtgccgta aagcagtaaa tcggaagggt 
aaacggatgc ccccatttag agcttgacgg ggaaagccgg cgaacgtggc gagaaaggaa 
gggaagaaag cgaaaggagc gggggctagg gcggtgggaa gtgtaggggt cacgctgggc 
gtaaccacca cacccgccgc gcttaatggg gcgctacagg gcgcgtgggg atgatccact 
agtacggatt agaagccgcc gagcgggtga cagccctccg aaggaagact ctcctccgtg 
cgtcctcgtc ttcaccggtc gcgttcctga aacgcagatg tgcctcgcgc cgcactgctc 
cgaacaataa agattctaca atactagctt ttatggttat gaagaggaaa aattggcagt 
aacctggccc cacaaacctt caaatgaacg aatcaaatta acaaccatag gatgataatg 
cgattagttt tttagcctta tttctggggt aattaatcag cgaagcgatg atttttgatc 
tattaacaga tatataaatg caaaaactgc ataaccactt taactaatac tttcaacatt 
ttcggtttgt attacttctt attcaaatgt aataaaagta tcaacaaaaa attgttaata 
tacctctata ctttaacgtc aaggagaaaa aaccccggat cggactacta gcagctgtaa 
tacgactcac tatagggaat attaagctat caattcgaag gaattcggta ccatgtggaa 
gctttggaga gctgaagagg gcgcggcggc gctcggcggc gcgctcttcc tgctgctctt 
cgcgctaggg gtccgccagc tgctgaagca gaggcggccg atgggcttcc ccccggggcc 
gccggggctg ccatttatcg gcaacatcta ttccctggca gcctcatccg agcttcccca 
tgtctacatg agaaagcaga gccaggtgta cggagagatc ttcagtttag atcttggagg 
catatcaact gtggttctaa atggctatga tgtagtaaag gaatgccttg ttcatcaaag 
cgaaattttt gcagacagac catgccttcc tttattcatg aagatgacaa aaatgggagg 
cttactcaat tccagatatg gccgaggatg ggttgatcac agacgattag ctgtaaacag 
ttttcgatat tttggatatg gccaaaagtc ttttgaatct aaaatcttgg aagaaaccaa 
atttttcaat gatgctattg aaacatacaa aggtagacct tttgacttta aacagttaat 
aacgaatgct gtttcaaaca taaccaatct gatcattttt ggagaacgat tcacttatga 
agacaccgat tttcagcaca tgattgagtt atttagtgaa aatgtggaac tagctgccag 
tgcctcagtc ttcttgtata atgcctttcc atggattggc atcctgcctt ttggaaaaca 
tcaacagctg tttagaaatg cagctgtagt ctatgatttt ctctccagac tcattgaaaa 
agcttcagtc aacagaaagc ctcagctacc tcagcatttt gttgatgctt atttagatga 
gatggatcaa ggtaaaaatg acccatcatc tactttctcc aaagaaaacc taattttctc 
agtgggtgaa ctcatcattg ctggaactga aactacaacc aatgtgctac ggtgggcgat 
tcttttcatg gccctttatc ctaatattca aggacaagtt cagaaagaga ttgatttaat 
tatgggccct aatgggaagc cttcttggga cgacaaatgc aaaatgcctt atactgaggc 
agttttgcat gaagttttaa gattctgtaa tatagttcca ttagggattt tccatgcaac 
ctctgaagat gcagttgtac gtggttattc cattcctaaa ggcacaacag taattacaaa 
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-continued 
tctttattct gtacactttg atgaaaagta ctggagagac ccagaagtgt tccatcctga 7200 
gcgatttctg gacagcagtg gatattttgc caagaaggaa gctttggttc ctttttccct 7260 
aggaagaaga cattgtcttg gagaacactt ggctcggatg gaaatgttct tgttttttac 7320 
agcattgctt cagaggtttc atttgcattt tccacatgaa ctagttccag atctgaagcc 7380 
caggttaggc atgacattgc agccccaacc ctacctcatc tgtgctgaaa gacgctacag 7440 
acgcccgggc gatcgcga 7458 
The invention claimed is: 7. The yeast cell according to claim 1, wherein the coacti-
1. A yeast cell comprising: 15 vator domain of the adapter polypeptide is a coactivator 
domain of a human coactivator, and wherein the coactivator 
domain is characterized as binding to the ligand-binding 
domain of the recombinant nuclear receptor polypeptide in 
(i) a yeast transcription modulating system comprising a 
first heterologous nucleic acid expression system encod-
ing a recombinant nuclear receptor polypeptide com-
prising a ligand-binding domain operably linked to a 
DNA-binding domain and optionally to a flexible hinge 20 
domain, wherein the recombinant nuclear receptor 
polypeptide, when expressed in the yeast cell in the 
presence of a nuclear receptor ligand specifically bind-
ing to the recombinant nuclear receptor polypeptide, 
activates expression of a selective genetic locus; and a 
second heterologous nucleic acid expression system 
encoding an adapter polypeptide comprising a coactiva-
the presence of a ligand. 
8. The yeast cell according to claim 1, wherein expression 
of the genetic locus allows proliferation of the yeast cell on a 
selective medium. 
9. The yeast cell according to claim 1, wherein expression 
of the genetic locus inhibits proliferation of the yeast cell on 
25 a selective medium. 
10. The yeast cell according to claim 1, wherein the heter-
ologous enzyme system for the generation of a nuclear recep-
tor ligand from a substrate comprises a modified enzyme, 
wherein said modified enzyme catalyzes the formation of a 
tor domain operably linked to a yeast transcriptional 
activator, and wherein the first heterologous nucleic acid 
expression system and the second heterologous nucleic 
acid expression system are each independently encoded 
by individual heterologous polynucleotides or are 
encoded by the same heterologous polynucleotide; 
30 receptor ligand characterized as binding to the recombinant 
receptor polypeptide. 
(ii) a nuclear receptor ligand generating system comprising 
11. The yeast cell according to claim 1, wherein the heter-
ologous enzyme system for the generation of a nuclear recep-
tor ligand from a substrate comprises vitamin D3 25-hydroxy-a third heterologous nucleic acid expression system 
encoding a heterologous enzyme system for the genera-
tion of a nuclear receptor ligand from a substrate, 
wherein the nuclear receptor ligand is characterized as 
specifically binding to the recombinant nuclear receptor 
polypeptide; and 
35 lase and 25-hydroxyvitamin D3 la-hydroxylase, wherein 
said heterologous enzyme system catalyzes the formation of 
la,25-dihydroxyvitamin D3 , and wherein the la,25-dihy-
droxyvitamin D3 binds to the recombinant nuclear receptor 
polypeptide comprising the ligand-binding domain of a vita-
(iii) a selective genetic locus expressed in the presence of 
the recombinant nuclear receptor polypeptide and a 
nuclear receptor ligand specifically bound to the recom-
binant nuclear receptor polypeptide. 
40 min D receptor, thereby inducing expression of a genetic 
locus allowing the yeast cell to proliferate on a culture 
medium not having histidine therein, wherein the genetic 
locus is HIS3. 
2. The yeast cell according to claim 1, wherein the coacti-
vator domain is SRC-1 or ACTR. 
12. A method of modulating the transcription of a gene of 
45 a yeast cell, comprising 
3. The yeast cell according to claim 1, wherein the third 
heterologous nucleic acid expression system comprises a het-
erologous polynucleotide encoding a heterologous polypep-
tide, said heterologous polypeptide having an enzymic activ-
ity characterized as generating a candidate nuclear receptor 50 
ligand from a substrate. 
4. The yeast cell according to claim 1, wherein the third 
heterologous nucleic acid expression system comprises a het-
erologous polynucleotide encoding a plurality of heterolo-
gous polypeptides, wherein said heterologous polypeptides 55 
cooperate to generate a candidate nuclear receptor ligand 
from a substrate. 
5. The yeast cell according to claim 1, wherein the third 
heterologous nucleic acid expression system comprises a plu-
rality ofheterologous polynucleotides encoding a plurality of 60 
heterologous polypeptides, wherein said heterologous 
polypeptides cooperate to generate a candidate nuclear recep-
tor ligand from a substrate. 
6. The yeast cell according to claim 1, wherein the ligand-
binding domain of the recombinant nuclear receptorpolypep- 65 
tide is a ligand-binding domain of a human nuclear receptor 
polypeptide. 
(1) providing a yeast cell or population of yeast cells, 
wherein said yeast cell or population of yeast cells com-
prises: 
(i) a yeast transcription modulating system comprising a 
first heterologous nucleic acid expression system 
encoding a recombinant nuclear receptor polypeptide 
comprising a ligand-binding domain operably linked 
to a DNA-binding domain and optionally to a flexible 
hinge domain, wherein the recombinant nuclear 
receptor polypeptide, when expressed in the yeast cell 
in the presence of a nuclear receptor ligand specifi-
cally binding to the recombinant nuclear receptor 
polypeptide, activates expression of a genetic locus; 
and a second heterologous nucleic acid expression 
system encoding an adapter polypeptide, comprising 
a coactivator domain operably linked to a yeast tran-
scriptional activator, and wherein the first heterolo-
gous nucleic acid expression system and the second 
heterologous nucleic acid expression system are each 
independently encoded by individual heterologous 
polynucleotides or are encoded by the same heterolo-
gous polynucleotide; and 
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(ii~ a nucle.ar receptor ligand generating system compris-
mg a thJrd heterologous nucleic acid expression sys-
tem encoding a heterologous enzyme system for the 
generation of a nuclear receptor ligand from a sub-
strate, wherein the nuclear receptor ligand is charac-
terized as specifically binding to the recombinant 
nuclear receptor polypeptide; 
(iii) a selective yeast genetic locus expressed in the pres-
ence of the recombinant nuclear receptor polypeptide 
and a nuclear receptor ligand specifically bound to the 10 
recombinant nuclear receptor polypeptide; and 
(2) culturing the yeast cell under conditions allowing the 
yeast cell to synthesize a nuclear receptor ligand from a 
s1;1bstrate, ~hereupon the nuclear receptor ligand spe-
cifically bmds to the recombinant nuclear receptor 
polypeptide, thereby inducing transcription of the selec-
tive yeast genetic locus. 
15 
13. The method of claim 12, wherein the step of providing 
a y.east. cell or population of yeast cells further comprises 
dehvenng to the population of yeast cells a plurality of third 
h 
w 
et.erologous nucleic acid expression systems encoding a plu-
rality of enzyme systems suspected of generating from a 
substrate a nuclear receptor ligand specifically binding the 
recombinant nuclear receptor polypeptide, and wherein the 
step of culturing the yeast cell under conditions allowing the 
yeast cell to synthesize a nuclear receptor ligand from a 
substrate identifies a third heterologous nucleic acid expres-
sion system encoding an enzyme system generating the 
nuclear receptor ligand. 
14. The method according to claim 12, wherein the sub-
strate is endogenous to the yeast cell. 
15. The method according to claim 12, wherein the sub-
strate is exogenous to the yeast cell. 
16. The method according to claim 12, further comprising 
the step of modifying the first heterologous nucleic acid 
expression system encoding the recombinant nuclear recep-
tor polypeptide, thereby providing a variant recombinant 
nuclear receptor polypeptide specifically binding to the 
nuclear receptor ligand. 
25 
30 
35 
17. The method according to claim 12, further comprising 40 
the step of modifying the third heterologous nucleic acid 
expression system encoding the heterologous enzyme sys-
tem, thereby allowing the heterologous enzyme system to 
generate the nuclear receptor ligand from the substrate. 
18. The method according to claim 12, wherein the third 
h 
~ 
eterologous nucleic acid expression system comprises a het-
~rologous polynucleotide encoding a heterologous polypep-
tide, the h.eterologous polypeptide having an enzymic activity 
charactenzed as generating a candidate nuclear receptor 
ligand from a substrate. 
19. The method according to claim 12, wherein the third 
heterologous nucleic acid expression system comprises a het-
erologous polynucleotide encoding a plurality of heterolo-
gous polypeptides, wherein said heterologous polypeptides 
cooperate to generate a candidate nuclear receptor ligand 
from a substrate. 
50 
100 
20. The method according to claim 12, wherein the third 
heterologous nucleic acid expression system comprises a plu-
rality ofheterologous polynucleotides encoding a plurality of 
heterologous polypeptides, wherein said heterologous 
polypeptides cooperate to generate a candidate nuclear recep-
tor ligand from a substrate. 
. 2~. The me~hod according to claim 12, wherein the ligand-
~md1.ng do~mn of the recombinant nuclear receptor polypep-
tide 1s denved from a ligand-binding domain of a human 
nuclear receptor polypeptide, or a variant thereof. 
22. The method according to claim 12, wherein the coac-
tivator domain of the adapter polypeptide is derived from a 
coactivator domain of a human coactivator, or a variant 
thereof, and wherein the coactivator binds to the ligand-bind-
!ng domain of the recombinant nuclear receptor polypeptide 
m the presence of a ligand to activate expression of a genetic 
locus. 
. 23. The method according to claim 12, wherein transcrip-
t10n of the yeast gene allows the yeast cell to proliferate on a 
selective culture medium. 
. 24. The method according to claim 12, wherein transcrip-
t10n of the yeast gene inhibits yeast cell proliferation on a 
selective culture medium. 
25. The method according to claim 12, wherein the method 
further comprises contacting the yeast cell with at least one 
compound suspected of modulating the activity of at least one 
enzyme ~fthe.heterologous enzyme system, thereby allowing 
the 1dent1ficat10n of the at least one compound as an activator 
or inhibitor of the at least one enzyme. 
26. The method according to claim 25, wherein the at least 
one compound is suspected of enhancing the activity of at 
least one enzyme of the heterologous enzyme system. 
27. The method according to claim 25, wherein the at least 
one compound is suspected of inhibiting the activity of at 
least one enzyme of the heterologous enzyme system. 
28. The method of claim 12, wherein the method further 
comprises contacting the yeast cell with at least one com-
poun~ suspected of modulating the transcriptional activity of 
the third heterologous nucleic acid expression system encod-
i~g a ~eterologous enzyme system, thereby allowing the iden-
t1ficat10n of the at least one compound as an activator or 
inhibitor of the transcriptional activity of the third heterolo-
gous nucleic acid expression system. 
29. The yeast cell according to claim 6, wherein the ligand-
~indi.ng dom~in of the recombinant nuclear receptor polypep-
tide 1s a vanant of the ligand-binding domain of a human 
RXR receptor, wherein the variant is selected from the group 
consisting of: variant 1268A, 1310S, F313V, L436F; variant 
1268A, 1310S, F313V, L436F; variant 1268V, A272V, 
1310M, F313S, L436M; variant 1268A, A272V, 1310A, 
F313A, L436F; variant 1268L, A271V, 1310L, F313L; vari-
ant 1268A, 1310M, F313A, L436T; variant 1268\7, A271V, 
1310L, F313V; variant 1268L, 1310V, F3131; variant 1268L, 
1310M, F313V; and variant 1268\7, 1310\7, F313S. 
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